Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library

School of Medicine

1989

Identification and characterization of a novel class
of pharmacologic agents for the reversal of
multidrug resistance
James Matthew Ford
Yale University

Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Recommended Citation
Ford, James Matthew, "Identification and characterization of a novel class of pharmacologic agents for the reversal of multidrug
resistance" (1989). Yale Medicine Thesis Digital Library. 2597.
http://elischolar.library.yale.edu/ymtdl/2597

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

YALE

MEDICAL LIBRARY

Permission for photocopying or microfilming of "_
"

rS

-

•

c/ a A&V* <Oja\ $
T

"

(Title of thesis)
for the purpose of individual scholarly consultation or refer
ence Is hereby granted by the author.

This permission is not

to be interpreted as affecting publication of this work or
otherwise placing it
serves all

in the public domain, and the author re¬

rights of ownership guaranteed under common law

protection of unpublished manuscripts.

Signature of Author

/ /S /
Date

Digitized by the Internet Archive
in 2017 with funding from
The National Endowment for the Humanities and the Arcadia Fund

https://archive.org/details/identificationchOOford

IDENTIFICATION AND CHARACTERIZATION OF
A NOVEL CLASS OF PHARMACOLOGIC AGENTS
FOR THE REVERSAL OF MULTIDRUG RESISTANCE

A Thesis Submitted to the
Yale University School of Medicine
in Partial Fulfillment of the Requirements
for the Degree of Doctor of Medicine

by
James Matthew Ford

ABSTRACT
IDENTIFICATION AND CHARACTERIZATION OF A NOVEL CLASS OF
PHARMACOLOGIC

AGENTS

FOR

THE

REVERSAL

RESISTANCE. James M. Ford and William N. Hait.

OF

MULTIDRUG

Section of Medical Oncology,

Departments of Internal Medicine and Pharmacology, Yale University School of Medicine,
New Haven, CT.
Phenothiazines and structurally related compounds inhibit cellular proliferation and
sensitize multidrug resistant (MDR) cells to chemotherapeutic agents. To identify more
potent pharmaceuticals, the structure-activity relationships of a series of phenothiazines
and related compounds were studied in MDR MCF-7/DOX human breast cancer cells.
Spectrophotometric microtiter assays were used to determine the antiproliferative and antiMDR effects of drugs alone or in combination with chemotherapeutic agents. Substitutions
on the phenothiazine ring that increased hydrophobicity increased antiproliferative and antiMDR activities.

For example, -Cl and -CF3

groups increased whereas -OH groups

decreased potency. Modifying the length of the alkyl bridge (4 C > 3 or 2) and the type of
amino side chain (piperazinyl > non-cyclic) also influenced potency. Compounds with
tertiary amines were better anti-MDR agents than those with secondary or primary amines,
but were equipotent antiproliferative agents.

The effects of these substituents w'ere

unrelated to hydrophobicity. The structure-activity relationships suggest that an ideal
structure for reversing MDR by phenothiazines has a hydrophobic nucleus w’ith a -CF3 ring
substitution at position 2, connected by a 4 carbon alkyl bridge to a para-methyl substituted
piperazinyl amine. Related compounds having certain of these properties were studied and
the thioxanthene class of antipsychotics were identified as having increased activity and
potency as chemosensitizers. For example, rrans-flupenthixol, the most effective of these
compounds, decreased doxorubicin, vinblastine and colchicine resistance, respectively, by
15-, 36-, and 8-fold in MCF7/DOX cells; by 35-, 40-, and 20-fold in the MDR human

carcinoma line KB-V1; and by 7-fold (doxorubicin) and 4-fold (vinblastine) in the murine
leukemia line P388/DOX. Trans-flupenthixol fully reversed 20-fold doxorubicin and 100fold colchicine resistance in an NIH 3T3 fibroblast line transfected with an expression
vector containing the mdr 1 gene. Equimolar concentrations of rrans-flupenthixol caused
1.5- to 2-fold greater antagonism of MDR than its stereoisomer m-flupenthixol, 1- to 3fold greater than the calcium channel blocker verapamil, and 2- to 12-fold greater than the
phenothiazine homolog fluphenazine. None of these agents altered drug resistance or
cross-resistance in a non-P-glycoprotein expressing MCF-7 cell line selected with
mitoxantrone, nor any of the parental drug-sensitive cell lines. 7>art.s-flupenthixol was not
accumulated more than c/5-flupenthixol in MDR cells, implying that their stereospecific
anti-MDR effects were not the result of selective differences in the access of the drugs to
intracellular targets. Both drugs caused increased accumulation of doxorubicin in MDR
cells, but not in sensitive cells, suggesting that they modulate MDR by interacting with a
uniquely overexpressed cellular target in these resistant cells.

The cis- and trans-

stereoisomers were equally active antagonists of protein kinase C and calmodulin. The
apparent lack of clinical toxicity of traAtf-flupenthixol makes it an attractive drug for further
investigation, and a pilot in vivo trial was performed in a murine tumor model, which
showed rra/is-flupenthixol caused increased doxorubicin accumulation in MDR ascites
cells in vivo, but was toxic to mice at the doses tested. This thesis shows that transflupenthixol, a drug that lacks extrapyramidal side effects in humans, is a potent,
stereospecific antagonist of MDR in cells that overexpress P-gp.
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Chapter I
INTRODUCTION

A. Overview of the Cellular and Molecular Biology of Multidrug Resistance
1.

Definition and Characteristics of the Multidrug Resistant Phenotype
Tumor cell resistance to chemotherapeutic drugs is considered to be a major problem in

the clinical treatment of cancer. One form of drug resistance, termed multidrug resistance
(MDR), is defined as the ability of cells exposed to a single cytotoxic agent to develop
resistance to a broad range of structurally and functionally unrelated drugs (24).
Experimental models of MDR have been obtained by growing cultured human, murine or
hamster neoplastic cell lines in progressively increasing concentrations of cytotoxic drugs,
although MDR transplantable tumors have been developed in vivo (48). Cells selected for
resistance to one drug display significant cross-resistance to the other drugs within the MDR
phenotype, which mainly include the "natural product" anti-cancer drugs such as the
anthracyclines, the Vinca alkaloids, the epipodophyllotoxins, colchicine, and actinomycin
D, but not drugs such as bleomycin, methotrexate or alkylating agents. The level of crossresistance displayed by MDR cells to individual drugs varies between cell lines. However,
the qualitative similarity in the pattern of drug resistance suggests a single underlying
mechanism is responsible for MDR. Since many of the drugs affected by MDR are believed
to possess different mechanisms of cellular toxicity', investigations into the determinants of
MDR have focused on the identification of a unifying cellular defense mechanism against
toxic agents rather than on individual alterations in target enzymes. The most consistent
changes found in MDR cell lines are an increased expression of a high molecular weight cell
surface glycoprotein (P-glycoprotein) and a decreased accumulation and retention of
cytotoxic drugs (186).
Several excellent and thorough reviews of MDR have been recently published (14, 27,
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168). Thus, a brief summary’ of the current understanding of the cellular pharmacology and
molecular biology of this form of drug resistance will be presented. Following this will be a
detailed discussion of the pharmacological reversal of MDR, since this field of research has
not been adequately reviewed.

2.

Cellular Pharmacology of Multidrug Resistance
The first experiments demonstrating that MDR cells were associated with a relative

decrease in intracellular cytotoxic drug accumulation when compared to sensitive, parental
cells were performed independently by Victor Ling and June Biedler, using Chinese hamster
ovary cells resistant to colchicine and daunomycin, respectively (138, 184). Subsequently,
every well-characterized MDR cell line has been shown to display decreased drug
accumulation, generally ascribed to enhanced efflux rather than diminished influx (107,
108). A number of investigators explored the basis for this decreased drug retention, and
found an energy-dependent mechanism responsible for the enhanced efflux. Accordingly,
experiments in which MDR cells were depleted of ATP-energy by removing glucose or
adding metabolic inhibitors caused a reversal of the accumulation defect, while replacing
glucose restored MDR (49). In contrast, anthracycline drug influx appeared to occur by
simple passive diffusion, and to be similar in sensitive and MDR cells (128). These and
other observations led to the acceptance of the still unproven hypothesis that an active efflux
pump of broad specificity is responsible for the transport defect in MDR cells and results in
altered sensitivity to multiple drugs (212).
It is important to note that alternative explanations have been advanced to explain
decreased efflux, including alterations in the binding of drugs to cellular proteins or
organelles, particularly for colchicine (14). The determinants of altered drug transport in
MDR cells are complex and remain to be fully defined. However, the drug efflux pump
hypothesis has remained consistent with recent advances in the understanding of the MDR
phenotype.

3
3.

Molecular Biology of Multidrug Resistance

3a. Overexpression of P-glycoprotein
An approximately 170 kDa plasma membrane glycoprotein associated with MDR cells,
but not detectable in drug-sensitive cells, was first identified by Ling’s group (121), and
found to correlate with both decreased drug accumulation and degree of resistance in
Chinese hamster ovary cells (125).

Since then, several monoclonal antibodies to P-

glycoprotein (P-gp) have been developed, and nearly every established MDR cell line from
mouse, hamster, or human origin has been shown to express a 150 - 180 kDa membrane
protein immunologically cross-reactive with the originally described P-gp (124, 125, 126).
A great deal of evidence has accumulated suggesting that P-gp may be the active efflux
pump of broad specificity as predicted by studies of the cellular pharmacology of MDR.
For instance, purified, solubilized P-gp has been shown to possess an ATPase function
(93). A number of radiolabelled drugs, such as [3H]-vinblastine, and photoactivatable drug
analogs, have been shown to bind in a specific, saturable manner to MDR plasma membrane
vesicles, but not to sensitive cell vesicles (43, 45).

Furthermore, the major labelled

membrane protein has a molecular weight of 170 kDa and is immuno-cross-reactive with
monoclonal antibodies to P-gp (43, 44, 198). Structural analyses of P-gp accomplished by
sequencing cDNA clones from P-gp encoding genes are particularly provocative (38, 82).
The deduced amino acid sequence of P-gp reveals it to be dimer consisting of 6
transmembrane segments, and bearing striking homology to the ATP-binding domains of a
group of multicomponent bacterial periplasmic transport proteins, including the bacterial
membrane a-hemolysin export pump (hylB) (100). Taken together, this experimental
evidence strongly suggests that expression of P-gp forms the genetic basis for MDR.
However, whether the protein binds and exudes drugs by an active transport process,
physically opens channels in membranes through which drugs pass, or even irreversibly
binds drugs and is removed altogether from the cell is not known.
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3b. Overexpression of mdr Genes
In certain MDR cell lines, such as the human epidermal KB lines, the amplification of
gene(s) coding for P-gp allowed the use of in-gel renaturation (187) to isolate and ultimately
clone mdr genes from hamster, mouse and human cell lines (83, 188).

Cloned gene

segments from the human KB cells (mdr 1 gene) hybridized to a 4.5 kb mRNA present in
MDR cells in proportion to the degree of drug resistance, to which complementary cDNAs
were prepared (38). Alternatively, monoclonal antibodies to P-gp were used as probes to
screen a cDNA expression library for P-gp encoding clones from a Chinese hamster ovary
MDR cell line (76). The cDNA clones obtained by these two methods were found to be
highly homologous and to hybridize strongly to each other, indicating that P-gp is the
product of the mdr 1 gene (236).

Sequencing these cDNAs revealed the structural

characteristics of P-gp discussed above.
Perhaps the most compelling evidence demonstrating that MDR is due to the expression
of a single gene came from transfection experiments. Transfer of total genomic DNA from
MDR human cells (207), and more recently transfection and expression of retroviral vectors
containing full length cDNAs coding for P-gp (235) into sensitive cells conferred the full
MDR phenotype in the wild-type cells.

B . Clinical Relevance of Multidrug Resistance
An important question posed by the tremendous advances made in understanding the
cellular and molecular biology of MDR is whether the expression of the mdr 1 gene product
and the MDR phenotype occur in human tumors and are responsible for intrinsic or acquired
anti-cancer drug resistance. Most experimentally induced MDR cell lines have been selected
for 100-fold or greater levels of drug resistance, whereas clinical drug resistance is generally
thought to be on the order of 2- to 5-fold (23).

Therefore, it is possible that the

pharmacologic characteristics displayed by highly MDR cell lines are a laboratory
phenomenon only, exploiting otherwise functionally unrelated cellular mechanisms, and
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bearing no relevance to clinical drug resistance. Nevertheless, the common observation that
patients who relapse from therapy with certain drugs often become refractor}' to treatment
with virtually all drugs is particularly suggestive of the MDR phenotype, and demands
careful exploration.

1 .

Expression of P-glycoprotein in Normal Human Tissues
Critical to the understanding of the clinical importance of MDR is the determination of

the normal physiologic role and tissue distribution of P-gp, particularly as a baseline to
which tumor expression may be compared. A variety of normal human tissues samples
have been studied for P-gp expression using immunohistochemical or immunoperoxidase
staining methods with monoclonal antibodies against P-gp. High levels of P-gp have been
found in adult adrenal glands, kidney and placenta (218), and more abundantly in adrenal
cortex than adrenal medulla (219). At a cellular level, P-gp has been localized to the luminal
or apical surface of liver, pancreas, kidney, colon, and jejunum (222), suggesting a possible
role in secretory' processes. Immunoblot assays have also demonstrated the presence of Pgp in liver, and low levels in small bowel (27). It was recently reported that endothelial
cells of human capillary blood vessels at the blood-brain barrier and blood-testis barrier also
express P-gp, but cells from larger blood vessels or other tissue capillaries do not,
suggesting that P-gp may assist these tissues in their known function of excluding various
soluble polar compounds from the CNS and other pharmacologic sanctuaries (42).
Examination of P-gp expression in non-neoplastic tissues has also been carried out at the
genetic level, utilizing mdr 1 gene hybridization probes and Northern or slot blot analysis.
An initial survey of tissue types found low levels of mdr 1 mRNA in most samples, with
higher levels in adrenal, kidney, liver and colon (65), although significant variability
existed.
Based on these findings, it is reasonable to believe that P-gp possesses a normal
physiologic function in human tissues, perhaps related to secretion and/or protection of
tissues from various naturally occurring toxins or even commonly encountered xenobiotics
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structurally related to the natural product antibiotic drugs. It is likely that the continued
analysis of this problem will eventually yield a natural substrate for P-gp, since it is doubtful
that evolution would have selected for and highly conserved across species a protein whose
primary function is to bind or extrude chemotherapeutic drugs.

2.

Expression of P-glycoprotein in Human Tumors
Identical methods to those just described have been used to analyze P-gp and mdr 1

mRNA expression in human tumor samples.

Immunoblot assays have revealed

overexpression of P-gp in 2 of 5 cases of advanced non-responsive ovarian cancer (18), and
in sequential biopsies from 2 patients with acute nonlymphoblastic leukemia (ANLL)
progressing on therapy (142). Similar findings of a relationship between P-gp expression
and clinical resistance to anti-cancer therapy was reported by Carulli et al (31) for 2 patients
with chronic myeloid leukemia (CML) in blast crisis and one patient with ANLL. Gerlach
et al (75) reported that approximately 20% of biopsies specimens from 46 patients with 12
different types of sarcomas expressed increased levels of P-gp, though a correlation was
not found between prior chemotherapy and P-gp expression.
Measurement of mdr\ mRNA has revealed high levels of expression independent of
treatment in certain tumors derived from tissues known to overexpress P-gp normally, such
as pheochromocytomas (from adrenal medulla) and adrenocortical tumors (from adrenal
cortex) (65). Similarly, mdr 1 mRNA expression in untreated renal cell carcinomas was
higher than in other urogenital tumors derived from tissues w'hich do not normally express
P-gp (122). Interestingly, the levels of mRNA from tumors in this study were shown to
correlate inversely with tumor cell vinblastine sensitivity, but not doxorubicin or cisplatin
sensitivity, as determined by an in vitro cellular toxicity assay.
The most extensive study of mdr 1 expression reported to date analyzed over 400
tumor samples taken from patients both treated and untreated with chemotherapeutic drugs
(79). Expression was found to be high in untreated colon cancer, renal cell carcinoma,
hepatoma, adrenocortical carcinoma, pheochromocytoma and CML in blast crisis, while
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untreated breast cancer, non-small cell lung cancer, CML in chronic phase and many other
tumor types had low or undetectable levels of mdr\ mRNA. Expression in tumors from
patients who initially responded but subsequently relapsed on chemotherapy was high in
non-Hodgkin's lymphoma, neuroblastoma, pheochromocytoma, breast cancer, and acute
lymphocytic leukemia.

Therefore, P-gp overexpression was observed independent of

treatment in a number of intrinsically resistant tumors, and seen to increase in frequency in
several tumor types which received treatment. However, to prove an association between
intrinsic or acquired drug resistance and P-glycoprotein expression, pre- and post-treatment
P-gp levels from individual patients must be determined, and careful analyses of the
possible correlations between P-gp levels and treatment responses performed.
These important initial studies have proven that P-gp is expressed in both normal and
neoplastic human tissues.

Whether P-gp expression is a marker for intrinsic drug

resistance; whether its increased expression is related to the development of acquired
resistance; or what its funcdonal role is in normal tissues, are all questions which will be the
focus of future studies.

In addition, this work demonstrates that immunological and

molecular diagnostic techniques may be successfully used to detect P-gp and mdr\ gene
expression in clinical samples, and suggests their use for identifying individual patients who
may be appropriate candidates for trials designed to circumvent or modify MDR in humans.

C. Alternative Mechanisms Involved in Multiple Drug Resistance
While the study of MDR has focused most extensively on P-gp associated experimental
models, a rapidly increasing number of biochemical and molecular alterations have been
recently described in cell lines selected for the expression of resistance to multiple drugs.
Certain of these changes appear to occur only in consort with overexpression of the mdr\
gene, suggesting they may be the product of genes passively transcribed along with mdr\
amplification. In fact, these type of findings have encouraged investigators to thoroughly
characterize and define MDR cell lines as "classic" P-gp associated cells with drug
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accumulation defects, or otherwise. The two best characterized alternative mechanisms for a
broad multiple drug resistance are changes in the expression of glutathione drug
detoxification enzymes, and changes in topoisomerase II.
The multifunctional phase II detoxification enzyme glutathione-S-transferase (GST)
catalyzes the conjugation of electrophilic substances and endogenous xenobiotics to the
tripeptide thiol, glutathione (GSH), forming stable, excretable metabolites, and prevents
oxidative damage through intrinsic, organic peroxidase activity (36, 115). GST has been
found to be increased in several cell lines associated with resistance to individual alkylating
agents (220). However, an anionic (7t) isozyme of GST has recently been found to be
greatly overexpressed in P-gp positive MCF-7/DOX cells selected for MDR with
doxorubicin (12). Transfection and expression of cDNA clones of this isozyme in drug
sensitive MCF-7 cells conferred low level (1.5- to 3-fold) resistance to alkylating agents,
but no increase in resistance to natural product drugs (151). Thus, GST's role in multiple
drug resistance involving non-alkylating agents has not yet been shown. Other evidence,
however, does suggest that the GSH system may have some role in ’non-P-gp’ multiple
drug resistance. For instance, depletion of MCF-7/DOX cellular GSH, the substrate for all
GST enzymes, with the y-glutamylcysteine synthetase inhibitor buthionine sulfoximine
(147), resulted in a 5- to 7-fold increase in cellular sensitivity to doxorubicin (54).
The topoisomerases are enzymes that catalyze the breaking and rejoining of DNA
required for genomic unwinding, and are necessary for DNA replication (140). Attention
has focused on the role of topoisomerase II in drug resistance, since it is an enzyme target
for many DNA intercalating and non-intercalating neoplastic agents such as doxorubicin,
mitoxantrone, etoposide, tenoposide and mAMSA (39, 156, 221). Alteration in the amount
or function of topoisomerase II has been suggested as a possible mechanism for cellular
resistance to this broad group of drugs (190), and in fact, several multiple drug resistant cell
lines characterized by decreased levels of topoisomerase II activity in the absence of P-gp
expression or accumulation defects have now been reported (15, 35, 171).
A great number of other changes in cells resistant to multiple drugs have also been
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described. For instance, several low molecular weight cytosolic proteins are uniquely
expressed in MDR, such as the Ca+^-binding protein sorcin (148), and others (59).
Similarly, several membrane proteins unique to MDR cells have been observed in addition
to P-gp, such as an 85 kDa glycoprotein in K562/ADM cells (91), and a 150 kDa protein
immunologically distinct from P-gp (146). Whether these membrane proteins are metabolic
products of P-gp degradation has not been adequately studied.
Many biochemical changes have been noted in MDR cells, particularly in MCF-7/DOX
cells, including changes in phase I cytochrome P450 enzymes like aryl hydrocarbon
anhydroxylase (114), alterations in the regulation of the hexose monophosphate shunt
(244), and increased activity of the drug metabolizing enzymes DT-diaphorase and
glucuronyl transferase (46).
It is unclear for most of these changes whether their presence or alteration in MDR cells
have a significant regulators’ or functional role, or are simply a coincidental result of the
selecting procedure, resulting from co-amplified genes related to P-gp expression by their
physical proximity to the mdr 1 gene, but having no other functional or mechanistic
involvement in the MDR phenotype.

Thus, numerous opportunities await researchers

interested in further defining the regulatory mechanisms for "classic” MDR, and in
exploring the molecular and biochemical basis for alternative forms of multiple drug
resistance.

D. Pharmacologic Reversal of Multidrug Resistance by Chemosensitizers
1 .

Introduction
A major goal in experimental as well as clinical investigations of any form of drug

resistance is to devise or discover unique methods by which to successfully reverse or
antagonize this resistance.

Great interest, therefore, has been recently focused on the

pharmacologic reversal of MDR, especially in in vitro models. Through the identification
of specific compounds or classes of agents which reverse MDR, investigators hope to gain a
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better understanding of the various biochemical mechanisms involved in this form of cellular
drug resistance, and to provide possible agents for use in clinical trials.
The first report of the pharmacologic reversal of MDR came from Takashi Tsuruo and
his colleagues, who showed that the calcium channel blocker verapamil greatly potentiated
the antiproliferative activity of vincristine, in association with an increased cellular
accumulation of vincristine, in a MDR murine leukemia cell line in vitro and in vivo (228).
Since this original observation, a large number of compounds have been shown to have
activity in a variety of cell lines and in in vivo tumor models when co-administered with
cytotoxics, for at least partially reversing MDR . Tables 1-1 through 1-

6

summarize the

pharmacologic agents, MDR cells lines, and cytotoxic drugs used to date, both in vitro and
in vivo, for demonstrating reversal of MDR. It must be noted that a variety of assays have
been used by various investigators to measure the antiproliferative or cytotoxic effects of
drugs, resulting in a broad range of reported values for similar agents. In general, these
chemical compounds, termed "chemosensitizers" or "resistance modifiers," act to alter the
drug accumulation defect present in MDR cells, and cause little or no potentiation of drug
cytotoxicity in wild-type, or intrinsically sensitive cells.

While there are exceptions,

investigators generally determine the magnitude of chemosensitizers' effects by comparing
the doses necessary to inhibit cell growth by 50% (IC50) for a cytotoxic drug to which cells
are resistant in the absence versus presence of a relatively non-toxic, fixed concentration of
chemosensitizer. The ratio of these two values is referred to by different investigators as the
the fold-sensitization, Dose Modifying Factor, Degree of Potentiation, or MDR Ratio. This
standard has been used to calculate the fold reversal of cellular drug resistance for each
chemosensitizer listed in Table 1-1 to 1-6.
Very little is yet known regarding the biochemical mechanism, or even the specific
molecular targets, for any of the structurally diverse group of identified chemosensitizers
(27), partly because many of these compounds have profoundly different effects on cellular
physiology, often including significant cytotoxicity of their own. Nevertheless, the results
from this field of study have generated considerable interest in the possibility of devising
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clinical protocols utilizing relatively non-toxic chemosensitizers to circumvent clinical drug
resistance in humans (149, 165, 214).
The chemosensitizers described to date may be grouped into five broad categories: (a)
calcium channel blockers, (b) calmodulin antagonists, (c) non-cytotoxic anthracycline and
Vinca alkaloid analogs, (d) otherwise unrelated hydrophobic, cationic compounds, and (e)
cyclosporines.

Though this diverse group of compounds share only broad structural

similarities, all are extremely lipophilic, and those in the first four groups are all
heterocyclic, amphipathic substances. This suggests that there may be one or more specific
receptor sites for anti-MDR drugs, which have unique, though as yet poorly defined,
structural requirements for efficient binding.
The following sections will review the literature to date regarding the effects of
chemosensitizers in vitro, in vivo, and in human trials, and will focus on the need to
carefully define the structural requirements for antagonism of MDR by chemosensitizers and
to elucidate their mechanism of action.

2.

In Vitro Effects of Chernosensitizing Agents

2a. Verapamil
Based on the knowledge that certain MDR cell lines displayed an increase in drug efflux
due to alterations in drug transport at the plasma membrane level (107), Tsuruo's group
examined the anti-MDR effect of the calcium channel blocker verapamil, presumably
because of its already known action on a membrane target (62) and its documented
inhibitor}' effect on several hormonal secretory functions (55). Using a tissue culture
growth inhibition assay, it was shown that 2.2 to 6.6 (iM verapamil completely reversed the
approximately 30-fold resistance to vincristine and 7-fold resistance to vinblastine displayed
by a MDR murine leukemia cell line, P388/VCR (228). Incubation with 6.6 fiM verapamil
for 5 hours also caused a 10-fold increase in accumulation of [3H]-vincristine in P388/VCR
cells. In addition, verapamil caused a 3-fold increase in the antiproliferative effect of
vincristine and vinblastine and a 2-fold increase in [3H]-vincristine accumulation in sensitive
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P388 cells (228). Doses of verapamil greater than 6.6 |lM had significant cytotoxicity
alone. Since verapamil was shown not to alter vincristine binding to tubulin, the apparent
cytotoxic target of Vinca alkaloids (164), it was concluded that verapamil's pharmacologic
anti-MDR effect was due to alterations in drug accumulation (228).
In subsequent reports, Tsuruo’s group similarly demonstrated that 6.6 |iM verapamil
fully reversed the 20-fold vincristine resistance and the 3-fold doxorubicin resistance in a
MDR human acute myelogenous leukemia line K562/VCR (230), and partially reversed the
40-fold doxorubicin resistance in P388/ADM cells (229). Again, this anti-MDR effect was
associated with modest (5-fold) increases in chemotherapeutic drug accumulation, shown to
be due specifically to inhibition of an energy-dependent efflux mechanism (229).
Since these early observations, a large number of investigators have demonstrated the
chemosensitizing activity of verapamil in various cell lines (Table 1-1) using a variety of
techniques. For example, resistance to chemotherapeutic selecting agents was partially
reversed by verapamil in vinblastine resistant human leukemic lymphoma CCRF-CEM cells
(13), and in doxorubicin resistant B16 murine melanoma cells (66), as measured by short¬
term cell growth inhibition.

Clonogenic assays revealed modest increases in drug

cytotoxicity by 1 (iM verapamil plus daunomycin in MDR Chinese hamster ovary cells (29),
and 6 pM verapamil plus doxorubicin in doxorubicin resistant C5 rat glioblastoma cells
(102). Slater and colleagues (215) showed that 2 to 6 pM verapamil caused significant
increases in the inhibition of DNA and RNA synthesis by daunomycin in daunomycin
resistant Ehrlich ascites carcinoma cells, as measured by [-H]-uridine and [^HJ-thymidine
incorporation. Several samples of fresh human tumor cells from patients who relapsed on
doxorubicin w’ere show-n to be more sensitive to the drug in the presence of verapamil by the
human tumor clonogenic assay (80). In addition, the sensitivity of most of the parental,
wild-type cells from w'hich the MDR lines were derived, as well as other intrinsically
sensitive cell lines, was not significantly affected by verapamil at non-cytotoxic doses.
The effect of the verapamil on modifying cellular cross-resistance to chemotherapeutic
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drugs other than those used for selection is of great interest, both with respect to the
mechanism and pharmacology of verapamil's anti-MDR activity, and in defining the
molecular mechanism of MDR itself. However, conflicting results have been reported,
complicated by the fact that many of these studies occurred before the characterization of cell
lines using molecular and immunologic probes for P-glycoprotein expression became
common. Using a MES-SA human uterine sarcoma cell line selected for 100-fold resistance
to doxorubicin and recently shown to overexpress the mdr\ gene product (211), Harker
and coworkers showed that 6 [lM verapamil caused a 7-fold enhancement of doxorubicin
effect, associated with increased [14C]-doxorubicin accumulation and retention (95).
Verapamil caused a similar partial reversal of this cell line's significant cross-resistance to
daunomycin, actinomycin D and mitoxantrone, but did not effect cell resistance to agents
such as etoposide or melphalan, drugs not included in the phenotypic definition of MDR.
Paradoxically, verapamil resulted in increased accumulation of [?H]-vinblastine in these
cells, but did not alter MES-SA/Dx5 resistance to vinblastine toxicity.
Conversely, Beck's group reported that 10 )iM verapamil caused a 75- and 87-fold
decrease in the 244- and 1163-fold CEM/VLBjqo cell resistance to vinblastine and
vincristine, respectively, but only a 2- to 5-fold potentiation of doxorubicin and
daunomycin, to which the cells were 100-fold cross-resistant (17).

Fojo el al (64)

demonstrated that 20 jiM verapamil caused a full reversal of the 20- to 70-fold cross¬
resistance to doxorubicin, vinblastine and vincristine in colchicine selected KB human
carcinoma cells, while causing only a 60-fold reduction in the 220-fold resistance to
colchicine.

Finally, in doxorubicin selected P388/ADR cells, the degree of cytotoxic

potentiation for a series of five anthrapyrazoles by 10 pM verapamil was shown to be
linearly related to the level of cross-resistance displayed to these drugs (131). Thus, while
verapamil equally affects cellular resistance to selecting agents and cross-resistance to other
drugs in some MDR cell lines, this finding is not true for other MDR cell lines. The
question of why various MDR cells display different degrees of resistance and crossresistance to drugs, and why some cross-resistance is refractors' to modulation by verapamil
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is presently unclear. An intriguing possibility is that alterations in the mdr 1 gene at the
genomic level (40) or post-translational modifications in P-glycoprotein may cause changes
in the affinity of certain drugs or drug classes for the putative drug-binding site(s), or may
render P-glycoprotein less susceptible to antagonism by verapamil. Alternatively, multiple
isoforms of P-glycoprotein, as well as multiple mechanisms of drug resistance to various
chemotherapeutic agents operating within a single cell line may also explain these
phenomena.
While the target and mechanisms for verapamil's pharmacologic effects on MDR cells
is unclear, the effect of verapamil on the well-characterized changes in drug accumulation
observed in MDR cells has been carefully documented.

Kessel and Wilberding (128)

probed the effect of verapamil on anthracycline cellular kinetics in P388/ADR cells. Drug
influx was not altered by verapamil nor by the metabolic inhibitor sodium azide, consistent
with a diffusional model of anthracycline inward transport.

Drug efflux from [^H]-

daunomycin loaded cells was also not affected by either modifying agent in P388 sensitive
cells, while MDR cell daunomycin efflux was inhibited by varying degrees with 2 to 20 (iM
verapamil, suggesting that verapamil specifically inhibits the energy-dependent drug efflux
mechanism described for these cells (108). More recently, similar studies were performed
with the human myeloma MDR cell line 8226/DOX40 (19). Accordingly, 10 |iM verapamil
caused an increase in net [14C]-doxorubicin accumulation in resistant, but not sensitive
cells, due to a decrease in drug efflux.

Verapamil was show'n not to alter initial

anthracycline influx during the first 60 seconds of drug exposure.

Furthermore, the

quantitative formation of single-stranded, double-stranded and protein-associated DNA
breaks in both sensitive and resistant cells after a one hour doxorubicin exposure in the
absence and presence of verapamil was determined by DNA alkaline elution techniques
(19), since a proposed mechanism for anthracycline cytotoxicity is through topoisomerase II
mediated DNA strand breaks (189). In resistant cells there was an approximately 5-fold
decrease in the formation of DNA lesions compared to sensitive cells. However, in the
presence of 10 pM verapamil, sensitive and resistant cells sustained equivalent amounts of
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DNA damage by doxorubicin.
Therefore, it has been clearly shown that verapamil inhibits the energy-dependent drug
efflux common to MDR cells. In addition, it is highly likely that the drug cytotoxicity'
potentiated by verapamil is secondary' to the resultant increase in intracellular drug
accumulation.
Verapamil is the best studied chemosensitizer to date, and is a potent and effective
antagonist of resistance to a number of drugs in most MDR cell lines, in vitro. However,
verapamil possesses potentially life-threatening vasodilatory effects in humans at plasma
levels in the 2 to

6

pM range (28, 50) and is cytotoxic itself at higher doses to normal (133)

and tumor tissue (17) in vitro. These facts have led to the search for more potent and less
toxic anti-MDR agents for possible clinical use.

2 b. Verapamil Analogs
An obvious first step in searching for less toxic, more selective chemosensitizing agents
is to examine the ability of structural analogs of verapamil to antagonize MDR (Table 1-2).
Kessel and Wilberding (129) studied the anti-MDR effects of the verapamil analog tiapamil,
and 13 additional analogs of tiapamil, in a P388/ADR cell clonogenic assay. Tiapamil,
which contains a dithiane tetraoxide substituent on the carbon backbone, was 50-fold less
potent than verapamil in causing a partial (15-fold) reversal of the 100-fold doxorubicin
resistance, while the analog Ro 1 1-3651 (DMDP) was only 7-fold less potent, and the
dithiane substituted analog Ro 11-2933 was 10-fold more potent than verapamil in
mediating this effect. The degree of doxorubicin potentiation by the four active tiapamil
compounds was found to correlate with their respective effect on drug accumulation (129).
Another group further examined the activity of DMDP in the same cell line, and found
that non-toxic doses of this tiapamil analog (3 |iM) and verapamil

(6

pM) caused similar

effects on doxorubicin cytotoxicity and accumulation, but that DMDP was
to cells than verapamil when used alone (IC50 = 14 jiM) (175).

-fold more toxic

6
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A Japanese group reported that a synthetic isoprenoid structurally related to verapamil,
SDB-ethylenediamine, caused a 2- to 5-fold increase in doxorubicin cytotoxicity in the
P388/ADR cell line, as well as partial reversal of cross-resistance to vincristine, vinblastine
and daunomycin (242). Antagonism of MDR was also found in P388A;CR cells and in
colchicine selected MDR human epidermal carcinoma KB-ChR-24 (155, 242).
Interestingly, this verapamil analog, which has a slightly modified carbon backbone and
contains a 9 carbon isoprene side group, has negligible activity as a calcium channel
blocking agent compared to verapamil (242).
Thus, certain compounds structurally related to verapamil partially reverse MDR, but
lack other physiological effects of verapamil. While of clear mechanistic interest (see
Section 4b, below), this also suggests that through structure-activity' relationships it may be
possible to identify and exploit those structural features necessary for anti-MDR activity,
while eliminating those important for antagonism of calcium channels or other interactions.

2c. Other Calcium Channel Blockers
Since a number of calcium channel blockers structurally dissimilar to verapamil have
been described and are in clinical use, it occurred to researchers to examine their effect
against MDR. While it subsequently became clear that these drugs’ pharmacologic effect on
slow inward calcium transport was completely unrelated to their anti-MDR activity (see
Section 4b, below), many were nevertheless found to be quite active antagonists of MDR
(Table 1-2) (96).

Indeed, in Tsuruo’s early observations of the anti-MDR effects of

verapamil, it is also noted that caroverine and prenylamine, agents known to block calcium
channels (26, 112), w'ere as active as verapamil in altering the sensitivity of P388/VCR and
K562/VCR cells to vincristine and P388/ADM cells to doxorubicin, though 2- to 3-fold less
potent (229, 230).
Additional studies specifically examined the effects of calcium channel blockers in
MDR cell lines and found that two other classes of structurally dissimilar drugs, diltiazem
and the nifedipine analogs, had significant anti-MDR activity (181, 227, 231).
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Interestingly, nifedipine itself, known to be a strong calcium channel blocker (63), was a
poor antagonist of MDR in P388/VCR and K562/VCR cells (227) and had no effect in
potentiating doxorubicin in P388/ADR cells (181). However, the dihydropyridine analogs
niludipine, nimodipine, and nicardapine were found to be potent antagonists of MDR, with
3.5 to 10 |iM nicardapine fully reversing vincristine resistance in P388A7CR and
K562/VCR cells (227, 231) and partially reversing doxorubicin resistance in P388/ADR
cells (181, 227).

These studies pointed out what was later proven to be the distinct

pharmacologic effects of these drugs on calcium channels and on MDR (102).
Several groups have shown that perhexiline maleate, another structurally unrelated drug
which has among other effects calcium channel blocking activity (62), can also antagonize
MDR. Non-toxic concentrations of perhexiline maleate (10 jiM) caused a slight increase in
the sensitivity of a MDR human breast cancer cell line MCF-7Ad to doxorubicin and
vinblastine (177), and a more substantial reversal of P388/ADR cell resistance to these same
drugs (67), along with concomitant increases in [3HJ-drug accumulation. Like verapamil,
however, perhexiline maleate is a clinically used vasodilator and is an unlikely candidate for
the modulation of tumor resistance in humans, due to its dose-limiting hemodynamic side
effects.
Finally, in the search for a calcium channel blocker with anti-MDR activity and less
vasodilator)' activity, bepridil was found to be a potent inhibitor of colchicine selected
Chinese hamster ovary cell resistance to doxorubicin (74-fold reversal) (203).

Drug

concentrations shown necessary for anti-MDR activity in vitro (2 to 4 pM) by this study
had been reported to be clinically achievable without resultant toxicity (20). When studied
in the MDR human ovary cell line 2780AD, bepridil was equally as active as verapamil, but
%

caused only a 10% increase in sensitivity to doxorubicin. However, of all the calcium
channel blockers studied to date, bepridil appears to be the most worthy of continued preclinical development for the in vivo reversal of drug resistance.
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2d. Calmodulin Antagonists
The second most studied group of anti-MDR agents are drugs which also possess the
ability to inhibit CaM-mediated processes, such as the Ca^CaM-dependent form of cyclic
nucleotide phosphodiesterase (137). While the activity of CaM antagonists against MDR
was first described by Tsuruo (229), Ganapathi has most extensively studied this group of
drugs, focusing on the phenothiazine (PTZ) antipsychotic trifluoperazine.
Based on the finding that verapamil functioned as a chemosensitizer in MDR cells,
Tsuruo examined several other compounds known to perturb the intracellular calcium
environment (Table 1-3). Non-toxic concentrations of the well known CaM antagonist,
trifluoperazine, caused a 5- to 10-fold increase in vincristine and doxorubicin sensitivity in
20- and 40-fold resistant P388/VCR and P388/ADM cells, respectively (229), and fully
reversed 17-fold K562/VCR resistance to vincristine (230). Like verapamil, trifluoperazine
also caused a 4- to 5-fold increase in pHJ-vincristine and pHJ-doxorubicin accumulation in
these cells, and did not significantly alter drug cytotoxicity or accumulation in their sensitive
counterparts (229, 230).

Although verapamil appeared to be more effective than

trifluoperazine in antagonizing MDR, higher concentrations of verapamil than the CaM
antagonist were used (6.6 pM versus 2 to 3 pM trifluoperazine) due to trifluoperazine's
greater toxicity when used alone (229).

Interestingly, equimolar concentrations of

trifluoperazine and verapamil (6.6 pM) were shown to produce equivalent increases in
[3H]-drug accumulation in all three cell line (229, 230). Unfortunately, no study directly
comparing the potency, toxicity and maximal anti-MDR effect of trifluoperazine and
verapamil in this or any other cell lines has been reported.
Ganapathi has focused on the effect of trifluoperazine in altering cellular drug
resistance, cross-resistance and drug accumulation (Table 1-3). In 100-fold doxorubicin
resistant P388/DOX cells (apparently a different MDR subline than Tsuruo's P388/ADM), 4
to 5 pM trifluoperazine caused a 5- to 10-fold increased inhibition of cellular proliferation
and cytotoxicity by doxorubicin in MDR, but not sensitive cells (69, 71), as measured by
cell growth and clonogenic assays. 5 |iM trifluoperazine also partially antagonized the
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resistance of a series of L1210 murine leukemia cell lines made variably resistant to
doxorubicin (5- to 40-fold), with the magnitude of this effect seemingly related to the degree
of acquired resistance (70) (Table 1-3).
Trifluoperazine's effect on cross-resistance is less clear. Similar to experiments with
trifluoperazine and doxorubicin, trifluoperazine enhanced the cellular accumulation and
cytotoxicity of the anthracycline daunomycin in the 100-fold cross resistant P388/DOX
cells, but not in sensitive P388 cells (71). However, trifluoperazine had significant effects
on the cytotoxicity of Vinca alkaloids in both MDR and sensitive cells, causing 2- to 10fold increases in the toxicity of vinblastine and vincristine in the 20- and 100-fold cross
resistant P388/DOX cells, respectively, as well as in sensitive P388 cells (72). Conversely,
trifluoperazine's effect on the accumulation of [-H]-vinblastine was not similar in the
P388/DOX and P388 sensitive cells, causing a 8-fold versus 2-fold increase, respectively
(72). Thus, trifluoperazine's enhancement of Vinca alkaloid cytotoxicity does not clearly
parallel its effect on cellular drug levels.
In fact, Ganapathi has argued extensively against a correlation between actual
intracellular levels of drug following exposure to trifluoperazine and resultant cellular
toxicity. For instance, Ganapathi compared the resultant P388/DOX cellular toxicity of
similar intracellular doxorubicin or daunomycin concentrations achieved by either treating
with 5 (iM trifluoperazine or by increasing extracellular drug concentration appropriately,
and found that cell kill occurred only with trifluoperazine treatment (74). Furthermore, the
cellular accumulation of doxorubicin in the absence and presence of 5 (iM trifluoperazine
was examined in a series of L1210 cell lines made 5-, 10-, 20-, and 40-fold resistance to
doxorubicin (70).

In the absence of trifluoperazine, cellular doxorubicin accumulation

progressively decreased with increasing resistance from 15 - 50% of parental L1210 cell
accumulation.

The presence of 5 (iM trifluoperazine caused a constant 1.5-fold

enhancement of doxorubicin accumulation in each resistant subline, independent of its level
of resistance.

In contrast, the effect of trifluoperazine in modulating doxorubicin

cytotoxicity was dependent on the level of resistance (Table 1-3), with the magnitude of
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chemosensitizing activity correlating with the level of resistance. However, if one re¬
analyzes Ganapathi's data to calculate the percent modulation of total doxorubicin resistance
by trifluoperazine in each subline as a function of the total difference in sensitivity from the
parental line, rather than purely the fold decrease in resistance, one actually finds a
progressive decrease in the percent reversal of resistance by trifluoperazine in increasingly
resistant sublines. This finding is in agreement with the calculated decrease in doxorubicin
accumulation relative to the total accumulation defect in increasingly resistant sublines.
Obviously, the effects of alterations in drug accumulation are extremely difficult to
assess since drug accumulation and retention are only one of many factors influencing the
cytotoxicity of chemotherapeutic agents. Compounding this problem is that drug activity
tends to be measured in terms of overall cell toxicity, rather than specific effects at a
biochemical or molecular level. Even independent of the effects of chemosensitizers, it is
not clear that intracellular drug levels are linearly related to cytotoxicity. In fact, this would
not be expected, since chemotherapeutic agents often have multiple targets with different
affinities through which they mediate their toxicity. For example, the basis for doxorubicin
cytotoxicity has been suggested to be due to a combination of cellular effects, including
DNA intercalation (53), membrane binding (223), free radical formation (9), transitional
metal ion binding (152), and topoisomerase II-mediated DNA strand breaks (221). Such a
multitude of targets implies a complex relationship between drug level and effect.

In

addition, cells themselves have various intrinsic mechanisms for protection from drug
toxicity, such as phase I and phase II drug-metabolizing enzymes and various DNA repair
enzymes, so that certain threshold levels of drug may be necessary before cell damage can
accumulate.
Nevertheless, the disparity between chemosensitizer modulated accumulation and
cytotoxicity in Ganapathi's studies suggests that trifluoperazine, a drug known to effect
many cellular enzymes and receptors (47, 167, 195) may alter cell sensitivity to drugs in
additional ways unrelated to changes in accumulation. Indeed, several investigators have
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shown that CaM antagonists such as trifluoperazine modulate cell sensitivity to bleomycin
through inhibition of DNA repair mechanisms (33, 134). These results also suggest that
certain N1DR cells may have multiple mechanisms of resistance, and reversing the
accumulation defect alone may not fully reverse cellular drug resistance. In fact, several
MDR cell lines have recently been shown to possess alternate mechanisms of resistance in
addition to P-glycoprotein, such as increased levels of the glutathione conjugating enzyme
glutathione-S-transferase in MCF-7/DOX cells and an MDR P388 line (12, 51), and
decreased levels of the drug target topoisomerase II in this same P388 line (52).
In summary', certain CaM antagonists, such as trifluoperazine, function as moderately
effective chemosensitizers and enhance cytotoxic drug accumulation and retention in MDR
cells. Though the PTZs generally are thought to be less active anti-MDR agents than the
calcium channel blocker verapamil, a comparison of Tables 1-1 and 1-3 reveal that the
concentrations of verapamil used in most studies are generally greater than trifluoperazine,
presumably due to the greater toxicity of the latter compound. Since there appears to be a
dose-response relationship for chemosensitizers' anti-MDR effect (19, 70, 211),
trifluoperazine's significant toxicity may limit its in vitro use to a less than maximally
effective chemosensitizing dose range. A number of investigators have clearly shown CaM
to be a target for the PTZs' cytotoxic actions (87, 113, 239), and it is therefore intriguing to
speculate on the possible selectivity for anti-MDR activity over cytotoxicity for this class of
agents if CaM is in fact not directly involved in the pharmacologic reversal of MDR.
Clearly, more comprehensive studies of the effects and mechanisms for reversal of MDR by
CaM antagonists are necessary' and indicated.

2e. Anthracycline and Vinca Alkaloid Analogs
Soon after the discovery' that MDR cells have reduced drug uptake secondary to an
increased active efflux mechanism (212), Skovsgaard tested the intriguing and logical
possibility that a specific drug efflux pump would be competitively inhibited by an excess of
a non-toxic substrate (213). The ideal anthracycline structural analog for this purpose was
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A-acetyl-daunorubicin, which lacks the free amino-group of daunomycin essential for
DNA intercalation, and thus has a lower affinity for DNA resulting in less cytotoxicity and
higher cytoplasmic concentrations (247). Skovsgaard found that a 30-fold excess of ATacetyl-daunorubicin caused marked inhibition of active daunomycin efflux in MDR, but not
sensitive, Ehrlich ascites cells, leading to increased net daunomycin uptake (213).

In

addition, A-acetyl-daunorubicin had a 7-fold low'er affinity for both sensitive and resistant
cell nuclei in whole cell lysate preparations, and did not compete with pHj-daunomycin
binding to DNA. The effect of A7-acetyl-daunorubicin on cellular resistance to daunomycin
w-as unfortunately not examined in vitro, though a 1:20 combination of daunomycin and its
structural analog did cause significant increases in the life span of mice w'ith MDR Ehrlich
ascites cells inoculated intraperitoneally (i.p.) compared to no effect of either drug alone
(213).
Inaba's group subsequently analyzed the chemosensitizing effects of three additional
non-toxic anthracycline analogs on MDR cells and found significant enhancement of
vincristine toxicity in P388/VCR cells in vitro when used in 100-fold excess (111).
Interestingly, one of these analogs also partially reversed the cross-resistance of the cells to
daunomycin, implying that either a similar drug efflux mechanism effects both
anthracyclines and Vinca alkaloids, or that the daunomycin analogs competitively inhibited
two different mechanisms. Similarly, Inaba also reported that a number of relatively non¬
toxic Vinca alkaloid analogs, such as vindoline, effectively antagonized both the primary
resistance and cross-resistance of MDR P388/ADM and P388/VCR cells (110) when used
in 1000-fold excess (Table 1-4). These analogs were 5- to 10-fold less potent than the
anthracycline analogs as chemosensitizers and as enhancers of cytotoxic drug accumulation.
These findings suggest that a single drug-binding site of broad specificity, rather than
multiple, independent binding sites, is responsible for cross-resistance between at least the
anthracyclines and Vinca alkaloids.

Indeed, these speculations agree with molecular

studies demonstrating that single base mutations wnthin the mdr 1 gene can alter the levels of
cross-resistance displayed by the expressed P-gp (40). It would also be of interest to see
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whether these non-toxic analogs competitively inhibit the binding to the photoaffinity
labelled vinblastine analog 125I-NASV (2) or the photoactive verapamil analog 12-I-NASAV
(197) to P-glycoprotein.

2f. Odxer Hydrophobic Cationic Compounds
The search for agents to circumvent MDR has led to the identification of numerous
compounds which are not known to be calcium channel blockers or CaM antagonists, and
are not otherwise pharmacologically related. Most of these compounds are amphipathic and
lipophilic in nature, and share a broad structural similarity that includes a tricyclic ring
nucleus separated by some distance from a cationic group. Chemosensitizing agents as
diverse as the antiarrythmics amiodarone (37) and quinidine (226), the alkaloid derivative
cepharanthine (209), the lysosomotropic amines chloroquine and propranolol (208, 245,
246), the antimalarial quinacrine (109, 246), the indole alkaloid reserpine (16), and the
antiestrogen tamoxifen and structurally related triparanol analogs (67, 178), have been
reported to partially overcome resistance and cross-resistance to cytotoxic drugs, and to
increase drug accumulation and retention in various MDR cell lines (Table 4). Whether
these many types of pharmacologic agents are acting through a common mechanism to
antagonize MDR, w-hether numerous drug-target interactions are capable of mediating this
effect, or whether as a result of their degree of hydrophobicity these drugs simply cause
non-specific membrane perturbations leading to increased drug accumulation, is presently
unclear.

2g. Cyclosporines
In addition to w'ell-known immunosuppressive and cytotoxic properties, cyclosporines
have been described as having chemosensitizing activity in sensitive and MDR tumor cell
lines (233).

Structurally and pharmacologically quite different than other known

chemosensitizers, cyclosporin A (CsA) is an extremely hydrophobic cyclic peptide of 11
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amino acids. Its primary immunosuppressive activity is through the specific inhibition of an
early stage of T lymphocyte activation, apparently by interaction with the cytosolic receptor
protein, cyclophilin (94). Interest in CsA's potential anti-MDR activity was in part due to
repons of its CaM binding properties (41), though it was later clearly shown that CsA does
not specifically inhibit CaM-mediated processes (85).
Though there were several earlier reports that CsA could potentiate various cytotoxic
drugs in tumor cells (132, 163), Slater et al first studied its effect in MDR cells (217). It
was found that CsA caused a 3- to 4-fold potentiation of daunomycin toxicity in Erhlich
ascites cells with a very low level of primary resistance (2-fold) to daunomycin. It is
difficult to know whether CsA was antagonizing the MDR process per se, or simply
potentiating anthracycline activity in general, since a 2-fold potentiation of daunomycin
cytotoxicity was also noted in sensitive Erlich ascites cells (217).

Since then, several

groups have found CsA to reverse resistance and cross-resistance in MDR, but not sensitive
cells (Table 1-5) (89, 232, 234), while others have shown cytotoxic drug potentiation in
both sensitive and resistant cells.

For example, CsA caused a 10-fold enhancement of

doxorubicin toxicity in sensitive Chinese hamster ovary Aux B1 cells, and a 90-fold
enhancement in MDR, colchicine selected CHR-5 cells (34).
Also unclear is CsA's effect on drug accumulation in MDR cells. Slater et al claimed
that CsA reversed resistance but had no effect on drug accumulation in a human T cell ALL
cell line selected for vincristine resistance, with low level cross-resistance to daunomycin
(216).

However, daunomycin accumulation rather than vincristine accumulation was

measured in this experiment, and since these cells do not display an accumulation defect to
daunomycin, it is probable that they were not of the MDR phenotype. Hait et al found that
while treatment with CsA enhanced the sensitivity to doxorubicin in MDR P388/DOX cells,
but not in sensitive P388 cells, it was associated with 40% increased doxorubicin
accumulation in both lines (89). Chambers and coworkers reported a similar degree of
increased doxorubicin accumulation (50%), along with enhanced doxorubicin cytotoxicity,
in both sensitive Chinese hamster ovary cells and MDR CHR-5 cells (34). Thus, it appears
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that if, in fact, CsA specifically antagonizes MDR, it is not solely due to modification of
drug transport. Interestingly, it has recently been reported that CsA itself is accumulated
less in the P-gp overexpressing CHR-5 cells than the parent Aux B1 line, and that this
difference could be reversed with the chemosensitizer verapamil (78). This suggests that
CsA may competitively modify MDR in a manner similar to the non-toxic anthracycline
analogs, perhaps in addition to other drug potentiating effects.
More carefully designed experiments probing the effects of CsA on both primary and
cross-resistance to a wide range of drugs in both sensitive and well-defined MDR cells lines
are clearly necessary' to determine if the chemosensitizing effects of CsA are unique to the
cells of the MDR phenotype, or rather if CsA synergistically enhances the effect of certain
drugs in all tumor cell lines. More specifically, it needs to be determined whether CsA is
effecting P-gp, cytotoxic drug targets, or both.
The activity of several non-immunosuppressive cyclosporine analogs on MDR is of
great interest with regard to their mechanism of action as well as clinical potential.
Twentyman first described the anti-MDR activity of three analogs, cyclosporin C, G and H
as correlating with their immunosuppressive effects in a human small cell lung cancer line
(234). However, this group later found that the non-immunosuppressive cyclosporines
W8-032 and 133-243 were actually more effective as chemosensitizers than identical
concentrations of CsA

(Table 1-5) (232).

Similarly, the non-immunosuppressive 11-

MeLeu analog has been shown to be less potent, but equally effective as CsA in sensitizing
P388/DOX cells to doxorubicin (89). These results suggest that cyclophilin binding is not
essential to the cyclosporines' chemosensitizing effects, and that clinical reversal of drug
resistance may be possible using analogs which lack the untoward immunosuppressive and
nephrotoxic effects of CsA.
In summary-, while the cyclosporines clearly modulate drug resistance in MDR cells, it
is uncertain whether the mechanism is through reversal of MDR, potentiation of
chemotherapeutic drug toxicity, or both.

Indeed, CsA has been show-n to potentiate a
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number of drugs in vitro and in vivo both in tumor cells and normal tissues (233).

If

cyclosporine does have additional, specific chemosensitizing activity against MDR cells, it is
likely that it is mediated through different mechanisms than most other chemosensitizers,
since it does not consistently alter drug accumulation. This leads to the intriguing possibility
that CsA, in combination with another chemosensitizing agent, such as verapamil or
trifluoperazine, may act synergistically to antagonize MDR.

3.

In Vivo Effects of Chemosensitizers
The goals in studying the in vitro effects of chemosensitizers on MDR are twofold: to

further elucidate the mechanism(s) involved in MDR through its antagonism, and to identify
and characterize compounds vshich may act as effective, non-toxic modulators of intrinsic or
acquired chemotherapeutic drug resistance in clinical tumors. A number of agents identified
as having anti-MDR activity in vitro have been tested in mouse tumor models with varying
success, and intense interest surrounds the results from current and proposed clinical trials
of these agents in humans.
The potential utility of any chemosensitizing agent in vivo depends both on its ability
to potentiate the cytotoxicity of anti-cancer drugs at clinically achievable concentrations, and
its associated toxicity and unwanted side effects.

In addition, to obtain the desired

therapeutic gain by treatment with chemosensitizers, it is crucial that the enhanced toxicity
against cancer cells is not accompanied by a similar enhancement of drug toxicity to host
tissue cells. Since an ideal chemosensitizer which specifically and selectively modifies tumor
cell sensitivity to cytotoxic drugs without intrinsic toxicity or other physiologic effects has
not been identified, it is necessary to carefully test the effect of the potential
chemosensitizers in appropriate animal models before human trials begin.

3a. Effects of Chemosensitizers in Murine Tumor Models
The role of murine tumor models in identifying efficacious anti-cancer drugs and
regimens is well documented (145).

The standard in vivo model for the study of
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pharmacologic reversal of MDR has been measurement of the effect on life span of
combinations of cytotoxic and chemosensitizing drugs, injected i.p. daily for 10 days into
mice inoculated i.p. with 1x10^ to 1 x 10^ sensitive or MDR ascites tumor cells (214). A
number of the chemosensitizing agents discussed in the preceding sections have been shown
to cause an increase in the mean or median life span (ILS) in this model (Table 1-6). For
instance, daily i.p. administration of verapamil at doses of 50 to 100 mgAg caused
approximately 30 to 50% ILS in P388/VCR-bearing mice treated with vincristine or
vinblastine (227, 228, 242), 25 to 40% ILS in P388/ADR-bearing mice treated with
doxorubicin (175, 227), and 120% ILS in daunorubicin resistant Ehrlich ascites-bearing
mice treated with daunorubicin (215). Doses of verapamil greater than 125 mg/kg proved
toxic when given to mice, particularly in combination with doxorubicin or vincristine (228).
Other calcium channel blockers have shown similar activity in vivo (Table 1-6).
Accordingly, daily treatment with 125 mg/kg diltiazem, 75 mg/kg nicardipine, or 75 mg/kg
niludipine in combination with doxorubicin or vincristine caused 30 to 50% ILS in
P388/DOX and P388/VCR-bearing mice (224, 227).
Two of the structural analogs of verapamil which possessed chemosensitizing activity
in vitro have also been tested in vivo.

The synthetic isoprenoid SDB-ethylenediamine

caused up to a 48% ILS in P388/VCR-bearing mice in combination with vincristine (242).
However, 15 to 60 mg/kg of the tiapamil analog DMDP was not effective in potentiating
doxorubicin activity in P388/ADR-tumor bearing mice (175). In fact, DMDP caused a
decrease in the mean survival time, presumable due to enhanced toxicity when in
combination with doxorubicin, since measurement of intracellular drug levels in ascites
tumor cells revealed adequate anti-MDR concentrations of the chemosensitizer.
The chemosensitizers quinidine and quinacrine also possess noteworthy activity in
vivo (109, 226), with the latter causing a 85% ILS in the P388/VCR model.

The

anthracycline analog, A-acetyl-daunorubicin, which possessed no demonstrable toxicity
when given in a ratio of 20:1 with daunorubicin, caused a 53% ILS in mice bearing Erhlich
ascites tumors resistant to daunorubicin (213).
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There has only been one report of the activity' of CaM antagonists in reversing MDR in
mouse tumor models. Tsuruo et al (227) found that the relatively low dose of 20 to 30
mg/kg clomipramine, in combination with vincristine or doxorubicin, caused a 31 to 33%
increase in mean survival time of mice bearing P388/VCR or P388/ADM tumors. There
have been no published results of the effect of PTZ CaM antagonists on MDR tumors in
mice, in contrast to the extensive w'ork done in vitro with these compounds, suggesting that
this class of chemosensiuzers has proven too toxic to be used effectively in animal studies.
By far the most successful in vivo murine trial of a chemosensitizer, to date, has been
with cyclosporin A. Slater et al found that up to 80 mg/kg of CsA could be given to mice
without toxicity, and that in combination with 0.3 mg/kg daunomycin daily for 5 days,
caused an ILS of more than 200% in daunorubicin resistant Erhlich ascites tumor bearing
mice, with 10 out of 10 mice treated surviving for greater than 60 days and apparently cured
(217). 80 mg/kg CsA or 0.3 mg/kg daunomycin, when used alone, caused only a 26% ELS
and 11% ILS, respectively, in the MDR murine model, while daunorubicin alone also cured
mice bearing sensitive Ehrlich ascites cells.

Interestingly, when the dose of CsA was

sequentially reduced, as little as 5 mg/kg CsA together with daunomycin still produced an
impressive 169% ILS in the MDR tumor bearing mice.
While these in vivo results provide an important corollary to the in vitro study of
chemosensitizers, the relative simplicity of the experimental design employed ignores many
critical factors which contribute to clinical effectiveness.

For example, since many

chemosensitizers are metabolized by the liver, i.p. injection of these drugs leads to extensive
first-pass metabolism. Also, the pharmacokinetics of chemosensitizers has been poorly
studied.

Measurements of the intracellular drug concentrations achieved in tumors, in

addition to steady state plasma concentrations, are important for optimizing treatment
regimens, since most lipophilic chemosensitizers are rapidly sequestered within tissue and
plasma cells. The pharmacokinetics and anti-MDR activity of chemosensitizer metabolites
also deserve attention, since they may or may not possess significant activity themselves.
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The use of human tumor xenografts in nude mice has proven to be a valuable model for
the study of chemotherapeutic drugs in human disease (77). This system may also prove
advantageous for study of the effects of chemosensitizers in vivo, through use of either
previously selected, well-characterized MDR human tumors, or sensitive human tumors
which have been previously studied and propagated in mouse models, into which a cloned
human mdr\ cDNA is transfected. The advantage of the latter is that drug sensitivity and
optimal treatment of the parent line would already be known, and drug resistance in the
MDR line w-ould be entirely due to expression of the human mdr 1 gene. Inoculation of
tumors in extraperitoneal, subcutaneous sites also enables a more careful measurement of
tumor response to anti-MDR treatment, and investigation of intracellular drug accumulation.
In summary, experiments performed using simple mouse tumor models have thus far
suggested that the clinical reversal of drug resistance may be feasible. However, it is critical
to the eventual development of successful chemosensitizer protocols in humans that more
carefully designed, sophisticated trials of these agents be done in mice, analyzing all the
available data to optimize the treatment regimens and better screen for activity.

3b. Effect of Chemosensitizers in Human Trials
The clinical experience with chemosensitizers for the modification of acquired or
intrinsic drug resistance in human tumors is as yet extremely limited.

The few trials

reported to date have been problematic due to the significant toxicity of chemosensitizer
treatment together with the lack of adequate diagnostic analyses verifying tumor resistance
mechanisms. For example, attempts to combine verapamil with single agent chemotherapy
have so far failed, due to the intolerable cardiac effects sustained at levels of verapamil
nearing the in vitro anti-MDR range (3 to 6 jlM). In a phase I study of escalating doses of
verapamil plus 1.5 mg/m2 vinblastine for 5 days in 17 patients w'ith advanced malignancies
unresponsive to unspecified chemotherapy, no objective tumor responses w'ere noted, and
the majority of patients developed significant ECG changes, including first-degree heart
block and junctional rhythms (21). Peak plasma verapamil concentrations achieved during
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the constant i.v. infusion (0.12 mg/kg/hr) were 0.45 |iM, well below the concentrations
necessary to produce anti-MDR effects in vitro (Table 1-1). Similarly, a pilot study of oral
verapamil and Adriamycin (50 mg/m* even' 3 weeks) in 13 patients with chemotherapy
resistant tumors (8 to Adriamycin) was limited by verapamil induced nausea, hypotension,
and cardiac arrhythmias (173). While one partial response and tw'o minor responses were
noted in patients who had received prior Adriamycin, plasma or tissue levels of Adriamycin
or verapamil were not measured. However, it is unlikely that oral verapamil administration
resulted in the necessary' anti-MDR levels, based on other reports of the pharmacokinetics of
verapamil (68). In neither of these studies did verapamil appear to potentiate the cardiac
toxicity or myelosuppression of chemotherapeutic drug treatment.
Finally, a trial of escalating dose i.v. verapamil plus Adriamycin (50 mg/m2) in 8
patients with refractory' ovarian cancer again produced unacceptable toxicity, manifested by
severe hypotension, heart block and congestive heart failure, without objective response to
therapy (165). How-ever, since none of the patients had received previous Adriamycin or
other natural product drugs, but rather combinations of cyclophosphamide and cisplatin,
there wras no clear reason to believe that their tumor resistance involved the MDR
mechanism. The intensive verapamil infusion (9 |ig/kg/min) led to median and peak plasma
verapamil levels of 2 and 5 |iM, respectively. Though these concentrations are within the
range of experimentally relevant anti-MDR concentrations, verapamil is clearly too toxic in
humans to be used in this manner and at these doses.
In a recently reported trial of the CaM antagonist, trifluoperazine, plus doxorubicin, 36
patients with either acquired or intrinsic tumor resistance to prior doxorubicin therapy were
evaluated (149).

60 mg/m2 doxorubicin was given as a constant infusion, with an

escalating oral dose of trifluoperazine from 20 mg/day to 100 mg/day. Interestingly, of the
one complete response and 6 partial responses that were seen, all were in patients w'ho had
acquired, rather than intrinsic, tumor resistance to doxorubicin. Dose-limiting side effects
of this regimen were the extrapyramidal effects associated with trifluoperazine, such as
motor restlessness, akathesia, facial dystonia, and resting tremor. Trifluoperazine plasma

31

levels ranged widely, but were all less than 0.3 jiM, and thus at least 10-fold less than those
found optimal in vitro (Table 1-3).
The major problem with all of these studies is that the concentrations of
chemosensitizers at which maximum activity is found in vitro are clinically unachievable
without severe toxicity and side effects. An additional flaw, however, is that the mechanism
of tumor resistance in patients has not been determined. With the recent advent of molecular
diagnostic techniques, measurement of P-gp expression and mdr 1 mRNA levels using
immunologic and genetic probes will better define the potential for anti-MDR
chemosensitizer treatment in specific patients. As more specific and potent chemosensitizers
with less clinical toxicity and side effects enter clinical trials, it wall be critical to carefully
plan and coordinate therapeutic and diagnostic procedures, by measuring MDR markers
before and after treatment, and analyzing both tumor and plasma drug pharmacokinetics.

4.

Mechanism of Action of Chemosensitizers in Multidrug Resistance
The second major goal of studying chemosensitizers is to better understand the

molecular and biochemical mechanism of MDR through its pharmacologic reversal. Given
the extremely broad range of compounds which have been shown to effectively alter MDR,
it is difficult to envision a single common cellular mechanism or target through which these
actions are mediated. It is possible that a number of interactions with different cellular
targets may result in a similar effect on cytotoxic drug potentiation and accumulation.
However, a specific mechanism of action has not been clearly elucidated for a single
chemosensitizer. The following sections will review' a number of hypothetical mechanisms
w'hich have been suggested to be relevant to chemosensitizers’ anti-MDR action.

4a. Effects on Membrane Properties
Several investigators have made observations regarding differences in plasma
membrane order or structure in MDR versus sensitive tumor cells. For instance, Ramu et
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al have noted that P388/ADR cells have altered cellular lipid content and composition, and
possess a higher degree of plasma membrane lipid structural order than their sensitive
counterparts (179, 180). Similarly, Seigfreid found that anthracycline resistance in sarcoma
180 cells correlated with progressive increases in membrane fluidity (210). It has been
suggested that these membrane differences may contribute to the alterations in drug
accumulation seen in MDR. Since cationic, amphipathic drugs, like most chemosensitizers,
are known to interact with polar lipids such as phosphatidylserine (141), it is speculated that
chemosensitizers may cause perturbations in MDR membrane order or fluidity, resulting in
further changes in cellular drug accumulation properties.
As a model of the possible effect of membrane perturbation or destabilization on MDR,
several investigators have shown that the surface active, nonionic detergent Tw-een 80
caused alterations in drug accumulation and cytotoxicity quite similar to verapamil, and that
this effect was seen in MDR, but not in sensitive P388 cells (131, 185). How-ever, using a
different MDR P388 cell line, Inaba and colleagues could not demonstrate this effect by
Tw'een 80 (106, 107).
In further studying the possible membrane related effects of chemosensitizers, Ramu
found that perhexiline maleate, a compound known to raise phospholipid content in
fibroblasts (6), also functioned to reverse MDR (177). While this w-as cited as evidence
favoring a membrane based mechanism of action, perhexiline maleate is also known to
block calcium channels (62), resulting in vasodilatory activity similar to verapamil and other
calcium channel blockers known to reverse MDR.
The "non-specific" membrane effects of PTZ CaM antagonists have also received a
great deal of attention, both with respect to their anti-MDR activity and their antipsychotic
and cytotoxic actions (191,204). Indeed, a number of other unrelated chemosensitizers are
similar to the PTZs in that their high degree of lipophilicity results in a preferential
partitioning into membrane structures (123). How-ever, this property certainly does not
preclude their significant interaction w-ith membrane proteins such as P-gp, or other
intracellular targets, in a specific, if yet undefined, manner.
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Thus, it is not known at this time how the structural organization of MDR membranes
or their alteration by chemosensitizers may relate, if at all, to changes in drug accumulation
properties. It may be that certain chemosensitizers act within the membrane to somehow
alter the local environment in the vicinity of P-glycoprotein, leading to structural
modification and inhibition of drug efflux. Alternatively, overexpression of the membrane
protein P-gp may directly cause the alterations in membrane properties noted in MDR cells,
and these changes may simply be an epiphenomenon unrelated mechanistically to drug
accumulation.

4b. Alteration in Calcium Homeostasis
The initial discovery that verapamil and other calcium channel blockers could
antagonize MDR (227, 228, 229) prompted the suggestion that calcium may play a role in
the development or maintenance of MDR, perhaps through a calcium-dependent efflux
mechanism, and that chemosensitizers may funcuon by altering calcium fluxes. However,
mounting evidence indicates that alterations in calcium homeostasis do not effect MDR. For
example, several investigators have shown that P388 sensitive and MDR cells have similar
levels of tota.1 intracellular Ca"^ content (128, 153). Furthermore, a number of groups have
demonstrated conclusively that unlike excitable tissues, neither MDR cells nor their sensitive
counterparts possess calcium channels, since calcium uptake was not altered by membrane
voltage potentials or calcium channel blockers in MDR or sensitive cells P388, Chinese
hamster ovary or

glioblastoma cells (29, 102, 128, 181). Similarly, whole-cell and

single-channel patch-clamp techniques demonstrated that both drug sensitive CCRF-CEM
and MDR CEM/VLBiqq cells lack voltage-gated calcium channels (135).
Even more compelling evidence against calcium fluxes effecting MDR was provided by
two studies which pharmacologically manipulated calcium levels to mimic the effect of
calcium channel blockers in those excitable tissues which express calcium channels.
Accordingly, treatment of MDR C6 cells with manganese ion, which produces a reduction
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in calcium uptake by a non-competitive inhibition of calcium fluxes, or the calcium
ionophore A23187, which causes increased calcium uptake through artificial channels, had
no influence on doxorubicin accumulation or cytotoxicity (102). Similar results were found
by alteration in net intracellular calcium by reduction of extracellular calcium concentrations
or chelation of calcium ions by EGTA (177).

In all of these states of altered calcium

homeostasis, verapamil maintained its anti-MDR activity without change.

Thus, it is

apparent that alterations in calcium flux do not alter the level of drug resistance in MDR or
sensitive cells, and that calcium channels are not the target of chemosensitizers in this
system.

4c. Inhibition of Calmodulin Mediated Processes
Similar to the situation for calcium channels blockers, the finding that PTZs and other
CaM antagonists modulate MDR implicated CaM in the regulation or reversal of MDR.
However, definitive evidence as to the role of CaM-mediated events in MDR is lacking. It
is known that CaM is involved in the regulation of a wide variety of critical cellular
functions (144). Particularly relevant to MDR is CaM's role as an activator of plasma
membrane Ca

-ATPase ion pumps (81, 159), and as a stimulator of protein kinase

mediated phosphorylation and dephosphorylation (201, 202), all processes which are
inhibited by CaM antagonists (176, 241).

Whether CaM may activate or regulate the

function of P-gp in MDR is a provocative, but unanswered, question.
Attempts to compare CaM levels in sensitive versus MDR cells found no gross
differences levels between P388 and P388/DOX cells (153), nor between CEM and
CEM/VLBjoo cells (13). Whether the primary structure or function of CaM in MDR cells is
in any way altered is not known. Several investigators have attempted to correlate the
potency of CaM antagonists as inhibitors of CaM-mediated processes with their
chemosensitizing activity in MDR cells, with conflicting results. For example, Ganapathi
studied three PTZ CaM antagonists, trifluoperazine, prochlorperazine and chlorpromazine,
and the naphthalene-sulfonamides W12 and W13 in P388/DOX cells, and found that their
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potency in this system was in general agreement with their relative anti-CaM potency (73).
Accordingly, trifluoperazine was more potent and more effective at equimolar concentrations
than prochlorperazine and chlorpromazine, and W13 was more effective than the poor CaM
inhibitor W12.

Unfortunately, a statistical analysis of the degree or significance of

correlation between anti-CaM and anti-MDR activity was not performed, nor were structural
analogs or metabolites lacking CaM inhibitor)' properties examined. It is of interest that
W12 and W13, drugs with similar hydrophobicity and structure (99), displayed relatively
different effects on MDR (Table 1-3), implying that non-specific hydrophobicity alone is not
sufficient to alter MDR, as some have suggested for inhibition of CaM (192). However,
both Tsuruo (229) and Akiyama (5) reported that the chemosensitizing activity of
trifluoperazine, thioridazine and chlorpromazine in KB-ChR-24 cells, respectively, did not
correlate with known IC$o’s for the inhibition of CaM by these drugs.

Furthermore,

Akiyama found that the potent CaM antagonists W7 and W5 were equally poor
chemosensitizers, although W7 was a significantly more potent CaM antagonist (99).
Clearly, the sample size in each of these studies was far too small to make any definate
conclusions regarding the role of CaM antagonism in the modulation of MDR. In addition,
the well known "non-specific" nature of PTZs and other CaM antagonists make attempts to
analyze their effects on whole cells extremely difficult for any system. Nevertheless, a more
rigorous and systematic study of the pharmacologic relationship between CaM antagonists
and reversal of MDR is certainly warranted. While a positive correlation would not directly
implicate CaM's role in MDR, it may suggests that anti-CaM activity is a useful marker for
chemosensitizer activity, possibly leading to the identification of novel modifiers of MDR.

4d. Inhibition of Protein Kinase C
A great deal of provocative evidence has been reported implicating a possible regulator)'
role for the phospholipid/Ca^-dependent protein kinase (PKC) in MDR, suggesting that
interaction of chemosensitizers with PKC may be important. For example, a number of
chemosensitizers, such as the PTZs and verapamil, are also known to inhibit the activity of
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PKC in isolated systems (150, 200). Several groups have found increased levels of PKC in
the MDR human breast cancer line, MCF-7/DOX (59, 166), and preliminary evidence
suggests that the pattern of expression of PKC isoforms may be altered in MDR cells (1,8).
Treatment of a variety of cell lines with activators of PKC, such as the phorbol ester 12-0tetradecanoylphorbol-13-acetate (TPA), results in transient increases in cellular drug
resistance as well as changes in drug accumulation. Specifically, treatment of sensitive
human KB cells with TPA caused a transient, 2-fold protection against the cytotoxicity of
VP-16, vincristine and mitoxantrone, which could be circumvented by co-administration of
verapamil (58). Similarly, phorbol ester increased the resistance of both sensitive MCF-7
and MDR MCF-7/DOX cells to doxorubicin and vincristine (59), and increased the
resistance of P388, though not P388/DOX, cells to daunomycin (127). Furthermore, the
relatively specific PKC inhibitor, l-(5-isoquinolinylsulfonyl)-2-methylpiperazine (FI-7),
inhibited the phorbol ester induced decrease in P388 cell vincristine uptake (105).
Since the activation of PKC by phorbol ester in MDR and other cell types results in the
phosphorylation of several proteins possibly associated with MDR (7, 59), it is intriguing to
speculate on the possible modulation of P-gp function by PKC.

Indeed, it has been

reported that phorbol ester causes an increase in P-gp phosphorylation (90). Paradoxically,
verapamil and trifluoperazine also have been reported to cause a hyperphosphorylation of Pgp, though apparently at different residues (32). Whether the effect of chemosensitizers on
P-gp phosphorylation states is mediated by PKC is presently not known.
Thus, it appears that within the calcium messenger system, PKC is a target for many
chemosensitizers, and may mediate the regulation or modulation of MDR. However, a great
deal of work is necessary to better define the doubtlessly complex regulatory mechanisms
effecting P-gp before the role of chemosensitizers in altering or modulating the system may
be determined.
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4e. Interaction with P-glycoprotein
Ln the preceding sections, several theories have been discussed regarding the possible
modulation of MDR by the known interactions of certain chemosensitizers with aspects of
the calcium mediated second messenger system.

It is also quite possible that

chemosensitizers act by directly blocking or altering the function of P-gp, and in fact,
several lines of evidence suggest that this may be the case for certain anti-MDR agents.
First, with the recent discover}’ of P-gp and its putative role as a membrane drug efflux
pump (38), it is important to recall the earlier studies demonstrating the chemosensitizing
effect of non-toxic anthracycline and Vinca alkaloid analogs (110, 213) (discussed in
Section A.2e). The apparent competitive inhibition of drug efflux in MDR cells displayed
by these compounds suggests that one or more specific drug binding sites may exist in Pgp, and that agents which bind to these sites with similar or greater affinity inhibit P-gp
mediated cytotoxic drug efflux and result in increased cellular cytotoxic effect
More recent evidence that cytotoxic drugs and some MDR antagonists bind to P-gp
came from experiments with preparations of P-gp enriched MDR membrane vesicles.
Cornwell et al first noted that [3HJ-vinblastine bound with an affinity constant of 1.5 |iM in
a specific, saturable, temperature-dependent manner to membrane vesicles from MDR KBC4 cells, but did not bind to sensitive KB-3-1 or revertant KB-R1 cell membranes (43).
This binding was strongly inhibited by excess unlabeled vinblastine, vincristine, and
verapamil, less so by daunomycin, and poorly inhibited by colchicine (43). Safa and others
used photoactive analogs of vinblastine ([^Hj-NABV and 125I-NASV) w'hich irreversibly
bind to MDR cell membrane fractions (45), to identify vinblastine acceptor proteins (198). A
150 - 180 kDa photoaffinity labelled membrane protein was found specifically in MDR cell
lines and was immunoprecipitated with a polyclonal antibody known to cross-react with Pgp from other cells. In addition, verapamil inhibited 125I-NASV photoaffinity labelling of a
170 kDa KB-V1 cell membrane protein which was immunoprecipitated with a monoclonal
antibody to P-gp (44). Further studies of the competitive binding of chemosensitizers to Pgp found that (i) KB-VI MDR vesicles bound 15- to 20-fold more verapamil and diltiazem
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than sensitive KB-3-1 vesicles, in a specific and saturable manner (44), (ii) the
chemosensitizers verapamil, nicardapine, quinidine, and to a lesser extent trifluoperazine,
inhibited [^HJ-vincristine binding to K562/ADM membrane vesicles (154), and (iii) INI¬
NAS V photoaffinity labeling of KB-V1 and CEM/VLB u<_ P-gp was effectively inhibited by
10 to 12.5 |iM concentrations of reserpine, cepharanthine, quinidine, and the isoprenoid
SDB-ethylenediamine, but poorly inhibited by up to 100 pM concentrations of the PTZ
chemosensitizers trifluoperazine, thioridazine and chlorpromazine (2, 16). These results
strongly suggest that certain chemosensitizers, such as the calcium channel blockers and
structurally related isoprenoids, compete with the Vinca alkaloids for a common P-gp
binding site. Additional experiments with photoactive, radiolabelled verapamil analogs,
such as [-H]-azidopine and 125I-NASAV, further implicate a common acceptor for these
drugs, since nifedipine, nicardapine, verapamil and vinblastine effectively inhibit their
irreversible binding to P-gp, but trifluoperazine, chlorpromazine, doxorubicin and
colchicine do not (196, 197, 199, 243).
In addition, MDR cell membrane vesicles have been shown to inwardly transport [3H]vinblastine in an A TP-dependent fashion (101). Using this simplified model of MDR,
investigators have shown that vinblastine transport is inhibited by competitive and non¬
competitive inhibition of ATP, as well as by vinblastine, vincristine, verapamil, quinadine,
and less potently by daunomycin and colchicine.
A fourth, independent line of evidence that chemosensitizers may interact w’ith P-gp
came from the recent purification and partial characterization of P-gp by Hamada and Tsuruo
(92, 93).

Enzymatically active P-gp w'as purified from human K562/ADM cells by

immunoaffinity chromatography, and found to possess ATPase activity (93). Interestingly,
while vincristine and doxorubicin did not affect the ATPase activity of immobilized P-gp,
the chemosensitizers trifluoperazine and verapamil caused increased activity (92). Since
PTZs are known to inhibit the activity of other ATPases (167, 176), it is possible that
trifluoperazine interferes with a P-gp mediated drug efflux mechanism in a similar manner,
although it is paradoxical as to why an increase is seen in ATPase activity. It is anticipated
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that further studies of the ATPase function of P-gp will focus on its possible role as a target
for chemosensitizers.
Thus, it appears that there are at least several sites on P-gp through which
chemosensitizers may interfere with the MDR process. Since a number of chemotherapeutic
drugs encompassed by the MDR phenotype, such as doxorubicin, daunomycin and
colchicine, do not appear to competitively bind to the calcium channel blocker/vinblastine
acceptor on P-gp, it is possible that there may be other independent drug binding sites
within the same molecule that lead to active efflux, or that a family of drug binding proteins
may exist, which display different affinities for various classes of compounds.
Chemosensitizers such as the PTZs may specifically bind to these additional sites and
antagonize MDR, although this cannot explain why such agents most often similarly affect
Vinca alkaloid, anthracycline and colchicine drug accumulation and resistance.
Alternatively, PTZs and other chemosensitizers may inhibit P-gp activity by interacting with
physically separate sites on P-gp, such as the ATPase or phosphorylation domains, or act
by altering the local membrane environment leading to structural or functional changes in PgP-

4f. Inhibition of Lysosomal Function
The demonstration by Akiyama and coworkers that verapamil affected the function of
lysosomes by inhibiting their degradation of cellular proteins (3, 4), led to the discovery that
certain other lysosomotropic agents, such as propranolol (226) and chloroquine (208, 245),
could also partially reverse MDR. These findings, together with the fact that cytotoxic
concentrations of vinblastine or doxorubicin caused an increased number of lysosomal-like
vacuoles in cells (245), suggested an alternative hypothesis for the cellular mechanism of
MDR, proposed by both Beck (14) and Sehested el al (205).

This theory can be

summarized as follows: lysosomes or other intracellular acidic compartments in MDR cells
protonate and entrap weakly basic drugs such as doxorubicin or vinblastine, which are then
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extruded from the cells by vesicular fusion with the plasma membrane. In this scheme, Pgp serves not as a drug efflux pump, but rather to alter or direct membrane turnover or
vesicular trafficking (14). Since verapamil and chloroquine appear to disrupt lysosomal
functions, they may therefore interrupt the ability of vesicles to transport drug out of cells,
resulting in increased drug reaching its cytotoxic target.

In support of this, the

microfilament-disrupting agent, cytochalasin B, also inhibited drug efflux and enhanced
cytotoxicity, though in sensitive as well as MDR cells (130, 225). Recently, however,
Beck's group reported that a number of additional lysosomotropic amines, such as
methylamin, suramin, trypan blue, and epinephrine, did not potentiate the cytotoxicity of
vincristine in MDR CEM/VLBiqo cells (246), from which it was concluded that the ability
to impair lysosomal function was not sufficient to alter MDR. It may be that lysosomes
function as an alternative, unrelated but reversible mechanism for drug detoxification in both
sensitive and MDR cells, although this remains to be determined.

5.

Future Directions
The preceding sections demonstrate that while a tremendous amount of data exists

regarding the effects of a host of chemosensitizers on the cellular pharmacology of MDR cell
lines, very' little is yet known about their mechanism of action. Since such a wide variety of
agents possessing remarkably varied cellular effects reverse MDR, it is clearly necessary to
carefully study the anti-MDR activity of drugs within a single pharmacologic class,
attempting to define their possible cellular targets and the structural features which enhance
their interaction with this target. Indeed, if specific structural features determine anti-MDR
activity, rather than non-specific properties, it is likely that their mechanism of action is
mediated by classical receptor-ligand interactions, implying that the rational design of
structurally optimal agents may result in increased specificity and potency.
To this end, systematic and statistically significant structure-activity relationships of the
chemosensitizing effects of individual classes of pharmacologic compounds need to be
performed to:
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(i)

Define the specific structural features, if any, necessary for the
pharmacological reversal of MDR, and possibly identify an optimal
'pharmacophore' for this activity' or target

(ii)

Identify the relevant target(s) for the chemosensitizing effects of a
particular class of drugs and characterize the drug-target interactions

(iii)

Identify more specific, potent and less clinically toxic drugs with which
to possibly antagonize MDR in a clinical setting

(iv)

Better define and elucidate the molecular mechanism of MDR itself

(v)

Identify the natural substrate for P-gp and define its biological role.

The present study addresses the first three of these points. Specifically, systematic
structure-activity relationships for the chemosensitizing effects of a series of closely related
PTZ CaM antagonists and structurally related compounds were performed, and the role of
non-specific hydrophobic effects versus specific interactions w’ith CaM assessed. Based on
the structural determinants found necessary' for PTZ anti-MDR activity, a novel class of
chemosensitizing agents w-as identified and their effect on MDR in vitro and in vivo was
extensively characterized. In addition, initial steps were taken toward characterizing their
mechanism of action for the antagonism of MDR.
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TABLE 1-1
Summary of Studies Using Verapamil to Reverse Multidrug Resistance

[Verapamil] (|iM)

Cell Line

Cytotoxic Drug
(Fold Resistance)

Fold
Reversal

Reference

P3 8 8/VCR

VCR
VLB
VCR
VLB

(31)
(7)
(31)
(7)

122
7
34
7

Tsuruo, 1981

3.3
6.6

P388ArCR

VCR (20)

26
84

Tsuruo, 1982

10

P388/VCR

VCR (20)
VLB (12)

40
7

Tsuruo, 1985

3.3
6.6

P388/ADM

DOX (43)

12
13

Tsuruo, 1982

10

P388/ADR

DOX (27)
DAU (19)

9
9

Tsuruo, 1985

30

P388/ADR

DOX (40)

28

Ramu, 1984

10

P388/ADR

DOX (51)
DAU (38)

11
9

Klohs, 1986

10

P388/DOX

DOX (37)

8

6

P388/ADR

DOX (100)

40

EA/DAU

DAU (5)

6.6

K562A'CR

VCR (17)
DOX (3)

61
4

Tsuruo, 1982

6

C6/DOX

DOX (20)

10

Huet, 1988]

1

CHO/B30

DAU (100)

8

10

8226/DOX40

DOX (50)

40

Bellamy, 1988

6

MES-SA/Dx5

DOX (100)
DAU (100)
MITO (60)
ActD (1200)
VLB (100)
VCR (240)

7
14
8
9
1
1

Harker, 1986

6.6
2.2

(Continued)

Kramer, 1988

11

Radel, 1988

4

Slater, 1982

Cano-Gauci, 1987
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TABLE 1-1
(Continued)

[Verapamil] (pM)

Cell Line

Cytotoxic Drug
(Fold Resistance)

Fold
Reversal

Reference

10

CE M/VLB j oo

VLB (420)

22

Zamora, 1988

10

CE M/VLB

VLB (930)

21

Beck, 1988

10

MCF-7/DOX

DOX (100)
VCR (100)

10
10

Fine, 1988

20

MCF-7/DOX

DOX (100)

7

20

KB-ChR 8-5-11 -24

CH (220)
DOX (21)
VLB (23)
VCR (73)

2

2780^

DOX (100)

4

Schuurhuis, 1987

1

2780^0

Rogan, 1984

1847^

DOX (170)
DOX (5)

6

1

6

63
23
38
183

Kramer, 1988
Fojo, 1985

22

DC-3F/AD

DOX (100)
ActD (4200)

20
85

Delaporte, 1988

6.6

NCI-H69/LX4

19
72
5
4

Twentyman, 1986

MOR/DOX
COR-L23/DOX

DOX (85)
VCR (750)
DOX (12)
DOX (12)

HCT-8
Colon 26
LoVo

DOX (NE)
DOX (NE)
DOX (NE)

4
4
3

10

Klohs, 1988

Abbreviations: ActD, actinomycin D; CH, colchicine; DOX, ADR, ADM, doxorubicin; DAU,
daunomycin; EA, Ehrlich ascites; MITO, mitoxantrone; VCR, vincristine; VLB, vinblastine.
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TABLE 1-2
Summary of Studies Using Verapamil Analogs and Other Calcium Channel
Blockers to Reverse Multidrug Resistance

Chemosensitizer

Fold
Reversal

Reference

DOX (100)

15

Kessel, 1985

P388/ADR
P388/DOX

DOX (100)
DOX (100)

15
19

Kessel, 1985
Radel, 1988

P388/ADR

DOX (100)

15

Kessel, 1985

34 Jig/ml

KB-ChR-24

DOX (28)
VCR (89)

35
55

Nakagawa, 1986

1 OOfig/ml

P388/ADM

DOX (37)
DAU (19)
VCR (17)
ActD(10)
VCR (8)
DOX (10)

3
2
3
4
33
10

Yamaguchi, 1986

DOX (51)
VCR (21)
VCR (20)
VLB (12)
DOX (27)
DAU (19)

3
9
29
7
9
5

Klohs, 1986
Tsuruo, 1983a
Tsuruo, 1985

[pM]

Cell Line

Tiapamil

500

P388/ADR

DMDP

20
3
1

Tiapamil Analog
(Ro-2933)
SDB-ethylenediamine

P388/VCR

Diltiazem

20
35

P3 8 8/ADR
K562/VCR
P3 8 8/VCR
P38 8/ADR

Cytotoxic Drug
(Fold Resistance)

100

P388/VCR
P388/ADM

VCR (15)
DOX (49)

29
16

Tsuruo, 1983b

Nifedipine

3
100

P388/ADR
P3 8 8/VCR
P388/ADM

DOX (50)
VCR (15)
DOX (49)

1
12
4

Ramu, 1984c
Tsuruo, 1983b

Niludapine

10

K562/VCR
P3 8 8/VCR
P3 8 8/VCR

VCR (21)
VCR (15)
VCR (20)
VLB (12)
DOX (49)
DOX (27)
DAU (12)

48
26
25
7
10
10
3

Tsuruo, 1983a
Tsuruo, 1983b
Tsuruo, 1985

P388/ADM
P388/ADM

(Continued)

Tsuruo, 1983b
Tsuruo, 1985
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TABLE 1-2
(Continued)

Chemosensitizer

[M-MJ

Cell Line

Cytotoxic Drug
(Fold Resistance)

Fold
Reversal

Reference

Nimodipine

35

K562/VCR
P3 8 8/VCR
P388/ADM

VCR (21)
VCR (15)
DOX (49)

54
26
15

Tsuruo, 1983a
Tsuruo, 1983b

Nicardapine

3

K562/VCR
P388/VCR
P388/ADM
P388/ADR

VCR (21)
VCR (15)
DOX (49)
DOX (50)

25
33
4
4

Tsuruo, 1983a
Tsuruo, 1983b

K562/VCR
P388/VCR
P3 8 8/VCR

VCR (21)
VCR (15)
VCR (20)
VLB (12)
DOX (49)
DOX (27)
DAU (19)

52
70
70
7
27
27
9

Tsuruo, 1983a
Tsuruo, 1983b
Tsuruo, 1985

P388/VCR
P388/ADM
K562/VCR

VCR (20)
DOX (40)
VCR (17)

19
8
11

Tsuruo, 1982

P388/VCR
P388/ADM
K562/VCR

VCR (20)
DOX (40)
VCR (17)

22
11
40

Tsuruo, 1982

CHR C5

DOX (195)

74

Schuurhuis, 1987

2780^

DOX (140)

10

Schuurhuis, 1987

10

P388/ADM
P38 8/ADR

Caroverine

Prenylamine

Bepridil

6.6

6.6

4

Ramu, 1984c

Tsuruo, 1983b
Tsuruo, 1985

Tsuruo, 1983a

Tsuruo, 1983a

Abbreviations: ActD, actinomycin D; CH, colchicine; DOX, ADR, ADM, doxorubicin; DAU,
daunomycin; VCR, vincristine; VLB, vinblastine.
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TABLE 1-3
Summary of Studies Using Calmodulin Antagonists to
Reverse Multidrug Resistance

Chemosensitizer
Trifluoperazine

Thioridazine

[pM]

Cell Line

Cytotoxic Drug
(Fold Resistance)

Fold
Reversal

Reference

3.3

P3 8 8/VCR
P38 8/ADM

VCR (20)
DOX (43)

10
5

Tsuruo, 1982

2

P388/ADR

DOX (51)

2

Klohs, 1986

4

P388/DOX

DOX (100)

5

Ganapathi, 1983b

4

P388/DOX

DOX (100)

10

Ganapathi, 1984a

5

P388/DOX

DOX (100)
DAU (100)

10
15

Ganapathi, 1984a

2

P388/DOX

VLB (20)
VCR (100)

5
7

Ganapathi, 1986

3.3

P388/ADM
P3 8 8/VCR
K562/VCR

DOX (27)
VCR (26)
VCR (17)

5
10
25

Tsuruo, 1983

6.6

K562/VCR

VCR (17)

25

Tsuruo, 1983a

5

KB-ChR-24

CH (115)
DOX (50)
DAU (36)
VLB (40)
VCR (68)

58
19
15
40
12

Akiyama, 1986

5

LI 210/0.025
LI 210/0.05
L1210/0.1
L1210/0.25

DOX
DOX
DOX
DOX

(5)
(10)
(20)
(40)

3
4
7
8

Ganapathi, 1988

1

P388/ADR

DOX (50)

3

Ramu, 1984c

4

KB-ChR-24

CH (115)
DOX (50)
DAU (36)
VLB (40)
VCR (68)

14
30
28
44
15

(Continued)

Akiyama, 1986
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TABLE 1-3
(Continued)

Cell Line

Cytotoxic Drug
(Fold Resistance)

Fold
Reversal

Chemosensitizer

[pM]

Chlorpromazine

4

P388/DOX

DOX (100)

3

Ganapathi, 1984b

10

CEM/VLB jqq

VLB (420)

11

Zamora, 1988

5

KB-ChR-24

CH (115)
DOX (50)
DAU (36)
VLB (40)
VCR (68)

4
9
7
4
2

Akiyama, 1986

Prochlorperazine

4

P388/DOX

DOX (100)

5

Ganapathi, 1984b

Clomipramine

10

P3 8 8/VCR
P388/ADM

VCR (20)
DOX (43)

22
4

Tsuruo, 1982

6.6

K562/VCR

VCR (17)

14

Tsuruo, 1983a

6.6

P3 8 8/VCR
P388/ADM
K562/VCR

VCR (26)
DOX (27)
VCR (17)

12
4
14

Tsuruo, 1983

W12

20

P388/DOX

DOX (100)

1

Ganapathi, 1984b

W13

20

P388/DOX

DOX (100)

2

Ganapathi, 1984b

Reference

Abbreviations: CH, colchicine; DOX, ADR, ADM, doxorubicin; DAU, daunomycin; VCR,
vincristine; VLB, vinblastine.
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TABLE 1-4
Summary of Studies Using Anthracvcline and Vinca Alkaloid Analogs,
Lysosomotropic Agents, and Other Drugs to Reverse Multidrug Resistance

Chemosensitizer

[pM]

Cell Line

Cytotoxic Drug
(Fold Resistance)

Fold
Reversal

Reference

ID-8279

2

P3 8 8/VCR

VCR (50)
DAU (10)

50
5

Inaba, 1984

Vindoline

10 (ig/ml

P388/VCR

VCR (50)
VLB (20)
DOX (10)
DAU (10)
DOX (200)
DAU (200)

50
50
10
10
100
100

Inaba, 1986

Zamora, 1988

P388/DOX

Chloroquine

50

CE M/VLB joo

VLB (420)

>42

10

CEM/VLB1K

VLB (930)

13

Beck, 1988

10

P388/ADR

DOX (50)

2

Ramu, 1984c

KB-ChR-24

DOX (38)
DAU (18)
VCR (139)
VLB (24)
ActD (24)

4
3
3
2
4

Shiraishi, 1986

50

CEM/VLB100

VLB (157)
VCR (600)
DOX (112)
DAU (124)

13
10
3
4

Zamora, 1986

50

CE M/VLB jog

VLB (420)

10

Zamora, 1988

50

CEM/VLB ii^

VLB (930)

10

Beck, 1988]

P3 8 8/VCR
P388/ADR

VCR (15)
DOX (240)

15
5

Inaba, 1988

5

CEM/VLB ioo

VLB (420)

12

Zamora, 1988

50

CEM/VLB u<^

VLB (930)

10

Beck, 1988

10

P3 8 8/VCR
K562/VCR
P388/ADM

VCR (16)
VCR (65)
DOX (41)

82
50
8

Tsuruo, 1984

CEM/VLB ioo

VLB (420)

>32

Zamora, 1988

2 (ig/ml

Quinacrine

Quinidine

Quinine

0.5 (ig/ml

100

(Continued)

49

TABLE 1-4
(Continued)

Chemosensitizer

[pM]

Cell Line

Cytotoxic Drug
(Fold Resistance)

Reversal

Reference

Fold

10

P388/ADR

DOX (20)
VLB (25)

12
14

Ramu, 1984a

10

MCF-7Ad

DOX (12)
VLB (500)

3
9

Foster, 1988

3

P388/ADR

DOX (32)

12

Ramu, 1984b

10

MCF-7Ad

DOX (12)
VLB (500)

3
8

Foster, 1988

Triparanol

3

P388/ADR

DOX (32)

10

Ramu, 1984b

Reserpine

5

CE M/VLB jqq

VLB (420)

>42

Zamora, 1988

5

CEM/VLB ^

VLB (930)

120

Beck, 1988

2 pg/ml

KB-ChR-24

DOX (117)
DAU (17)
VCR (105)
ActD (43)

25
16
87
39

Shiraishi, 1987

Perhexiline Maleate

Tamoxifen

Cepharan thine

Amiodarone

4

DHD/K12/TR

DOX (NR)

32

Chauffert, 1986

Dipyridamole

10

P388/ADR

DOX (50)

15

Ramu, 1984c

Friend Leukemia

DOX (1000)
DAU (1000)

2
3

Tapiero, 1988

Aclacinomycin A 5 pg/ml

Abbreviations: ActD, actinomycin D; Ch, colchicine; DOX, ADR, ADM, doxorubicin;

DAU, daunomycin; VCR, vincristine; VLB, vinblastine.
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TABLE 1-5
Summary of Studies Using Cyclosporines to Reverse Multidrug Resistance

Chemosensitizer
Cyclosporin A

[fig/ml]

Cell Line

Cytotoxic E>rug
(Fold Resistance)

Fold
Reversal

Reference

13.2

EA/DAU

DAU (2)

3

Slater, 1986b

13.2

GM3639/L100

VCR (60)
DAU (5)

50
4

Slater, 1986a

10}iM

Hepatoma 129

DAU (NR)

2

Meador, 1987

5

NCI-H69/LX4

DOX (60)
VCR (1200)

25
200

Twentyman, 1987

2

NCI-H69/LX4

DOX (100)
VCR (150)

9
32

Twentyman, 1988

1

CHR C5
Aux B1 (S)

DOX (90)
DOX (1)

90
10

Chambers, 1988

1

P388/DOX

DOX (100)

8

Cyclosporin C
Cyclosporin G

5
5

NCI-H69/LX4
NCI-H69/LX4

DOX (60)
DOX (60)

8
90

Twentyman, 1987
Twentyman, 1987

Cyclosporin H

5

NCI-H69/LX4

DOX (60)

2

Twentyman, 1987

32W8-032

2

NCI-H69/LX4

DOX (100)
VCR (150)

9
167

Twentyman, 1988

B3-243

2

NCI-H69/LX4

DOX (100)
VCR (150)

55
50

Twentyman, 1988

11-MeLeu CsA

1

CHR C5
Aux B1 (S)

DOX (90)
DOX (1)

8
10

Chambers, 1988

11-MeLeu CsA

1

P388/DOX

DOX (100)

8

Hait, 1989

Hait, 1989

Abbreviations: CH, colchicine; DOX, doxorubicin; DAU, daunomycin; EA, Ehrlich ascites;

S, sensitive; VCR, vincristine.
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TABLE 1-6
Summary of In Vivo Studies to Reverse Multidrug Resistance

Chemosensitizer

Tumor

_Dose (mg/kg)
CS
Drug

Verapamil

P388/VCR

Verapamil

EA/DR

Verapamil

P388/DOX

0
0
75

Verapamil

Sarcoma 180

Verapamil

0
0
50
50
100
100
0
25
50

Schedule

0.03
0.2
0.1
0.2
0.03
0.1
0.4
0.4
0.4

qd x 10

DOX

0
1.0
1.0

0
10
10

BOU

P388/VCR
P388/ADM

100
125

SDB-ethylenediamine

P388/VCR

DMDP

ILS
(+%)

Reference

0
0
34
29
29
45
8
120
106

Tsuruo, 1981

qd x 8

2
7
25

Radel, 1988

0.6
0.0
0.6

qd x 4

0
5
45

Chitnis, 1985

VCR
ADM

0.1
1.0

qd x 10

45
37

Tsuruo, 1983

0
0
40
40
40

VCR

0.03
0.1
0.0
0.03
0.1

qd x 8

10
22
12
48
44

Yamaguchi, 1986

P388/DOX

0
60
60

DOX

10
0
10

qh x 4 (DMDP)
qd x 1 (DOX)

16
4
-36

Diltiazem

P388/ADM

100
125

DOX

1.0
1.0

qd x 10

27
40

Tsuruo, 1983b

Diltiazem

P388A/CR
P388/ADM

125
125

VCR
ADM

0.1
1.0

qd x 10

32
40

Tsuruo, 1983

Nicardapine

P388/ADM

75

DOX

1.0

qd x 10

43

Tsuruo, 1983b

Nicardapine

P3 88/VCR
P38 8/ADM

100
125

VCR 0.1
ADM 1.0

qd x 10

51
43

Tsuruo, 1983

Niludapine

P388/ADM

75

DOX

1.0

qd x 10

33

Tsuruo, 1983b

Niludapine

P388/VCR
P388/ADM

100
125

VCR 0.1
ADM 1.0

qd x 10

50
33

Tsuruo, 1983

VCR

DAU

(Continued)

qd x 5

Slater, 1982

Radel, 1988
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TABLE 1-6
(Continued)

Chemosensitizer

Tumor

Clomipramine

P388/VCR
P388/ADM

N-AcetylDaunorubicin

EA/DR

Quinidine

Dose (ms/kc)
CS
Drug

Schedule

ILS
(+%)

Reference

100
125

VCR
ADM

0.1
1.0

qd x 10

31
8

Tsuruo, 1983

0
30
30

DAU

1.5
0.0
1.5

qd x 4

0
0
53

Skovsgaard, 1980

P388/VCR

0
0
125
125

VCR

0.0
0.2
0.0
0.2

qd x 10

0
19
2
41

Tsuruo, 1984

Quinacrine

P388/VCR

0
0
40
40

VCR

0.0
0.1
0.0
0.1

qd x 5

0
30
29
85

Inaba, 1988

Cyclosporine A

EA/DR

0
0
80
12.5
5

DAU

0.0
0.3
0.3
0.3
0.3

qd x 5

0
11
>215
183
169

Slater, 1986b

Cyclosporine

Hep 129

0
0
10
10

DAU

0.0
0.4
0.0
0.4

qd x 2

0
26
10
69

Meador, 1987

Abbreviations: BOU, bouvadin; ; DOX, ADM, doxorubicin; DAU, daunomycin; EA/DR,

Ehrlich ascites/daunomycin resistant; VCR, vincristine.
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Chapter II
STRUCTURE ACTIVITY RELATIONSHIPS OF PHENOTHIAZLNES
AND RELATED DRUGS FOR INHIBITION OF CELL GROWTH AND
REVERSAL OF MULTIDRUG RESISTANCE

A. Introduction
The recent demonstration and elucidation of the phenomenon of MDR has led to the
search for drugs that could sensitize highly resistant cancer cells to chemotherapeutic agents.
As reviewed in Chapter I (Section D.2), several PTZs have been shown to be among the
group of drugs known to modify MDR. As a class of chemosensiuzers, the PTZs present a
unique opportunity to study the importance of molecular structure on the antagonism of
MDR, since a large number of PTZs and structurally related compounds have been
synthesized but have not been studied as MDR chemosensitizers.
PTZs are also known to inhibit the activity of several cellular enzymes (167, 193, 195)
and block the function of critical cellular receptors, such as those for dopamine (47).
Among these cellular targets is calmodulin, a mulufunctional calcium-binding protein (137)
that has been implicated in the regulation of numerous cellular events, including that of
normal and abnormal cellular proliferation (86, 182, 238).

Consistent with these

observations was the demonstration that PTZs and other CaM antagonists possess
antiproliferative and cytotoxic effects (113) in proportion to their anti-CaM activity (84, 87,
136, 239). Although the mechanism by which PTZs and other drugs modulate MDR is not
clear, it has been suggested that their pharmacological properties may be mediated by the
calcium messenger system, since the active compounds are known to inhibit voltagedependent calcium channels (62), CaM (241), and protein kinase C (200).
To elucidate the structural features required for the activity of PTZs and related
compounds against cellular proliferation and MDR, the effects of a series of drugs with
single molecular alterations have been studied for their ability to inhibit cell growth and to
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sensitize the human MDR breast cancer cell line MCF-7/D0X to doxorubicin. Furthermore,
to clarify the role of CaM in these processes, the anti-CaM effects of these compounds have
been compared to their effects on cellular proliferation and MDR.

B . Materials and Methods
1.

Cell Lines and Culture
MCF-7 human breast cancer cells, and the multidrug resistant subclone MCF-7/DOX

(kindly supplied by Dr. Ken Cowan, National Cancer Institute, Bethesda, Maryland),
selected by stepwise exposure of parental cells to increasing concentrations doxorubicin,
were maintained in exponential growth in Coming 75 cm- tissue culture flasks in RPMI
1640 medium supplemented with 5% fetal bovine serum in a humidified atmosphere of 5%
CO2 and 95% air.

MCF-7/DOX cells were approximately 200-fold more resistant to

doxorubicin than the parental cell line, and maintained a stable MDR phenotype while grown
in drug-free medium for a period of at least 3 months, after which they were discarded. Cell
lines were routinely tested and found to be free of contamination by mycoplasma or fungi.

2.

Effect of Drugs

on

Cellular Proliferation

and Multidrug Resistance

Cells in exponential growth were digested with 0.5% trypsin (Gibco, Grand Island,
New' York) in 10 mM phosphate-buffered saline (PBS), disaggregated into single cell
suspensions, counted electronically (Coulter, Hialeah, FL), and dispensed in 100 pi
volumes into 96-well microtiter plates with a multichannel pipet (Flow Labs, Titertek) at a
concentration of 0.5 x 104 sensitive, or 1.0 x 104 resistant cells per well.

Cells were

allowed to attach to the plastic and to resume growth for 24 hours prior to the addition of
100 pi of drug-containing medium. Drugs were dissolved in small amounts of sterile water
or 1% DMSO (final culture concentration < 0.05% DMSO) before dilution with medium.
Controls were exposed to vehicle-containing medium.

Following a 48 hour incubation at

37° C, the cellular supernatants of each well were gently aspirated, and cells were fixed and
stained with 100 pi of 0.5% methylene blue (Sigma) in 50% ethanol (w/v) for 30 minutes at
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room temperature, as previously described (60).

Unbound stain was removed by

decanting, followed by emersion in three, 1-liter washes of distilled, deionized water. The
plates w'ere dried for 12 hours and the stained protein w'as solubilized with 200 )il of sodium
N-lauroyl sarcosine (Fluka, Switzerland) solution (1% v/v in PBS). The optical density of
each well was determined by absorbance spectrophotometry' at a wavelength of 600 nm with
a microculture plate reader (Titenek Model MCC/340) interfaced to an Apple He computer.
Inhibition of cell growth was expressed as a percentage of absorbance of vehicle-treated
control cultures.
To determine the optimal conditions for this assay, plates were inoculated in duplicate
with various initial cell concentrations.

One half plate w'as assayed daily for five

consecutive days by standard trypsin digestion and electronic cell counting, while the other
half of each plate was stained as described above.

Figure 2-1 demonstrates the linear

correlation betw-een A50Q from stained wells and actual cell number for the MCF-7/DOX cell
line with final cell concentrations between 0 and 50,000 cells per well. Similar results were
obtained for the sensitive cell line. Final assay conditions were chosen to ensure that optical
density measurements fell on the linear portion of this curve. This system has proven
extremely reproducible, with less than 5% variability between IC50 values from doseresponse curves from different experiments run on different days.
The effect of PTZs on cellular proliferation was examined by exposing cells grown in
the dark to 0 - 100 |iM drug as described above with each condition repeated in
quadruplicate. IC50 was the concentration of drug that reduced staining (A^oo)10 50% of
vehicle-treated controls.

Final IC50 values represent the average of 3 to 5 separate

experiments.
The effect of PTZs on MDR was studied by exposing cells to 0 -100 pM doxorubicin
in the absence or presence of a concentration of PTZ derivative that alone produced 10%
inhibition of growth (IC10) as determined by 3 to 5 experiments run in quadruplicate.
Dose-response curves were corrected for the 10% inhibition of cell growth caused by the
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PTZs alone. The MDR Ratio was defined as the ratio of the IC50 for doxorubicin alone
divided by the IC50 for doxorubicin in the presence of modifier. This ratio represents the
increase in apparent potency of doxorubicin produced by each PTZ derivative.
MDR Ratio = IC50 Doxorubicin Alone + IC50 Doxorubicin + Chemosensitizer

3.

Drugs
Doxorubicin was obtained from Sigma Chemical Co. (St. Louis, MO) and was freshly

prepared in distilled water for each experiment. PTZ derivatives and related drugs were
generously donated as follows:

chlorpromazine hydrochloride, trifluoperazine

dihydrochloride, chlorpromazine sulfoxide hydrochloride, 2-chloro-10-[2-(dimethylamino)
ethyljphenothiazine hydrochloride, 2-chloro-10-[4-(dimethylamino)butyl]phenothiazine
hydrochloride, promazine hydrochloride, trifluopromazine hydrochloride,

2-thiomethyl-

promazine hydrochloride, 1-chloropromazine hydrochloride, 3-chloropromazine hydro¬
chloride, 4-chloropromazine hydrochloride and prochlorperazine ethanedisulfonate by Dr.
Charles Zirkle of Smith Kline and French Laboratories (Philadelphia, PA); 7-hydroxychlorpromazine, 3,8-dihydroxychlorpromazine, 7,8-dihydroxychlorpromazine, desmethylchlorpromazine hydrochloride and didesmethylchlorpromazine hydrochloride by Dr. Albert
Manian of the National Institute of Mental Health (Bethesda, MD); promethazine
hydrochloride by Wyeth Laboratories (Radnor, PA); chlorproethazine hydrochloride by
Rhone-Poulenc (Paris, France); imipramine hydrochloride and 2-chloroimipramine
hydrochloride by Geigy Pharmaceuticals (Summit, NJ); haloperidol, pimozide, penfluridol
and 4-(4-chloro-a,a,a-trifluoro-m-tolyl)-1 -[4,4-bis(/?-flourophenyl)butyl]-4-piperidinol
(R-6033) by Dr. Pierre Laduron of Janssen Pharmaceutica (Beerse, Belgium); quinacrine
dihydrochloride by Sterling-Winthrop Research Institue (Renssalear, NY); fluphenazine by
Dr. S. J. Lucania of E. R. Squibb and Sons. The following thioxanthene derivatives were
generously supplied by Dr. John Hyttel of H. Lundbeck (Copenhagen, Denmark): cis- and
rrans-flupenthixol, cis- and rrarcs-clopenthixol, cis- and rranj-chlorprothixene, N 751,
N 753 A, N 753 B, N 762 A, N 762 B, N 768 A, N 768 B, N 789, N 796 A, N 796 B,
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and N 7006. A-(4-amino-hexyl)-5-chloronaphthalenesulphonamide (W7) and its
derivatives 5-iodo-l-Cg, 5-iodo-l-Cg, 5-iodo-l-C]2> and 5-cyano-l-Cg were kindly
supplied by Dr. Shiela MacNeil (Northern General Hospital, Sheffield, UK). CGS 9343B
was a gift of Dr. Jon Norman (CIBA-GEIGY, Summit, NJ). l-(5-isoquinoline-sulfonyl)2-methylpiperazine (H-7), perphenazine and amitriptyline were obtained from Sigma. Other
reagents were of analytical grade and were obtained from general commercial sources.

4.

Statistical Analysis
Statistical analysis of each dose-response curve was performed by the method of

Finney (61).

Accordingly, ICso’s ± standard errors for the inhibition of cellular

proliferation by drugs alone or in combination were determined by linear regression analysis
of the logit transformed data. The significance of each MDR Ratio was then determined
using Student’s two-tailed t test, and was expressed in terms of P values. 95% confidence
intervals for each MDR Ratio were calculated by Fieller's Ratio of Means as modified by
Bliss (25). Student's t test was also employed to analyze the significance of differences
between MDR Ratios or ICso’s for inhibition of cellular proliferation by various drugs.

C. Results
1.

Effect

of

Modifying

the

Phenothiazine

Nucleus

on

Cellular

Proliferation and Multidrug Resistance
Table 2-1 shows the structures, IC50 values for inhibition of cell growth and MDR
Ratios for a series of promazine derivatives having different substitutions on the PTZ
nucleus. The unsubstituted PTZ, promazine, inhibited cell growth (IC50 = 26 pM) and
sensitized MCF-7/DOX cells to doxorubicin by 20% (MDR Ratio = 1.2, P<0.05 as
compared to doxorubicin alone). Adding a chlorine at positions 1, 2, 3, or 4 increased
potency against cell growth by up to 3-fold, with the most potent compound
(chlorpromazine) having a chlorine at position 2 (IC50 = 8 pM). This latter compound also
had the greatest effect against MDR, sensitizing resistant cells to doxorubicin by 60% (MDR
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Ratio = 1.6, PcO.OOl as compared to doxorubicin alone). Similarly, adding a -CF3 group
at position 2 increased potency against cell growth and MDR.
trifluopromazine (IC50 = 16 |iM) was a

1.6-fold

Accordingly,

more potent cytostatic agent than

promazine (P<0.001), and was 67% more potent (PcO.OOl) against MDR (MDR Ratio =

2.0).
Conversely, adding a -OH to the PTZ nucleus decreased the potency against both
processes. For example, 7-hydroxychlorpromazine was 2-fold less potent than promazine
in inhibiting cell growth (PcO.OOl), while the dihydroxylated analogs, 7,8- and 3,8dihydroxychlorpromazine, were up to 15-fold less potent than promazine as inhibitors of
cellular proliferation (PcO.OOl), having ICso's of 63 (iM and 400 pM, respectively. In
addition, the hydroxylated analogs had no significant chemosensitizing activity, and further
increased resistance to doxorubicin (MDR Ratios < 1.0). Oxidation of the bridge sulfur
(chlorpromazine sulfoxide) markedly reduced antiproliferative activity (IC50 = 500 pM), but
increased activity against MDR (MDR Ratio = 2.2).

2.

Influence of the Side Chain Amino Group on Cellular Proliferation
and Multidrug Resistance
Table 2-2 shows that PTZs containing tertiary amines (chlorpromazine and

chlorproethazine), secondary amines (desmethylchlorpromazine), and primary amines
(didesmethylchlorpromazine) possess similar activity against cellular proliferation (ICso’s =
8

- 12 pM). However, PTZs having tertiary amines were more potent antagonists of MDR

than those with secondary or primary amines, producing a 1.6- to
sensitivity to doxorubicin.

2.2-fold

increase in

For example, the ICso's of chlorpromazine

desmethylchlorpromazine were equal

(8

and

pM), whereas chlorpromazine was more potent

than desmethylchlorpromazine against MDR (MDR Ratios = 1.6 versus 1.2, PcO.Ol).
Other changes in the type of amino group also affected anti-MDR activity. For example,
piperazinyl derivatives increased potency against MDR. Accordingly, the MDR Ratios for
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trifluoperazine (3.4) and fluphenazine (2.7), compounds with piperazinyl amino side
chains, were greater than that of trifluopromazine (MDR Ratio = 2.0, P<0.001 and 0.001,
respectively), a compound with an identical hydrophobic ring-substitution, but possessing
an aliphatic side chain.

Similarly, perphenazine and prochlorperazine (MDR Ratios = 2.0

and 2.6) were more potent antagonists of MDR than chlorpromazine (MDR Ratio = 1.6,
P<0.01 and 0.001, respectively). This series also points out the importance of the -CF3
substitution at position 2 for anti-MDR activity.

For example, the MDR Ratio for

trifluoperazine (3.4) was greater than that of prochlorperazine (MDR Ratio = 2.6, P<0.01).
These PTZs have identical structures except that the former has a -CF3 instead of a -Cl at
position 2. A similar relationship is seen by comparing the MDR Ratio for fluphenazine
(2.7) to perphenazine (MDR Ratio = 2.0, P<0.01), also identical molecules except for the CF3 ring substitution. Finally, a para-methyl substitution on the piperazine appeared more
potent than an ethanol group for anti-MDR activity of compounds, as seen by comparing the
MDR Ratios for prochlorperazine (2.6) to perphenazine (2.0, P<0.05), or trifluoperazine
(3.4) to fluphenazine (2.7, P<0.001).

3.

Influence

of Alkyl

Bridge

Length

on

Cellular

Proliferation

and

Multidrug Resistance
Table 2-3 shows the effect on cell growth and on MDR of a series of 10-[alkyldimethylamino]phenothiazines in which the length of the alkyl bridge connecting the PTZ
nucleus to the amino group was varied. Increasing the distance between the ring nucleus
and the amino group from two to four carbons increased the antiproliferative and
chemosensitizing effects of these compounds.

For example, 2-chloro-10-[4-

(dimethylamino)butyl]phenothiazine, which has a four carbon alkyl bridge, was a more
potent antiproliferative agent (IC50 = 7 fiM) and anti-MDR agent (MDR Ratio = 2.0) than
any of the other four compounds w’ith two or three carbon alkyl chains.

Conversely,

promethazine, which has an isopropyl side chain was a less potent inhibitor of cell growth
than promazine, which has a three carbon chain.
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4.

Influence

of

Hydrophobicity

of

Phenolhiazines

on

Cellular

Proliferation and Multidrug Resistance
To determine the influence of hydrophobicity on the effect of PTZs on cellular
proliferation and MDR, the octanohbuffer partition coefficients were compared for each of
the 10 ring-substituted promazine derivatives as previously determined (174), to the ICso's
for inhibition of cell growth and to the MDR Ratios. Figures 2-2 A and B demonstrate the
excellent correlation between hydrophobicity and both antiproliferative activity (r = - 0.73, P
= 0.016) and MDR antagonism ( r = 0.86, P = 0.0015).
To determine if the differences in potency of compounds with side chain alterations
were also due to changes in overall hydrophobicity, we compared the octanofbuffer
partition coefficients for each of the drugs in Tables 2-2 and 2-3 that had -Cl substitutions at
position 2 of the PTZ ring to their ICso's for inhibition of cell growth and to their MDR
Ratios (Figures 2-2 C and D).

In contrast to the results for ring-substituted PTZs, no

statistically significant correlation was found between hydrophobicity and potency of
compounds with side chain alterations for inhibition of cell growth (r = 0.54, P = 0.27) or
antagonism of MDR (r = 0.59, P = 0.21).

5.

Correlation

Between

Anti-Calmodulin

Activity

and

Inhibition

of

Cellular Proliferation and Multidrug Resistance
To examine the role of CaM as a possible target for the effect of PTZs on cellular
proliferation and MDR, the ICso's for the inhibition of CaM by PTZs and structurally
related compounds (174) were compared to their ICso's for the inhibition of cell growth,
and to their effect on MDR when used at equimolar (3 |iM) concentrations. Figures 2-3 A
and B show a good correlation between anti-CaM activity and antiproliferative activity (r =
0.58, P = 0.0009), whereas no correlation was found between anti-CaM activity and
chemosensitizing activity (r = 0.17, P = 0.44). Similar results were found for equitoxic
concentrations of PTZs.
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6.

Effect

of Plienothiazines

and Structurally

Related Compounds

on

Doxorubicin-Sensitive Cells
The activity of all PTZs and structurally related compounds against cell growth and as
modulators of sensitivity to doxorubicin was examined against the doxorubicin-sensitive
MCF-7 cell line. Each of the drugs tested were equally potent antiproliferative agents
against the doxorubicin-sensitive cell line as compared to their activity against the resistant
MCF-7/DOX cell line (data not shown). No compound sensitized the MCF-7 cells to
doxorubicin.

7.

Effect of Specific Inhibitors of Calmodulin and Protein Kinase C on
Cell Growth and Multidrug Resistance
Table 2-4 shows the reported values for inhibition of CaM and PKC by several

"specific" inhibitors of each, and their effect on cell growth and MDR, respectively. While
a wide range of anti-CaM activities are reported for the W7 derivatives, these compounds
had approximately similar antiproliferative effects (18-22 pM), and showed only little or
no chemosensitizing activity (MDR Ratios = 1.0 to 1.5). The relatively specific CaM
antagonist CGS 9343B displayed slightly greater chemosensitizing effects, causing a 2-fold
reversal of doxorubicin resistance when used at the non-toxic concentration of 6 pM. FI-7,
a competitive inhibitor of PKC, was an extremely non-toxic substance, showing significant
antiproliferative effects only at concentrations > 200 |iM. Therefore, much higher ICjo
doses were used than for most of the PTZs (30 |iM). Nevertheless, FI-7 had no anti-MDR
activity, and actually caused a significant, though slight, enhancement of doxorubicin
resistance.

8.

Effect of Compounds Structurally Related to the Phenothiazines on
Inhibition of Cellular Proliferation and Multidrug Resistance
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Tables 2-5 and 2-6 show the structures, IC50 values for inhibition of cell growth and
effect on MDR for several classes of compounds that incorporate certain structural features
identified as important for activity from the PTZ studies. Penfluridol and quinacrine (Table
2-5) were potent antiproliferative agents (IC50 = 3 pM), but were relatively poor antagonists
of MDR (MDR Ratios = 2.0 and 1.3, respectively).
Table 2-6 shows that many of the thioxanthene isomers were particularly effective
chemosensitizers. This class of compounds differ from the PTZs by a carbon substitution at
position 10 of the PTZ nucleus, and an exocyclic double bond to the side chain.
Each of the active chemosensitizing thioxanthene isomers caused a significantly greater
potentiation of doxorubicin activity than their respective PTZ homolog (Tables 2-1 to 2-3),
as demonstrated by comparing the MDR Ratios for rrarcs-chlorprothixene to chorpromazine
(7.0 versus 1.6, PcO.OOl), trans-16% to chlorproethazine (7.2 versus 2.2, P<0.001),
trans-196 to trifluoperazine (2.8 versus 2.0, P<0.01), rrart.y-clopenthixol to perphenazine
(15.0 versus 2.0, P<0.001), and rra«5-flupenthixol to fluphenazine (15.2 versus 2.7,
PcO.OOl).
In addition. Table 2-6 demonstrates that the thioxanthenes displayed stereospecificity in
their effect on MDR, since the trans-isomer of each active pair of thioxanthenes was 2- to
6-fold more effective then the c/s-isomer for the reversal of MDR at equitotoxic
concentrations. For example, Figure 2-4 displays representative dose-response curves of
MCF-7/DOX cells to doxorubicin in the absence or presence of PTZ and thioxanthene
isomers, and shows that rraAis-flupenthixol was a 3-fold more effective chemosensitizer
than cfr-flupenthixol, and 6-fold more effective than the PTZ homolog fluphenazine, at
equitoxic doses. This relationship also was true for equimolar concentrations of PTZs and
thioxanthenes (data not shown).
Similar to the PTZs, alterations in the length or type of side chain affected anti-MDR
activity for the thioxanthenes. Aliphatic side chains of two carbons in length had little
chemosensitizing activity (cis- or trans-162), while several thioxanthenes with three
carbon aliphatic side chains possessed increased activity (frarts-chlorprothixene, trans-
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768). It was also necessary for cyclic ring side chains substituents to be a distance greater
than tw'O carbons from the thioxanthene ring nucleus for activity, as demonstrated by trans7006 (MDR Ratio = 1.6) compared to rrarts-clopenthixol (MDR Ratio = 15.0), otherwise
identical molecules except for a two carbon versus three carbon alkyl bridge.
The most effective thioxanthene chemosensitizers, rrarts-clopenthixol, transflupenthixol and trans-753, caused an approximately 15-fold reversal of MDR, and each
possessed cyclic piperazinyl or piperadinyl substituents at a distance of three carbons from
the thioxanthene ring, in a trans configuration. Slightly higher concentrations of transflupenthixol

(8

|iM) sensitized MDR cells to doxorubicin by 35-fold, a 10-fold greater anti-

MDR activity than equitoxic (ICjq) doses of trifluoperazine, the most potent PTZ antagonist
of MDR (data from Section III.C.6).
In contrast to the anti-MDR effects of these compounds, the thioxanthene isomers
displayed a relative lack of potency and stereospecificity as antiproliferative agents. For
example, cis- and trans-flupenthixol possessed only modest activity against cell growth
(ICso’s of 24 and 25 ^iM), similar in potency to its PTZ homolog fluphenazine (IC50 = 23
pM) and less potent than many of the other PTZs tested. Similar comparisons may be made
for each of the thioxanthene isomers and their PTZ homologs.

D. Discussion
The results presented in this chapter demonstrate that specific structural features of the
PTZ molecule affect its activity against cellular proliferation and MDR, that the antagonism
of CaM does not appear to be direcdy related to the PTZs’ anti-MDR activity, and that the
thioxanthene class of antipsychotic drugs are more effective chemosensitizers than the
PTZs.
The data presented show that even slight modifications in the chemical structure of the
PTZs can dramatically alter their potencies as antiproliferative and chemosensitizing agents,
and suggest that these two actions of the PTZs are mediated by different mechanisms.
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Specifically, increasing the hydrophobicity of the PTZ nucleus increased potency against
cellular proliferation and against MDR, whereas decreasing the hydrophobicity decreased
potency (Table 2-1). Thus, the -CF3 substituted compounds were the most potent drugs,
whereas -OH substitituted compounds were the least potent drugs.

Chlorpromazine

sulfoxide, the oxidative metabolite of chlorpromazine, lost most of its antiproliferative
effect. However, it retained its effect against MDR, suggesting that first-pass hepatic
metabolism of these drugs may not present a major impediment to the clinical use of PTZs
as chemosensitizers.
The type of amino group also significantly affected potency against MDR but not
against cellular proliferation. For example, tertiary amines were more potent than primary
or secondary amines, and piperazinyl amines were more potent than non-cyclic groups.
Moreover, piperazinyl structures that possessed a para-methyl group had consistently
greater activity than others (Table 2-2).
The distance between the amino group and the PTZ nucleus was important for both
inhibition of cell growth and antagonism of MDR. A four carbon chain was superior to
alkyl bridges of shorter lengths (Table 2-3). Whether an alkyl bridge of greater than four
carbons would further increase activity could not be determined in the present study since
these derivatives were not available.
It has been postulated that the effects of the PTZs may be due solely to non-specific
membrane interactions resulting from their high degree of lipophilicity (191). A careful
analysis of the relationship between hydrophobicity and inhibition of cellular proliferation or
antagonism of MDR showed a correlation for ring-substituted PTZ derivatives (Figures 2-2
A and B), but not for compounds with specific side chain alterations (Figures 2-2 C and D).
Thus, the degree of lipophilicity of each drug, while important, was not the sole determinant
of potency for the antiproliferative or anti-MDR activity of PTZs. In fact, specific structural
features of the side chain also determine potency, such as the nature and distance between
the amino groups and PTZ nucleus, suggesting electrostatic interactions between the
positively-charged amine and a particular cellular target protein may also be important.
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This profile is reminiscent of that displayed by the interaction of PTZs with CaM.
Studies of the structural features of PTZs that influence CaM antagonism revealed that ringsubstitutions that increased hydrophobicity increased potency, while modifications of the
type or length of the amino side chain affected potency in a manner unrelated to
hydrophobicity (174).

Similarly, studies with N-(6-aminohexyl)-1-naphthalene-

sulfonamide (W5) and N-(6-aminohexyl)-5-chloro-l-naphthalenesulfonamide (W7) (97),
and a series of 15 derivatives of W7 (143), demonstrated that both halogenation of the
naphthalene ring with chlorine, iodine or cyano groups, and increasing the length of the
alkyl side chain from 4 to 12 carbons increased their potency against CaM.
Drug binding studies with synthetic peptides and molecular modeling provided a
rationale for the importance of both hydrophobicity and molecular structure for the PTZ CaM interaction. The induction of a-helix formation by the binding of Ca

to CaM results

in two distinct regions, a hydrophobic pocket containing two aromatic phenylalanine
residues (Phe 89 and 92) oriented to form a charge transfer complex with the aromatic,
tricyclic nucleus of the PTZs, and a hydrophilic region at a distance of one-half helical turn
formed by glutamic acid residues (Glu 83, 84 and 87), which interact with the positivelycharged nitrogen atom of the PTZ side chain (183). The relationship between structure and
hydrophobicity of the PTZs and their antiproliferative and anti-MDR activities suggests that
in these systems, similar to CaM, the PTZs interact in both a hydrophobic and electrostatic
manner with a protein target. Like CaM, it is likely that this target possesses a hydrophobic
domain in close proximity to a negatively-charged amino acid.
The site(s) of action of PTZs and structurally related compounds for inhibition of
cellular proliferation and antagonism of MDR have not been identified. The current data
demonstrate that the antiproliferative activity of these drugs used individually against the
malignant breast cancer cell lines MCF-7 and MCF-7/DOX correlate with their potency as
CaM antagonists (Figure 2-3 A), supporting and extending previous observations with a
limited number of PTZs in MDA-MB-231 human breast cancer cells (239), C6 astrocytoma
cells (136), HL-60 human leukemia cells, L1210 murine leukemia cells, and HCT-8 human
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colonic carcinoma cells (84). These data are consistent with the known role of CaM in
cellular proliferation (86, 182), and suggest a role for CaM as the PTZ target involved in cell
growth inhibition by PTZs. However, the complete lack of correlation between anti-CaM
activity and antagonism of MDR by equimolar (Figure 2-3 B), as well as equitoxic (data not
shown) concentrations of PTZs, points toward an alternative mechanism of inhibition for
this effect. This is in contrast to conclusions reached by Ganapathi (73), who compared the
anti-CaM and anti-MDR activity of trifluoperazine, chlorpromazine, and prochlorperazine in
murine P388/DOX cells.

If one examines the present data for these 3 drugs alone, a

correlation also is found between anti-CaM and anti-MDR activity (Figure 2-3B).
However, in the context of the much larger sample size in the present study, this correlation
does not remain significant.
Since the PTZs are considered non-specific probes for CaM function in cell systems
due to their activity as inhibitors of PKC (200) and dopamine receptors (47), the
chemosensitizing effect of several compounds w'ith relatively increased specificity for CaM
or PKC were examined.

While several analogs of the naphthalene sulphonamide W7

possess far less PKC inhibitory activity, along w'ith increased anti-CaM activity (143), these
compounds caused little or no potentiation of doxorubicin toxicity in MCF-7/DOX cells
(Table 2-5). Similarly, the CaM antagonist CGS 9343B, which also lacks potency as an
inhibitor of PKC (160), was found to be a fairly poor chemosensitizer in MDR cells (Table
2-4). These data further support the previous evidence that antagonism of CaM is not
directly involved in the reversal of MDR by chemosensitizers. However, it appears that
inhibition of CaM may be a useful marker for potential MDR chemosensitizers, since the
structural requirements for both are similar, and many of the presently studied
chemosensitizers are also potent CaM antagonists.
Finally, the isoquinolinesulfonyl H-7, a potent and competitive inhibitor of PKC (98,
162), had no chemosensitizing effect on MDR cells, but slightly enhanced the resistance of
cells to doxorubicin (Table 2-4), in agreement with preliminary results reported by
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Ganapathi (70). It is interesting to note that Ido et al (105) found H-7 capable of inhibiting
a TPA-induced decrease in vincristine accumulation in sensitive P388 cells. Therefore, it
appears that while PKC activation by phorbol esters may induce MDR, the inhibition of
PKC does not necessarily sensitize MDR cells.
The information gained from these studies enabled the identification of additional drugs
with certain of the important structural features for chemosensitizing activity. A number of
tricyclic compounds with cationic amino group side chains were studied for
chemosensitizing activity. Several, such as imipramine and 2-chloroimipramine had modest
anti-MDR activity. Interestingly, quinacrine, a compound described as sensitizing several
other MDR cell lines (109, 246), showed essentially no anti-MDR activity in the present
study, probably because a very low does was used due to its potent antiproliferative effects
(IC10 = 0.75 pM).
The most interesting results were displayed by the thioxanthene class of antipsychotic
drugs (Table 2-6).

Nearly every rrans-thioxanthene

isomer possessed greater

chemosensitizing activity than their respective PTZ homologs, and several, such as transflupenthixol, trans-clopenthixol, and trans-153, were 5- to 7-fold more effective at
equitoxic or equimolar concentrations. Many of the structural features important for PTZ
anti-MDR activity were also effective for thioxanthenes. For example, thioxanthenes with
aliphatic or cyclic side chains of three carbons in length were more effective than those with
two carbon alkyl bridges. Also, piperazinyl or other cyclic side group substitutions resulted
in greater activity than aliphatic side groups. The most effective pair of thioxanthenes, cisand rra/u-flupenthixol, have a -CF3 substitution at position 2 of the hydrophobic
thioxanthene ring, possess a piperazinyl amino side chain, and have a 3 carbon alkyl bridge.
While the thioxanthene isomers are more hydrophobic than PTZs due to the substitution
of a carbon for a nitrogen in the cyclic ring, this alone cannot explain their cellular effects.
For example, the octanokbuffer partition coefficients (log P) for both flupenthixol isomers
= 4.25 versus 4.04 for chlorpromazine (161), but they are less potent antiproliferative
agents than chlorpromazine and other less hydrophobic PTZs. In addition, while the
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isomers are equally hydrophobic, frans-flupenthixol is a 3-fold more potent anti-MDR
agent (Figure 2-4), and both isomers are more potent than agents with greater
hydrophobicity, such as pimozide (log P = 4.88).
The orientation of the side chain amine in relation to the tricyclic nucleus was an
important determinant of anti-MDR activity, but not of antiproliferative activity for the
thioxanthenes. For example, trans-flupenthixol displayed greater activity than the cisflupenthixol against MDR (Figure 2-4), but was equal to that of the cis-isomer against
cellular proliferation (Table 2-6). In fact, for every pair of active thioxanthene isomers, the
trans-isomer was uniformly more effective than the cis- for reversing MDR,while no
consistent stereoisomerism was seen for the antiproliferative effects of these compounds. It
is intriguing that compound 789, which is identical to clopenthixol except for a single
instead of a double bond connecting the piperazinyl side chain to the thioxanthene ring
nucleus, was nearly as effective as rran^-clopenthixol, and far more effective than cisclopenthixol or perphenazine. This suggests that the superior anti-MDR activity of the
thioxanthenes may be due to specific binding to a receptor with greater affinity for
compounds in the trans configuration, or compounds w'hich are able to assume the trans
configuration, and that drugs locked into a cis orientation by a double bond are unable to
bind with high affinity possibly due to steric hindrance.
Taking into account all of the principles derived from this analysis of PTZ-like
compounds, structural features important for a drug to alter MDR include a hydrophobic
thioxanthene ring nucleus with a -CF3 substitution at position 2, an exocyclic double bond
in the trans configuration, and a piperazinyl amine with a para-methyl or ethanol group,
joined by a 3 or 4 carbon alkyl bridge to the nucleus. These findings agree with similar
structural features identified as important for modulating MDR in human leukemic cells in a
recent study with derivatives of indole alkaloids (246). Therefore, the present structureactivity studies more clearly define the ’pharmacophore’ necessary for specific anti-MDR
activity for PTZs and structurally related classes of drugs, and have identified a previously
undescribed class of chemosensitizers, which contain several lead compounds worthy of

69
further examination.
Clinical trials of the antipsychotic effects of the thioxanthene flupenthixol in humans
showed that m-flupenthixol was far more effective than rra«5-flupenthixol, and that the
latter was far less toxic (116). This observation may be explained by biochemical and
crystallographic evidence that c/5-flupenthixol is a potent antagonist of dopamine receptors
(103, 172), whereas rrans-flupenthixol, which displays the greater potency against MDR,
has virtually no activity as a dopamine antagonist. This may explain the apparent lack of
extrapyramidal side effects seen with this agent (157). Extrapyramidal side effects have
proven to be dose limiting in Phase I trials that combined trifluoperazine with bleomycin
(88) or doxorubicin (149).

Therefore, further in vitro and in vivo characterization of

chemosensitizing activity of cis- and rrartf-flupenthixol were undertaken.
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TABLE 2-1

Effect of Modifying the Phenothiazine Nucleus on Activity Against Cell
Growth and Multidrug Resistance

Inhibition of cell growth was determined by exposing MCF-7/DOX cells to 0 - 100 |iM of
each PTZ. IC50 is the mean concentration ± S.E. that produced 50% inhibition of cell
growth compared to vehicle-treated controls, as described in Materials and Methods
(Section B.2). To determine the MDR Ratio, MCF-7/DOX cells were exposed to 0-100 fiM
doxorubicin in the presence or absence of PTZ at a concentration that alone produced 10%
inhibition of cellular growth. MDR Ratio is the IC50 for doxorubicin alone divided by the
IC50 doxorubicin in the presence of PTZ. 95% confidence intervals and P- values for
comparison of IC5q's for cell growth inhibition by doxorubicin in the absence versus
presence of each modifier were derived as described in Methods. All values represent the
mean of three to five separate experiments; each experiment was done in quadruplicate.

71

TO

o

-O

-O

-Q

-O

O

O

TO

-O

.O

-Q

—;c\jc\icoc\joocococ\ic\jc0'^f

ro oooooooddooo

CC

cc

g +1 +i +i +1 +l +i -H +i +1 +1 +i

Q

cr> CMCOCDCO^OOOOlfiOOJ

Effect of Modifying the Phenothiazine Nucleus

2

y~~ O O ▼— C\i C\i

t— t— t— y~~

"r^iOT-cMnNinojcoom
LLi
cm
<y>
CO +1 -H -H +1 +1 +1 -H +1 -H +1 +1

0CO

cooinoocoocoo

CO

o

LO O CD CM

S CM CM

of

CM

in

CD

CD

N
CO

N
CO

C C

/

CD
C
*N

\
CM

CM

CM

✓O

_X _ X _ X -

in GO

o

o

o

o

c

CD
C

"n

'n

E

E

Q.
O

CL CL >» -D -D ^

o
CD
c
'n
CO

h-

co

CL

CO
EZ

o
V— 2

o

S §

o-o

XL

O z o o
r^Oco ■<3-

>N Q Q

X

CD
C

sz
o o
>N

o
2 o
O CL O

E -c O -C
o

X

CD

co

Nx”

£
3
CO

o
co o
»_ k.
E CL CL
o
i— o _o

CO

X

CD

TO

E E

Sr

E

o

■i JC

®

S’S

E g

2
§
CL

§ eo

00 CO

co

I—

O

ao qo

co
•»— CM CO ^ CM* CM CM CM CM in
c

ro
cco

X X

O O

I I

X X* X~ co
O O O X

_
ooooooocboo
I I I I I T T I I II

'c

g>

in
o
d
v
CL

10

o
o o
o c
v
CL 0.
TO .O o

72

TABLE 2-2

Effect of Modifying the Type of Side Chain Amino Group on Activity
Against Cell Growth and Multidrug Resistance

MCF-7/DOX cells were treated as described in Table 2-1. IC50 values ± S.E. and MDR
Ratios with 95% confidence intervals and P- values for comparison of IC5q's for cell
growth inhibition by doxorubicin in the absence versus presence of each modifier were also
determined as described in Table 2-1. Each value represents the mean of three to five
separate experiments; each experiment was done in quadruplicate.
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TABLE 2-3

Effect of Modifying the Length of the Side Chain Amino Group on Activity
Against Cell Growth and Multidrug Resistance

MCF-7/DOX cells were treated as described in Table 2-1. IC50 values ± S.E. and MDR
Ratios with 95% confidence intervals and P- values for comparison of IC5q’s for cell
growth inhibition by doxorubicin in the absence versus presence of each modifier were also
determined as described in Table 2-1. Each value represents the mean of three to five
separate experiments; each experiment was done in quadruplicate.
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TABLE 2-4

Effect of Specific Inhibitors of Calmodulin and Protein Kinase C
on Cell Growth and Multidrug Resistance

MCF-7/DOX cells were treated as described in Table 2-1. IC50 values ± S.E. and MDR
Ratios w'ith 95% confidence intervals and P- values for comparison of IC5o’s for cell
growth inhibition by doxorubicin in the absence versus presence of each modifier were also
determined as described in Table 2-1. Each value represents the mean of two to three
separate experiments; each experiment was done in quadruplicate. Values for inhibition of
CaM and PKC are from MacNeil et al (1988) for W7 and derivatives, Norman et al
(1987) for CGS 9343B, and Hidaka et al (1984) for H-7.
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TABLE 2-5

Effect of Compounds Structurally Related to the Phenothiazines
on Cell Growth and Multidrug Resistance

Compound

Structure

Cell Growth Inhibition

MDR RaUo

IC50±s e OiM)

± 95% C.l.

Quinacrine

3 ±.1

1.3 ±0.1 b

Imipramine

19 ±5

2.5 ±0.9a

20 ±2

2.0 ±0.6a

40 ±5

1.3 ± 0.1c

3 ± .2

2.0 ± 0.3a

Pimozide

50 ±20

1.3±0.5C

R-6033

27 ±4

1.1 ±0.2d

2-Chloroimipramine

(XXX

CH,

CHf-CHj-CH,—N
CH,

Amitriptyline

Penfluridol

Haloperidol

a
b
c
a

750 ±300

3.3

±.7a

P<0 001
P < 0 05
P< 001
P - not significant

MCF-7/DOX cells were treated as described in Table 2-1. IC50 values ± S.E. and MDR Ratios with 95% confidence
intervals and P- values for comparison of IC50's for cell growth inhibition by doxorubicin in the absence versus
presence of each modifier were also determined as described in Table 2-1. Each value represents the mean of three to
five separate experiments; each experiment was done in quadruplicate.
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TABLE 2-6

Effect of Thioxanthene Stereoisomers on Cell Growth
and Multidrug Resistance
6

5

4

R
R

X

Name

Cal Growtfi hfibtor
C M + S.E. (jiM)

/CH3
—Cl

/CH3
= C H —C H

—Cl

1.1 ± 0.2 0

Vans- 762 (A)

40 ± 6

1.3 ±0 1 c

20 ± 2

20± 0 6 *

13 ± 2

7.0 ±0 9 *

as- chlorprothixene
Vans-

/CH2CH3

as- 768 (B)

17 ± 3

4.0 ± 0 3 4

^ch2ch3

Vans- 768 (A)

18 ±3

7.2 ±0.6 8

= CH —CH 2—CH ^—N

as-

796 (A)

28 ± 4

1 8± 0.2 6

nch3

Vans-

796 (B)

14 ± 3

2 8 ±0.3 *

as- 753 (B)

20 ± 3

6.7 ± 1.8 *

40 ± 5

15 0 ±2.5 *

8 ± 2

1.8 ±0.3 6

= C H —C H ^—C H 3—N

= C H —C H ^—C H 2—

CH2
Vans-

—Cl

/—V
= CH—CH^-CH^-N_NH

—Cl

—CH—CH g—N

—Cl

= CH—CH^—CH^—N
y

-cf3

—Cl

chlorprothixene

\
o
X
o>
-^F3

30 ± 4

C H j—N
nch3

—Cl

as- 762 (B)

=CH—CHj—N
nch3

—Cl

MDR Rat
1»S% C.l.

N—CH 2CH2 OH

= CH—CH^—CH^—M

—CH^—CHg—CHg—N^

N—CH -CH ~ OH
y

N—CH2CH2OH

N—CH2CH2 OH

753 (A)

racemic 751

Vans- 7006

13 ± 3

1.6 ±0

as- clopenthixol

20 ± 2

2.6 ±0 4 *

Vans- clopenthixol

15 ±2

15.0 ±2.3 1

4 b

as-

flupenthixol

24 ± 4

4.8 ±0.6 *

Vans-

flupenthixol

25 ±4

15.2 ±1.9 *

789

22 ±5

9.7 ±2.7 *

a P< 0.001

b P< 0 05
c P< 0.01
d P - not significant

MCF-7/DOX cells were treated as described in Table 2-1. IC50 values ± S.E. and MDR Ratios
with 95% confidence intervals and P- values for comparison of IC50's for cell growth inhibition
by doxorubicin in the absence versus presence of each modifier were also determined as
described in Table 2-1. Each value represents the mean of two to three separate experiments;
each experiment was done in quadruplicate.
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Cells per Well ( x 10 )

Figure 2-1. Correlation between absorbance (A ^qq) of stained cellular protein
and cell count. MCF-7/DOX cells were grown in 96-well microtiter plates at initial
concentrations of 10,000 cells/well and enumerated after 24, 48, 72, 96 and 110
hour incubations by either absorbance spectrophotometry or with a Coulter Counter,
as describe in Materials and Methods.

Each point represents the mean of

quadruplicate determiniations. Bars represent the standard error when greater than
the symbol.
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Ring-Substituted Phenothiazine Derivatives

2-Chloro Phenothiazine Derivatives

Figure 2-2. Relationship between hydrophobicity and activity of phenothiazine derivatives as
antiproliferative and anti-MDR agents. (A) and (B): correlation between octanohbuffer partition
coefficients, as previously determined (Prozialeck and Weiss, 1982), and the IC50's for inhibition
of cell growth (r = - 0.73, P = 0.016) and antagonism of MDR (r= 0.86, P = 0.0015)) for a series of
phenothiazine derivatives with ring-substitutions (Table 2-1). (C ) and (D): lack of correlation
between octanohbuffer partition coefficients and IC50's for inhibition of cell growth (r = 0.54, P =
0.27) and antagonism of MDR (r = 0.59, P = 0.21) for a series of 2-C1 substituted phenothiazine
derivatives with side chain alterations (Tables 2-2 and 2-3). Numbered points represent; (1)
promazine, (2) 1-chloropromazine, (3) chlorpromazine, (4) 3-chloropromazine, (5) 4chloropromazine, (6) 7-hydroxychlorpromazine, (7) 3,8-dihydroxychlorpromazine, (8) 7,8dihydroxychlorpromazine, (9) thiomethylpromazine, (10) trifluopromazine, (11) 2-chloro-10-[2(dimethylamino)ethylj phenothiazine, (12) 2-chloro-10-[4-(dimethylamino)butyl] phenothiazine,
(13) didesmethylchlorpromazine, (14) desmethylchlorpromazine, and (15) chlorproethazine.
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Figure 2-3.

Relationship between anti-calmodulin activity and antiproliferative or anti-

MDR activity for phenothiazine derivatives.

(A):

correlation between the IC^o's for

inhibition of calmodulin-induced activation of phosphodiesterase and the IC5q's for
inhibition of cell growth (r = 0.58, P = 0.0009) for phenothiazine derivatives. (B): lack of
correlation between the IC5q's for inhibition of calmodulin-induced activation of
phosphodiesterase and antagonism of MDR by modifiers used at a standard concentration of
3 fiM (r = 0.17, P = 0.44) for phenothiazine derivatives. All IC50 values for the inhibition
of calmodulin are from Prozialeck and Weiss (1982) and represent the concentration of drug
necessary to inhibit by 50% the calmodulin-induced activation of the Ca^-dependent form
of cyclic nucleotide phosphodiesterase.

IC5Q values for the inhibition of cellular

proliferation are from Tables 2-1 to 2-6.

MDR Ratios are the mean of two or more

experiments, each run in quadruplicate, and were determined as described in Materials and
Methods, except that an equimolar concentration (3 pM ) of each modifier was used instead
of an equitoxic concentration. Numbered points represent; (1) promazine, (2) 1-chloropromazine, (3) chlorpromazine, (4) 3-chloropromazine, (5) 4-chloropromazine, (6) 7hydroxychlorpromazine, (7) 3,8-dihydroxychlorpromazine, (8) 7,8 dihydroxychlorpromazine, (9) thiomethylpromazine, (10) trifluopromazine, (11) 2-chloro-10-[2-(dimethylamino)ethyl] phenothiazine, (12) 2-chloro-10-[4-(dimethylamino)butyl] phenothiazine, (13)
didesmethylchlorpromazine, (14) desmethylchlorpromazine, (15) chlorproethazine, (16)
promethazine, (17) prochlorperazine, (18) trifluoperazine, (19) m-flupenthixol, (20)
rra/u-flupenthixol, (21) quinacrine, (22) imipramine, (23) 2-chloroimipramine, (24) pen¬
fluridol, (25) pimozide, (26) R-6033, (27) haloperidol, and (28) chlorpromazine sulfoxide.
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Figure 2-4.Effect on the sensitivity of MDR cells to doxorubicin by PTZs and
structurally related modifiers. MCF-7/DOX cells were exposed to 0- 00 jiM dox¬
orubicin for 48 hours in the absence ( □) or presence of fluphenazine (■ ),
cis-flupenthixol (o), or trans-flupenthixol (•) at concentrations that alone produced
10% inhibition of cell growth. Cell growth was determined by a microtiter assay as
described in Materials and Methods. Each point represents the mean of quadruplicate
determinations which differed by less than 5%.
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Chapter III
/A7 VITRO CHARACTERIZATION OF THE CHEMOSENSITIZING
EFFECT OF THE THIOXANTHENES

A. Introduction
The analysis of structural determinants important for PTZs' anti-MDR activity,
discussed in the previous chapter, enabled the identification of a novel class of
chemosensitizing agents, the thioxanthenes. As outlined in Section I.B.2., the efficacy of
chemosensitizers may be best evaluated by studying their effect on cytotoxic drug
resistance, cross-resistance and drug accumuladon in carefully defined MDR cell lines. The
discovery that rranj-thioxanthene isomers more effectively potentiate doxorubicin in MCF7/DOX cells than m-isomers provides a unique opportunity to probe the stereoisomeric
specificity of these chemosensitizers on MDR, and to compare their anti-MDR activities with
their degree of stereoisomerism in other cellular and enzymatic systems, as a means of better
defining their possible mechanism(s) of action.
Accordingly, studies were performed comparing the effects the thioxanthene
chemosensitizers cis- and rrans-flupenthixol, the PTZ homolog fluphenazine, and the
structurally unrelated chemosensitizer verapamil, on primary drug resistance, cross¬
resistance, and accumulation in several MDR cell lines, including three well-characterized,
P-gp expressing human and mouse MDR lines (MCF-7/DOX, KB-V1, and P388/DOX), a
murine fibroblast cell line transfected with a human mdr 1 gene expression vector and
selected for P-gp overexpression and resistance to colchicine (3T3/MDR1), and an 'atypical'
MDR cell line which displays characteristics of MDR, including cross-resistance and
decreased drug accumulation, but does not overexpress P-gp. In addition, the thioxanthene
isomers cis- and rrarcs-flupenthixol were studied for their potency and stereospecificity as
inhibitors of CaM and PKC, cellular enzymes potentially important for reversing MDR.
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B . Materials and Methods
1 .

Cell Lines and Culture
MCF-7 and MCF-7/DOX human breast cancer cells were maintained as described in

Section II.B.l. The latter cell line has been been shown to uniquely overexpress P-gp and
the glutathione-S-transferase n isozyme (12, 56).
Human epidermoid carcinoma KB-3-1 cells and the vinblastine selected MDR subline,
KB-VI (kindly supplied by Dr. Michael M. Gottesman, National Cancer Institute,
Bethesda, MD), were grown in monolayer culture at 37° C in Dulbecco's modified Eagle's
medium with 10% fetal bovine serum and L-glutamine, in the continuous presence of 1
(ig/ml vinblastine. These cells are > 200-fold resistant to vinblastine, doxorubicin and
colchicine (206), demonstrate decreased drug accumulation (64), overexpress P-gp (236),
and possess a 100-fold amplification of the mdr 1 gene (188).
Murine leukemic P388 cells and the classic MDR cell line P388/DOX (from Dr. Ram
Ganapathi, Cleveland Clinic Foundation, Cleveland, OH) were grown in suspension in
RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% fetal bovine serum and 10
jiM 2-mercaptoethanol.
Murine NIH 3T3 fibroblasts and a MDR 3T3 line (3T3/MDR1) transfected with a
retrovirus expression vector containing a full-length cDNA from the human mdr\ gene
(235) and selected for resistance to colchicine (kindly provided by Drs. Michael M.
Gottesman and Steven Currier) were grown in monolayer in RPMI 1640 supplemented with
10% fetal calf serum, in the continuous presence of 1 |ig/ml colchicine.
MCF-7/MITOX cells (generously supplied by Dr. William S.Dalton, University of
Arizona Cancer Center, Tucson, AZ), selected for resistance to mitoxantrone, were grown
similarly to the other MCF-7 lines, except that RPMI 1640 medium w-as supplemented with
10% fetal bovine serum, and cells were continuously growrn in 8 x 10'8 M mitoxantrone.
These cells display characteristics of MDR including cross-resistance to anthracyclines and
Vinca alkaloids and decreased drug accumulation, but do not overexpress P-gp.
Cell lines grown in the presence of selecting agents were passaged 2 to 3 times out of
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drug before use in experiments. Cell lines were routinely tested and found to be free of
contamination by mycoplasma or fungi.

2.

In Vitro Drug Sensitivity Assays
The individual antiproliferative effect of cytotoxic drugs, PTZs or thioxanthenes in the

various cell lines were determined using microtiter spectrophotometric assays.

All

monolayer cell lines (MCF-7, KB, and NIH 3T3 derived lines) w-ere assayed using the
methylene blue cell staining method of Finlay et al (60) as described in Section D.B.2.,
with the following modifications.

Correlations between cellular grow-th and spectro¬

photometric absorbance were performed for each cell line, as described for MCF-7/DOX
cells in Figure 2-1, and the initial cell plating density and optimal assay conditions chosen to
ensure optical density measurements fell on the linear portion of each curve. 0.5 x 104
MCF-7 sensitive cells, 1.0 x 104 MCF-7/DOX cells, 1.2 x 104 MCF-7/MITOX cells, 0.8 x
104 KB-3-1 cells, 1.0 x 104 KB-V1 cells, 0.6 x 104 NIH 3T3 cells, and 1.0 x 104
3T3/MDR1 cells were dispensed in 100 pi volumes medium into each well of 96-well
microtiter plates. Cells were allowed to attach and grow for 24 hours, at w'hich time 100 pi
of drug-containing medium was added. Cells were incubated at 37° C with drugs for 48
hours, except for MCF-7/MITOX cells, which required a 72 hour incubation for optimal
growth, and stained with methylene blue, solubilized, and their optical density (A6qo)
determined spectrophotometrically, as described in Section II.B.2.
Inhibition of growth for the P388 and P388/DOX suspension cell lines was determined
using the modified MTT assay (30), based on the ability of live cells to reduce a tetrazolium
based compound 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to
a blue formazan product that can be measured spectrophotometrically. Briefly, 0.5 x 104
P388 or P388/DOX cells in 100 pi aliquots growth medium were plated into each well of
96-well microtiter plates, and allowed to equilibrate for 2 to 4 hours. Drugs dissolved in
small amounts of sterile water or ethanol (final concentration <0.1%) and diluted in medium
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were added in 100 pi volumes at appropriate concentrations, with each condition performed
in quadruplicate. Control wells received 100 pi medium with vehicle, alone. Cells were
incubated at 37° C for 3 days, at which time 50 pi MTT (Sigma) solution (2 mg/ml PBS)
was added to each well for an additional 4 hour incubation. Plates were centrifuged at 450 x
g for 5 minutes, and cellular supernatants gently aspirated, leaving approximately 25 pi
medium in each well. Insoluble formazan crystals were dissolved by adding 150 pi 100%
DMSO to each well, and plates thoroughly mixed on a mechanical plate shaker for 10
minutes. The optical density of each well was determined by absorbance spectrophotometry
at a wavelength of 550 nm using a Titertek Multiscan MCC/340 plate reader. Correlations
between cell number and spectrophotometric absorption were performed as described for the
the methylene blue staining assay, and plating densities and assay conditions chosen to
ensure linearity. Inhibition of cell growth was expressed as a percentage of absorbance of
vehicle-treated control cultures.
The relative resistance and cross-resistance of each cell line to various drugs was
determined by dividing the IC50 concentration for resistant cell lines to each drug by the
IC50 for that drug in the respective parental, sensitive cell line.
The effect of chemosensitizers on drug resistance and cross-resistance was studied by
exposing cells to a range of concentrations of cytotoxic drugs in the absence or presence of
equimolar concentrations of chemosensitizers that alone produced < 10% inhibition of
growth. Except where otherwise indicated, 5 pM concentrations of chemosensitizers were
used for all experiments. Dose-response curves were corrected for the inhibition of cell
growth caused by chemosensitizers alone, and MDR Ratios, as defined in Section II.B.2.,
were calculated for each drug plus chemosensitizer combination.
MDR Ratio = IC50 Drug alone + IC50 Drug + Chemosensitizer

3.

Cellular Accumulation of Thioxanthenes
Duplicate aliquots of 3 x 106 MCF-7/DOX cells in a total volume of 2 ml were

incubated at 37° C for 3 hours in the presence of 0 - 100 pM of each drug. Cells were
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washed three times in cold PBS and centrifuged at 100 x g for 10 minutes, resuspended in 2
ml of 0.3 N HC1 in 50% ethanol, and sonicated for 10 pulses at 200 watt seconds with a
Tekmar cell sonicator (Tekmar, Cincinatti, OH). Following centrifugation at 1000 x g for
30 minutes, the cell supernatant was removed and assayed for drug concentration with a
Perkin-Elmer 512 spectrofluorometer (Norwalk, CT). Optimal excitation and emission
wavelengths for both thioxanthene isomers were determined to be 320 nm and 400 nm,
respectively. Cellular drug content (nmoles/106 cells) was computed from standard curves
prepared with known amounts of drug in 0.3 N HC1 in 50% ethanol.

4.

Cellular Accumulation of Doxorubicin
Sensitive and MDR MCF-7 cells were each seeded in three 40 ml volumes of medium

at a density of 1.67 x 106 cells/ml. 100 pi of concentrated stock drug solutions were added
to obtain a final doxorubicin concentration of 10 pM, in the absence or presence of either
equitoxic

(ICjq) concentrations of cis- or trans-flupenthixol (3 pM and 6 pM,

respectively), or equimolar (5 pM) concentrations of all chemosensitizers. Cells were
incubated at 37° C for 3 hours. At various times after the addition of drugs, three 1.5 ml
aliquots of cellular suspension were removed from each cell solution, immediately
centrifuged for 60 sec at 11,000 x g, and washed three times with cold PBS using an
Eppendorf 5415 microcentrifuge. Control samples were removed at time zero, immediately
before drugs were added.

Cell pellets were extracted with 0.3 N HC1 in 50% ethanol,

sonicated and centrifuged as described above. Cell supernatants were removed and assayed
fluorome trie ally for doxorubicin content using excitation and emission wavelengths of 470
nm and 585 nm, respectively, as previously described (69). Cellular content of doxorubicin
(pmoles/106 cells) was computed from standard curves prepared with known amounts of
drug.

The presence of chemosensitizers was shown not to effect the absorbance or

emission spectra of doxorubicin.

5.

Isobologram

Analyses
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After determining the IC50 for doxorubicin and the IC50 for individual chemosensitizers
against MCF-7/DOX cells, a series of dose-response curves to rrans-flupenthixol in the
presence of fixed concentrations of doxorubicin were done by the microtiter assay system.
The individual concentrations of doxorubicin plus rran^-flupenthixol that together resulted
in 50% inhibition of growth of MCF-7/DOX cells were plotted and this IC50 isobole
compared to the calculated line of additivity, using criteria previously described (22).
Similarly, a MDR isobologram analysis was designed to study the in vitro additivity,
synergy or competitiveness of rrans-flupenthixol plus verapamil for reversing MDR.
Accordingly, multiple dose-response curves for MCF-7/DOX cells to doxorubicin were
performed, in the absence or presence of various combinations of rrarcs-flupenthixol plus
verapamil. Those concentrations of chemosensitizers that together caused a 15-fold reversal
of MCF-7/DOX cell resistance to doxorubicin were graphed and compared to a theoretical
line of chemosensitizing additivity. An MDR Ratio = 15 was arbitrarily chosen as the
defined 'response,' for which particular doses of chemosensitizers were necessary to
achieve, analogous to the IC50 response as defined for a traditional isobologram.

6.

Inhibition of Calmodulin by Thioxanthenes
The activity of bovine brain CaM (Calbiochem) was determined by its ability to activate

a CaM-dependent cyclic nucleotide phosphodiesterase prepared from rat cerebrum, as
previously described (137). Phosphodiesterase activity was measured by the luciferinluciferase method (246). One unit of CaM was defined as the amount needed to produce
50% of the maximal activation of phosphodiesterase. Briefly, to assay CaM activation, each
reaction vessel contained 50 mM glycylglycine buffer, pH 8.0, containing 25 mM
ammonium acetate, 3 mM MgCl2> 0.1 mM CaC^, 0.25 mM phosphoenolpyruvate, 5 mM
dithiothreitol, 1 nM ATP, 1 pg myokinase, 0.5 pg pyruvate kinase, 0.4 mM cyclic AMP,
and the phosphodiesterase preparation in a total volume of 100 pi. Samples were incubated
at 37° C for 30 min, and then placed in a boiling water bath for 5 min to destroy the
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phosphodiesterase activity.

After cooling, an additional 25 p.1 of glycylglycine buffer

containing 2 jig of myokinase and 1 jig pyruvate kinase were added and the sample
reincubated for 30 min at 37° C. The firefly luciferin-luciferase reagent was added, and the
hydrolysis of cyclic AMP measured using a Luminescence Biometer.

The effect of

thioxanthenes on the activity of calmodulin was determined by their ability to inhibit the
activation of phosphodiesterase in the presence of 10 units of calmodulin. The specificity of
this assay was shown by determining the basal inhibition of phosphodiesterase in the
absence of CaM.

7.

Inhibition of Protein Kinase C by Thioxanthenes
PKC was partially purified by modifications of previously described methods (57,

124). Briefly, 1 x 108 MCF-7/DOX cells were washed once with PBS by centrifugation at
100 x g at 4° C and the pellet resuspended in 1.5 ml of 20 mM Tris HC1 buffer containing 2
mM EDTA, 0.5 mM EGTA, 2 mM PMSF and 5 mM 2-mercaptoethanol, pH 7.5. The cells
were allowed to swell for 5 minutes and then gently homogenized with 30 strokes of a
Dounce Homogenizer with a loose fitting glass pestle.

Sucrose was added to a final

concentration of 0.33 M and the homogenate centrifuged at 100,000 x g for 1 hour. The
soluble supernatant fraction was then added batchwise to DE52 preequilibrated with sample
buffer. The resin was washed twice with the sample buffer containing 0.33 M sucrose and
the enzyme was eluted with 20 mM Tris HCL buffer containing 100 mM NaCl, 2 mM
PMSF and 5 mM 2-mercaptoethanol. All procedures were carried out at 4° C. The activity
of the enzyme was purified approximately 15-fold.
The activity of PKC was determined by measuring the incorporation of 32P from [y32P]-ATP into lysine rich histone by modifications of previously described methods (169).
A reaction mixture consisted of 40 jig histone, 4 pg/ml diolein, with or without 25 |ig/ml
phosphatidylserine and 50 |il of the partially purified enzyme (approximately 1 jig) in 20
mM Tris HC1 containing 10 mM MgCl2, 0.5 mM CaCl2, pH 7.5. The reaction was initiated
by the addition of 20 pM ATP containing

0.66 pmol of [y-22P]-ATP (6.66 x 106
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cpm/pmol) in a final volume of 200 pi Following a 10 minute incubation at 30° C, 25 pi
aliquots of the reaction mixture were spotted onto P81 cation exchange paper. Tie filters
were washed 3 times in 75 mM phosphoric acid and counted in 5 ml of Ecoscint using a
Beckman LS 7500 liquid scintillation counter. Assay conditions were chosen to insure
linearity of the reaction with time of incubation and concentration of tissue.

8.

Drugs and Reagents
Fluphenazine was provided by Dr. S. J. Lucania (E. R. Squibb and Sons), cis- and

rrans-flupenthixol by Dr. John Hyttel (H. Lundbeck, Copenhagen, Denmark), bleomycin
(Blenoxane) by Dr. Emmanuel Losada (Bristol Laboratories, Wallingford, CT), and
mitoxantrone by Hank Durivage (Section of Medical Oncology, Yale University School of
Medicine).

Doxorubicin, vinblastine sulfate, colchicine, verapamil, adenosine mono¬

phosphate, L-phosphatidyl-L-serine, 1,3-diolein, and histone (type III-S) were obtained
from Sigma. Myokinase and pyruvate kinase were obtained from Boehringer-Mannheim
(Indianapolis, IN) and firefly luciferin-luciferase was from E.I. Dupont de Nemours & Co.
(Wilmington, DL).

[y-32P]-ATP was obtained from New England Nuclear Research

Products, Inc. (Boston, MA). Whatman DE52 ion exchange cellulose was purchased from
Macalaster Bicknell (New Haven, CT). P81 cellulose phosphate paper was purchased from
Whatman (Hillsboro, OR). Other reagents were of analytical grade and were obtained from
general commercial sources.

C. Results
1.

Inhibition of Cellular Proliferation by Chemosensitizers
Table 3-1 shows the IC50 concentrations for inhibition of cell growth by cis-

flupenthixol, rrans-flupenthixol, fluphenazine or verapamil in each of the cell lines studied.
In general, the P388 sensitive and P388/DOX cells were more sensitive, and the NIH 3T3
and 3T3/MDR1 cells more resistant to the antiproliferative effects of each of the four
chemosensitizers used alone, than the MCF-7 or KB derived cell lines. C/T-flupenthixol,
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rrarcj-flupenthixol and fluphenazine were 2- to 10-fold more potent antiproliferative agents
than verapamil, but were equitoxic to each other in each of the cell lines used. In addition,
the PTZ and thioxanthene chemosensitizers were equally or slightly more toxic to each of
the sensitive cell lines when compared to their MDR sublines (1- to 3-fold); no MDR line
was collaterally sensitive to any of the chemosensitizers.

The concentration of

chemosensitizers necessary to inhibit growth by less than 10% was also determined for each
cell line (data not shown), and these ICjo doses used for experiments combining
chemosensitizers with cytotoxic drugs. 5 pM concentrations were found to be appropriate
for all four chemosensitizers in each cell line except the P388 lines, in which 1 jiM PTZ and
thioxanthenes were used, and the NLH 3T3 lines, in which up to 12 pM chemosensitizer
could be used without significant toxicity.

2.

Relative Resistance and Cross-Resistance of Cell Lines to Cytotoxic
Drugs
Table 3-2 shows the IC50 values for the inhibition of cell growth by several different

cytotoxic drugs in each of the cell lines, and the calculated degree of resistance (relative
resistance) displayed to each drug. As can be seen, each of the resistant sublines displayed
a typical MDR phenotype, with significant cross-resistance to anthracyclines (doxorubicin,
mitoxantrone), Vinca alkaloids (vinblastine), and other natural product drugs (colchicine),
but little or no resistance to bleomycin. Most, but not all, of the MDR cell lines were more
resistant to the drug used for selection (primary resistance), than to the other drugs tested
(cross-resistance).

For example, MCF-7/MITOX cells were 100-fold resistant to

mitoxantrone, but only 50-fold, 20-fold and 10-fold resistant to doxorubicin, colchicine,
and bleomycin, respectively. Conversely, MCF-7/DOX cells were 200-fold resistant to the
selecting agent doxorubicin, but displayed greater cross-resistance (400-fold) to colchicine.
The MDR KB-V1, P388/DOX and 3T3/MDR1 lines all possessed greater levels of primary
than cross-resistance.
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3.

Reversal of Multidrug Resistance by Chemosensitizers
To compare the effects of each of the chemosensitizers for reversing primary and cross-

resistance to cytotoxic drugs in sensitive and MDR cells, the IC^'s for cells to each drug in
the absence and presence of nontoxic, equimolar concentrations were determined, and MDR
Ratios calculated for each. Table 3-3 shows the fold reversal of resistance (MDR Ratio) of
each cell line to different drugs caused by c/s-flupenthixol, rra«5-flupenthixol,
fluphenazine and verapamil. None of the chemosensitizers displayed significant activity in
potentiating the effect of any of the cytotoxic drugs tested in the sensitive cell lines, MCF-7,
KB-3-1, P388 or NIH 3T3, except for verapamil plus doxorubicin in P388 cells (MDR
Ratio = 2.3), and fluphenazine and vinblastine in MCF-7 cells (MDR Ratio = 2.0).
Similarly, the chemosensitizers did not alter the primary resistance to mitoxantrone or cross¬
resistance to doxorubicin and vinblastine in the non-P-gp expressing MDR cell line MCF7/MITOX, with 5 pM of each resulting in MDR Ratios = 1.0.
All four chemosensitizers were effective in partially reversing primary or cross¬
resistance in the remaining, well-characterized MDR cell lines, with fr<2/is-flupenthixol
possessing the greatest activity. For example, in the MCF-7/DOX, KB-V1 and P388/DOX
MDR cells, rrans-flupenthixol caused an 8- to 36-fold, 20- to 40-fold, and 4- to 7-fold
reversal, respectively, of cell resistance to doxorubicin, vinblastine and colchicine. Transflupenthixol was stereospecific in its anti-MDR effects, since in these three MDR cell lines,
equimolar concentrations of frarcs-flupenthixol caused 1.5- to 2-fold greater antagonism of
MDR than its stereoisomer, c/s-flupenthixol, and 2- to 12-fold greater antagonism than its
PTZ homolog fluphenazine. In addition, rram,-flupenthixol was up to 3-fold more effective
for reversing MDR than the chemosensitizer verapamil. Conversely, in the colchicine
selected 3T3/MDR1 cell line, rra/is-flupenthixol was a 1- to 2-fold less effective
chemosensitizer than its isomer c/j-flupenthixol, or verapamil, though still significantly
more effective than fluphenazine.

However, both thioxanthenes and verapamil were

extremely effective at reversing MDR in this mdr 1 transfected line, with nontoxic
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concentrations of 12 |iM causing approximately 40-fold reversal of the 100-fold colchicine
resistance, and fully reversing the 20-fold doxorubicin cross-resistance to doxorubicin.
Finally, the thioxanthenes and verapamil caused a greater reversal of resistance to
doxorubicin or vinblastine than colchicine in those cells selected with either of the former
drugs (MCF-7/DOX and KB-V1), while the chemosensitizers caused a significantly greater
potentiation of colchicine than doxorubicin in the 3T3/MDR1 colchicine selected cells.

4.

Drug Accumulation Studies
It was next determined whether the difference in the anti-MDR activity of the

thioxanthenes could be attributed to differences in their cellular accumulation. After a 3 hour
incubation in 3 - 100 pM concentrations of thioxanthenes, cell associated cis- and transflupenthixol concentrations (nmoles/106 cells) were 1.29 ±0.11 versus 0.41 ± 0.04 at 3
pM (P<0.001), 4.34 ± 0.65 versus 2.22 ± 0.16 at 10 pM (P<0.001), and 14.52 ± 0.66
versus 12.2 ± 330 at 0.66 pM (P >0.1).
The effect of both equitoxic and equimolar concentrations of chemosensitizers on the
accumulation of doxorubicin in both sensitive and MDR cell lines was also studied. Figure
3-1 demonstrates that after a 3 hour incubation in 10 pM doxorubicin, by which time
steady-state concentrations were reached, MCF-7/DOX cells accumulated approximately 10fold less doxorubicin than the sensitive cell line. The addition of 3 pM cis- or 6 pM transflupenthixol (IC^q concentrations) had no significant effect on the accumulation of
doxorubicin in the sensitive MCF-7 line. However, they increased by 2.4 and 4.6-fold,
respectively, the accumulation of doxorubicin in the resistant MCF-7/DOX cells.
Similarly, Figure 3-2 shows that after a 3 hour incubation with equimolar (5 pM)
concentrations of c/s-flupenthixol, rranj'-flupenthixol or verapamil, rra«5-flupenthixol
caused a 5-fold increase in doxorubicin accumulation, while ciT-flupenthixol caused a 3fold and verapamil caused a 4-fold increase, in MCF-7/DOX cells.
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5.

Isobologram

Analyses

To rigorously study the magnitude of potentiation of doxorubicin by transflupenthixol, their multiple drug effects were studied by isobologram analysis. Figure 3-3
demonstrates the synergistic action of doxorubicin and rra/is-flupenthixol, evident by
comparing the actual concentrations necessary for 50% inhibition of cell growth to those
predicted for drugs which are simply additive.
To determine whether mznj-flupenthixol and verapamil are additive, competitive, or
synergistic in their ability to potentiate the cytotoxicity of doxorubicin in MCF-7/DOX cells,
a series of dose-response curves to doxorubicin were performed in the presence of various
combinations of the two chemosensitizers. Figure 3-4 shows a plot of the concentrations
that either alone or in combination caused a 15-fold reversal of doxorubicin resistance in
these cells. As can been seen, frarcs-flupenthixol and verapamil were exactly additive in
their chemosensitizing effects.

6.

Potency of Chemosensitizers
To compare the anti-MDR potency of rra/u-flupenthixol versus verapamil, dose-

response curves to doxorubicin in the absence and presence of various concentrations of
individual chemosensitizers were performed.

Figure 3-5 shows that while both

chemosensitizers displayed linearly increasing anti-MDR effects with increasing doses,
rra/u-flupenthixol was 2- to 3-fold more potent than verapamil in producing equivalent
effects. For example, to cause a 15-fold reversal of MDR (MDR Ratio = 15), 5 fiM transflupenthixol versus 12 jiM verapamil were necessary.

7.

Effect of Thioxanthenes on Calmodulin and Protein Kinase C
Since PTZs and thioxanthenes are both known to antagonize CaM, the effect of cis-

flupenthixol, rra/u-flupenthixol and fluphenazine as inhibitors of a CaM-dependent form of
cyclic nucleotide phosphodiesterase were determined and compared to their
chemosensitizing effects. Table 3-4 showss that c/j-flupenthixol, tranj-flupenthixol and
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chemosensitizing effects. Table 3-4 showss that c/T-flupenthixol, frarcs-flupenthixol and
fluphenazine were all potent CaM antagonists. However, their anti-CaM activity did not
correlate with their effects on MDR. Specifically, while rra/is-flupenthixol was a slightly
more potent CaM antagonist than m-flupenthixol (IC50 = 7 pM versus 11 pM), both were
slightly less potent than fluphenazine (IC50 = 5 pM), a far less effective chemosensitizers
than either thioxanthene.
Cis- and /ra/ij-flupenthixol were also examined for their effect on the inhibition of
PKC. Table 3-4 shows that the thioxanthenes were extremely similar in their anti-PKC
effect, with the trans-isomer being slightly more potent (1.4-fold).

D. Discussion
The results presented in this chapter characterize the stereospecific effects of transflupenthixol and several related chemosensitizers on MDR, and suggest that the
thioxanthene class of MDR antagonist mediates this effect through P-gp. Specifically, it
was found that the chemosensitizing activity of the thioxanthenes, verapamil, and to a lesser
extent fluphenazine, were limited to ’classic' MDR cell lines.

For example, trans-

flupenthixol caused significant reversal of primary and cross-resistance in MCF-7/DOX,
KB-VI, P388/DOX, and 3T3/MDR1 cell lines, each known to display decreased drug
accumulation and an increased expression of P-gp or mdr 1 mRNA (56, 64, 71, 206, 235).
However, neither rra/is-flupenthixol, nor the other chemosensitizers tested, caused any
potentiation of drug toxicity in the MCF-7/MITOX multiple drug resistant cell line. It is
interesting to note that while these cells display decreased drug accumulation and crossresistance to a typical MDR spectrum of drugs, extensive studies utilizing Western blot
analysis with several different monoclonal antibodies to P-gp and Northern blotting with
cDNA probes to the mdrl gene have failed to detect any expression of P-gp mRNA or
protein.1 The mechanism of drug resistance is as yet unclear for these cells, although an
increased amount of a 150 kDa membrane protein has been identified by gel electrophoresis
Gallon, W„ personal communication.
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The chemosensitizers studied did not significantly modulate the toxicity of drugs nor
cause an increased accumulation of doxorubicin in sensitive, parental cell lines. These
results together suggest that the chemosensitizing effects of the thioxanthenes and verapamil
were mediated through a target(s) overexpressed in MDR cells, such as the putative drug
efflux pump, P-gp (38). As discussed in Chapter I, a current hypothesis regarding the
mechanism by which MDR cells reduce cellular accumulation of anthracyclines and other
drugs is through the increased expression of this plasma membrane glycoprotein in MDR
cells (27), and that compounds which antagonize MDR compete with cytotoxic drugs for
specific drug-binding sites on the protein (44). Though calcium channel blockers such as
verapamil can inhibit binding of a photoaffinity labelled vinblastine analog to Pglycoprotein, PTZs were far less effective (2). The failure of PTZs to block vinblastine
binding to P-glycoprotein does not rule out the interaction or chemosensitizers with other
sites on the protein. For example, Hamada and Tsuruo have recently demonstrated ATPase
activity of the molecule (93), and shown that agents which inhibit active drug efflux, such
as trifluoperazine and verapamil, cause an increase in P-glycoprotein ATPase activity, while
doxorubicin and vincristine, agents which may interact with the putative drug-binding
region, do not affect this ATPase activity (92). Alternatively, Center (32) demonstrated that
trifluoperazine increased phosphorylation of this protein in MDR Chinese hamster lung cells
and enhanced doxorubicin accumulation and cytotoxicity, suggesting the PTZs may
indirectly affect P-gp.
However, the remarkably similar effects of frans-flupenthixol and verapamil in each of
the sensitive and MDR cell lines strongly suggests that the thioxanthenes may share a
common target with verapamil for reversing MDR . In support of this, it was shown in
Figure 3-4 that rrans'-flupenthixol and verapamil were exactly additive in their in vitro antiMDR effect in MCF-7/DOX cells, implicating a common pharmacologic mechanism.
Therefore, the decreased P-gp binding shown for PTZs (2) may actually explain the relative
lack of potency and low MDR Ratios found for fluphenazine, trifluoperazine, and the many
other PTZs tested for chemosensitizing activity in Chapter II, rather than implicating an
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alternative mechanisms of reversal.
It will be critical to the understanding of the thioxanthenes' mechanism of action and
stereospecificity in antagonizing MDR, to study their interaction with P-gp. In fact, efforts
are currently in progress to determine the ability of rran^-flupenthixol, m-flupenthixol and
fluphenazine to competitively inhibit the binding of photoactivatable vinblastine analogs to
KB-V1 membrane P-gp, similar to previous studies with verapamil (44).

Also,

radiolabelled [-H]-trans-flupenthixol has recently been synthesized, and studies measuring
its specificity and saturability binding to MDR KB-V1 membrane vesicle preparations will
commence shortly.
It is extremely interesting that while rr^Azr-flupenthixol was a more potent and effective
chemosensitizer than its stereoisomer, c/s-flupenthixol, in each of the in vitro (MCF7/DOX, KB-V1) or in vivo (P388/DOX) derived MDR cell lines, rrans-flupenthixol was
equal, or even less effective than ds-flupenthixol at antagonizing MDR in the 3T3/MDR1
line (Table 3-3). The fact that this particular fibroblast line transfected with an mdr 1 gene
expression vector should theoretically display a particularly 'pure' form of P-gp mediated
MDR suggests several possible explanations. First, Roninson's group has elegantly shown
that mutations in the mdr\ gene caused by colchicine selection result in a single amino acid
change at position 185 of the transcribed P-gp protein, and that this genetic event is
associated with a preferential increase in resistance to colchicine, possibly due to alterations
in the affinity of P-gp drug binding sites (40). Since the 3T3/MDR1 transfected cell line
used in the present studies was also selected with colchicine, in contrast to the other MDR
cell lines used (selected with doxorubicin or vinblastine), it is intriguing to speculate that the
apparent loss or reversal of flupenthixol's stereospecificity for antagonism of MDR may
also be due to this mutation, thereby altering the affinity of a chemosensitizer and/or drug
binding domain for cis- versus rra^-flupenthixol. This may also explain why all the
chemosensitizers caused a greater reversal of colchicine resistance than doxorubicin or
vinblastine resistance in this cell line alone. Indeed, if this hypothesis is true, it may be
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possible to target individual MDR subtypes, defined by their particular pattern of crossresistance and mdrl sequence, with chemosensitizers that preferentially bind to that P-gp
molecule.
Alternatively, cis- and rranj-flupenthixol may possess equivalent effects on P-gp in all
MDR cell lines, but have stereospecific effects on addiuonal cellular targets which regulate
or modulate MDR in certain cell lines. This hypothesis could explain rnartf-flupenthixol's
loss of stereospecificity in the genetically manipulated mdrl transfectant, a line which may
lack regulatory mechanisms or important co-induced gene products common to the other
MDR cell lines. To begin exploring this possibility, the effect of thioxanthenes and PTZs
on several cellular enzymes which may have a regulatory role in MDR was examined.
Similar to previous reports (161), cis- and rranj-flupenthixol were found to be nearly
identical antagonists of CaM, and were less potent than their PTZ homolog, fluphenazine
(Figure 3-6) This data supports that presented in Chapter II demonstrating the lack of
correlation between antagonism of CaM and reversal of MDR for PTZs.
Several groups have suggested that PKC may play an important role in MDR (58,
105). Drugs that stimulate PKC, such as the phorbol esters, produce increased levels of
anthracycline resistance in MCF-7/DOX cells, and induce a MDR-like phenotype in
sensitive MCF-7 cells (59). These effects were reversed by PTZs at concentrations similar
to those used in the present study. Furthermore, MCF-7/DOX cells, in particular, have up to
a 15-fold increased level of PKC acuvity compared to the parental MCF-7 cells (59, 166).
In isolated systems, the concentrations of PTZs required to inhibit PKC have been reported
to be many fold higher than those presently found sufficient to antagonize MDR. For
example, in one study, the ICsq's for inhibition of PKC by trifluoperazine, chlorpromazine
and fluphenazine were 38 - 50 |iM, 59 - 84 pM, and 78 - 114 pM, respectively (200), 10to 50-fold greater than those found to antagonize MDR. Many thioxanthenes are particularly
poor inhibitors of PKC, with IC5q's in the millimolar range reported (200), though the PKC
inhibitory activity of cis- or rrarts-flupenthixol have not been previously studied. Figure
3-7 demonstrates that both flupenthixol isomers are potent inhibitors of PKC purified from
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3-7 demonstrates that both flupenthixol isomers are potent inhibitors of PKC purified from
MCF-7/DOX cells. While rram'-flupenthixol is slightly more potent for this effect, it seems
unlikely that the small difference (1.4-fold) can adequately explain their differences in
chemosensitizing activity in this cell line (3-fold). Thus, while the activation and inhibition
of PKC offers an attractive hypothesis for the modulation of MDR, it appears that the antiMDR effects of the PTZs and thioxanthenes are not likely to be mediated solely through this
enzyme.
Another cellular enzyme of particular relevance to the mechanism of MDR is
glutathione-S-transferase, shown to be elevated in MCF-7/DOX cells (12).

Recent

evidence has shown that selectively reducing glutathione levels in MCF-7/DOX cells with
buthionine sulfoximine leads to dramatically increased cellular verapamil toxicity, though
causes no change in the sensitivity of cells to rran^-flupenthixol.2 Therefore, it appears
that GST or the GSH redox system may be a target mediating verapamil, but not transflupenthixol, toxicity and/or chemosensitizing effect in MDR cells.

Supporting this is

preliminary data showing that rrj/w-flupenthixol does not sensitize MCF-7 cells transfected
with a GSTji expression vector to doxorubicin.3
Finally, a simple explanation for the differences in anti-MDR activity observed for the
thioxanthene stereoisomers would be differences in their cellular accumulation and therefore
differences in access to intracellular targets.

However, MDR cells actually accumulate

significantly more cis- than rrans-flupenthixol at effective anti-MDR doses (3 - 10 jiM),
the opposite of what would be expected if their potency as antagonists of MDR reflected
differences in their intracellular accumulation. This implies that the difference in anti-MDR
activity between these stereoisomeric thioxanthenes is indeed due to differences in their
ability to interact with a unique cellular target(s). Since the most potent anti-MDR agent
studied, rrans-flupenthixol, reduced the 10-fold difference in doxorubicin accumulation
2Ford, J.M. and W.N. Hait, manuscript in preparation.
3Ford, J.M., J.A. Moscow, K.H. Cowan, and W.N. Hait, manuscript in preparation.
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chemotherapeutic drug efflux. However, because of the many cellular effects of the PTZs
and thioxanthenes, it is possible these agents exert their effect through more than one
mechanism.
In summary, rrans-flupenthixol was a potent and effective chemosensitizer in each of
the MDR cell lines studied, and appeared to function through a direct or indirect modulation
or inhibition of P-gp function. 7><2AL5'-flupenthixors 2- to 3-fold greater potency and 1- to
3-fold greater efficacy than verapamil (Figure 3-5), along with its previously discussed lack
of known clinical activity or side effects (Section HD), indicate that future studies of the in
vivo toxicity and efficacy of rraAis-flupenthixol in combination with doxorubicin and other
chemotherapeutic agents are warranted to elucidate the potential of this drug for clinical use
against MDR tumors.
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TABLE 3-1
Inhibition of Cellular Proliferation by Chemosensitizers Alone

IC™ (uM) Chemosensitizers
Cell Line

cL-FPT

trans-FPT

FLU

VRP

8

9

18

100

MCF-7/DOX

24

25

23

200

MCF-7/MITOX

18

18

20

200

KB-3-1

15

15

15

35

KB-VI

32

17

32

35

MCF-7

P388

1.4

0.8

0.8

12

P388/DOX

0.9

0.6

1.2

12

NIH 3T3

30

30

60

70

3T3/MDR1

40

20

60

40

Inhibition of cell growth was determined by exposing cells to 0 - 100 jiM cL-flupenthixol
(c/s-FPT), rrans-flupenthixol {trans-FPT), flupenazine (FLU) or verapamil (VER) for 48
to 72 hours. IC50 is the mean concentration that produced 50% inhibition of cell growth
compared to vehicle-treated controls, as described in Materials and Methods. All values
represent the mean of two to three separate experiments; each experiment was done in
quadruplicate.
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TABLE 3-2
Relative Resistance of Cells to Cytotoxic Drugs

ICcn (uM) and Relative Resistance_
Cell Line

DOX

MCF-7

.06 (1)

MCF-7/DOX

12 (200)

0.1 (100)

3 (50)

.03 (30)

MCF-7/MITOX

KB-3-1

0.3 (1)

KB-V1

60 (200)

P388

.01 (1)

P388/DOX

1 (100)

NM 3T3

0.5 (1)

3T3/MDR1

10 (20)

VLB

.001

(1)

.002

(1)

1

(500)

.002

(1)

COLCH

.005 (1)
2

(400)

0.1 (20)
.018 (1)
3 (166)

MITO

BLEO

1.0(1)

15 (1)

20 (20)

15 (1)

100(100)

150(10)

0.2(1)

100 (1)

4(20)

.0013 (1)
.016 (12)

.04 (20)

100 (1)

1 0)
1

0)

•05 (1)
5 (100)

Inhibition of cell growth was determined by exposing cells to various concentrations of
doxorubicin (DOX), vinblastine (VLB), colchicine (COLCH), mitoxantrone (MITO) or
bleomycin (BLEO) for 48 to 72 hours. IC50 is the mean concentration that produced 50%
inhibition of cell growth compared to vehicle-treated controls, as described in Materials and
Methods. The relative resistance of each cell line to different drugs was calculated by
dividing the IC50 of a MDR cell line to a drug by the IC50 of its parental drug-sensitive cell
line to the same drug. All values represent the mean of two to three separate experiments;
each experiment was done in quadruplicate.
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TABLE 3-3
Reversal of Multidrug Resistance by Chemosensitizers

MDR Ratio
Cell Line

Drug

[CS] (fiM)

cB-FPT

trans-FPT

FLU

VRP

MCF-7

DOX
VLB
MITO
COLCH

5
5
5
5

1.0
1.1
1.5
1.1

1.0
1.6
1.7
1.0

1.0
1.3
1.0
1.0

1.0
2.0
1.0
1.0

MCF-7/DOX

DOX
VLB
COLCH

5
5
5

7
25
5

15
36
8

13
33
4

3
20
1.3

5
5
5

1.0
1.0
1.0

1.0
1.0
1.0

1.0
1.0
1.0

1.0
1.0
1.0

MCF-7/MIT0X MITO
DOX
VLB

KB-3-1

VLB
DOX
COLCH

5
5
5

1.1
1.0
1.1

1.2
1.0
1.0

1.7
1.0
1.1

1.4
1.0
1.2

KB-V1

VLB
DOX
COLCH

5
5
5

20
20
17

40
35
20

15
30
20

10
3
4

P388

DOX
VLB

1
1

1.4
1.0

1.0
1.0

2.3
1.0

1.7
1.0

P388/DOX

DOX
VLB

1
1

5
3

7
4

6
ND

2
3

NIH 3T3

COLCH
DOX

5
5

1.2
1.0

1.0
1.0

1.0
1.0

1.0
1.0

3T3/MDR1

COLCH 5
COLCH 12
DOX
5
DOX
12

10
40
13
36

10
37
14
20

20
43
15
40

3
10
5
13

Cells were exposed to various concentrations of doxorubicin (DOX), vinblastine (VLB), colchicine
(COLCH) or mitoxantrone (MITO), in the absence or presence of cri-flupenthixol (cz's-FPT), transflupenthixol (trans-¥PT), flupenenazine (FLU) or verapamil (VRP) at concentrations that alone produced <
10% inhibition of cell growth ([CS]). Each MDR Ratio is the IC50 for cytotoxic drug alone divided by the
IC50 for drug in the presence of chemosensitizer, and was derived as described in Materials and Methods.
All values represent the mean of 2 to 3 separate experiments; each experiment was done in quaduplicate.
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TABLE 3-4

Inhibition of Calmodulin and Protein Kinase C by Chemosensitizers

IC5n (uM) Chemosensitizers
Chemosensitizer

CaM

PKC

m-Flupenthixol

11

38

rraflj-Flupenthixol

7

28

Fluphenazine

5

Antagonism of CaM by chemosensitizers was determined by their ability to inhibit by 50%
the activition of a CaM-dependent form of cyclic nucleotide phosphodiesterase, as
described in Materials and Methods. Effect of thioxanthenes on PKC was determined by
their ability to inhibity by 50% the activity of enzyme purified from MCF-7/DOX cells
approximately 15-fold, as described in Materials and Methods.
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Figure 3-1. Effect of thioxanthene isomers on the accumulation of doxorubicin in
sensitive MCF-7 (open symbols) and MDR MCF-7/DOX cells (closed symbols). Cells
were incubated with 10 jiM doxorubucin in the absence (circles) or presence of 3 |iM cisflupenthixol (triangles) or 6 pM /rarcs-flupenthixol (squares), equitoxic concentrations
that alone produced 10% inhibition of cell growth. Cell associated doxorubicin at various
times after the addition of drug was determined spectrofluorometrically as described in
Materials and Methods. Values are means from triplicate determinations, with standard
error bars when greater than 5% of the mean.

108

c

o
ro
3

E
3
O
o
<
c
o
JO
3

k.

o
X
o

D

Chemosensftizer (5 pM)

Figure 3-2. Effect of equimolar concentrations of chemosensitizers on the accumulation
of doxorubicin in sensitive MCF-7 and MDR MCF-7/DOX cells. Cells were incubated for
3 hours with 10 |iM doxorubucin in the absence (No CS) or presence of 5 |iM cisflupenthixol (c/s-FPT), rrans-flupenthixol (rrani'-FPT) or verapamil (VRP). Cell
associated doxorubicin (pmoles/106 cells) was determined spectrofluorometrically as
described in Materials and Methods. Values are means from duplicate determinations.
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Figure 3-3.

Isobologram analysis of the interaction between doxorubicin and

/r<3rts-flupenthixol. IC5Q isobole for inhibition of MCF-7/DOX cell growth
by various combinations of doxorubicin andtrarts-flupenthixol (points) was
determined by exposing cells to drug combinationsfor 48 hours as described in
Materials and Methods. The straightline represents the predicted K50 isobole
for drugs which haveadditive antiproliferative effects. 12 pM doxorubicin and
25 pM tran^-flupenthixol alone caused 50% inhibition of cell growth.

Each

point represents the mean value of quadruplicate determinations whichliffered
by less than 5%.
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Figure 3-4.

MDR isobologram analysis of the chemosensitizing interaction between

verapamil and rra/u-flupenthixol. MDR isobole for 15-fold reversal of MCF-7/DOX
doxorubicin resistance by various combinations of verapamil and rrans-flupenthixol
(squares) was determined by exposing cells to 0 - 100 fiM doxorubicin plus combinations
of chemosensitizers for 48 hours and identifying those combinations that together caused
an MDR Ratio =15. The straight line represents the predicted MDR isobole for modifiers
which have additive chemosensitizing effects.

10 p.M verapamil and 5 |iM trans-

flupenthixol alone caused an MDR Ratio = 15. Each point represents the mean value of
quadruplicate determinations which differed by less than 5%.

Ill

[chemosensitizer] (pM)

Figure 3-5. Potency of chemosensitizing activity formz/is-flupenthixol and verapamil in
MDR cells. MCF-7/DOX cells were exposed to 0 - 100 |iM doxorubicin for 48 hours in
the absence vesus presence of various concentrations of each chemosensitizer. Inhibition
of cell growth and MDR Ratios were determined as described in Materials and Methods.
Each point represents the fold reversal of MDR caused by that concentration of
chemosensitizer, and was the result of quadruplicate determinations, which differed by less
than 5%.

112

Chapter IV
IN VIVO EFFECT OF 77L4 VS-FLUPENTHIXOL
ON MULTIDRUG RESISTANCE

A. Introduction
The results presented in Chapters II and

in demonstrate

that tranj-flupenthixol is a

potent chemosensitizer in MDR cell lines in vitro, equal or more effective than verapamil,
and much more effective than any of the previously or currently studied PTZs. While
verapamil has been shown by several investigators to potentiate the effects of both
doxorubicin and vinblastine in vivo in MDR mouse tumors (Table 1-5), the potent
vasoactive effects of this drug have severely limited its potential anti-MDR use in clinical
trials in humans (165). Similarly, the use of the active antipsychotic drug trifluoperazine as
a chemosensitizer in humans has been limited by CNS side effects associated with its
neuroleptic activity (88, 149).

Conversely, rrarts-flupenthixol has been shown to be

inactive compared to its c/s-isomer as an antipsychotic agent in humans, and has not been
associated with any notable side effects at clinically tested doses (116). In fact, in in vivo
mouse studies, rra^^-flupenthixol has been shown to be 100- to 1000-fold less potent in a
number of standard assays used to measure the side effects and neuroleptic potential of
drugs, such as inhibition of spontaneous motor activity, cataleptic reaction, ptosis-inducing
effects, and inhibition of apomorphine and amphetamine induced stereotypy (157, 158). In
addition, in vitro studies demonstrate that [3H]-rra/ty-flupenthixol completely lacks specific
dopamine receptor binding activity (104), in contrast to the highly specific, potent dopamine
D1 and D2 receptor binding activity displayed by [3H]-ci\y-flupenthixol (103).

Also,

trani'-flupenthixol has little or no a-adrenergic, P-adrenergic or 5-HTj blocking activity
(104).
Therefore, the preclinical and clinical data reported for fraAW-flupenthixol suggest it
may be an excellent candidate for the in vivo clinical modulation of MDR. To begin
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studying the in vivo activity of rra/u-flupenthixol as a chemosensitizer, the P388 murine
ascites tumor model was chosen. Using P388 and P388/DOX-tumor bearing mice, the
toxicity of tra^-flupenthixol and its effect on survival and cellular drug accumulation alone
and in combination with doxorubicin was studied.
B . Materials and Methods
1.

Drugs
Doxorubicin was obtained from Sigma, 7>fl/ty-flupenthixol was generously supplied

by Dr. John Hyttel (H. Lundbeck, Copenhagen, Denmark).

Both drugs were freshly

dissolved in distilled water immediately before each use.

2.

Tumor Cells
P388 sensitive and P388/DOX cells (from Dr. Ram Ganapathi) were maintained in

exponential growth in suspension culture in 75 cm2 Coming tissue culture flasks in RPMI
1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 10 |iM 2mercaptoethanol in a humidified atmosphere of 5% CO2 and 95% air. The P388/DOX cells
were approximately 100-fold resistant to doxorubicin, and maintained a stable MDR
phenotype while grown in drug-free medium for periods of up to 3 months, after which
they were discarded. Cell lines were routinely tested and found to be free of contamination
by mycoplasma or fungi.

3.

Toxicity of Trans-Flupentliixol in Mice
To determine the chronic toxicity of daily i.p. rrans-flupenthixol administration, 5 to 6

week old female Swiss Webster Mice (Jackson Laboratories, Bar Harbor, Maine) weighing
18-22 mg were divided into 4 groups of 5 mice each. Tranj-flupenthixol was dissolved
in small amounts of disdlled water and diluted with physiologic saline. Drug was injected
i.p. daily for 7 days at doses of 50 to 200 mg/kg in 0.1 ml volumes. Mice were weighed
daily, food and water consumption and urine and stool production noted, and mortality data
collected daily. LD5q's were determined by the method of Litchfield and Wilcoxon (139).
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4.

Evaluation of Antitumor Activity
Exponentially growing P388 and P388/DOX cells were washed once in PBS, and 1 x

106 cells in 0.1 ml PBS inoculated i.p. into 8 to 10 week old female DBA/2J mice (Jackson
Laboratories), weighing 19-23 gm each. Mice were divided into groups of 5 each, and
drugs were administered daily for 10 days, starting 1 day after tumor implantation, by the
method of Tsuruo (227). Accordingly, rranj-flupenthixol (50 mg/kg) and/or doxorubicin
(1-3 mg/kg), both dissolved in saline, were injected i.p. into mice in 0.1 ml volumes, with
rrans-flupenthixol treatment preceding doxorubicin. Response to therapy was evaluated by
measuring the mean survival time for each group of mice and determining the percent
increase in life span (%ILS).

5.

Pharmacokinetic Studies
To determine the accumulation of doxorubicin and rrans-flupenthixol in ascites tumor

cells in vivo, 2 groups of 5 DBA/2J mice each were inoculated i.p. with 1 x 106 P388
sensitive or P388/DOX cells. Ascites cells were allowed to grow without drug treatment for
8 days, at which time tumor bearing mice were injected i.p. with 50 mg/kg transflupenthixol and/or 1-3 mg/kg doxorubicin in 0.1 ml saline.

One hour after drug

treatment, mice were etherized, and sacrificed by cervical dislocation. Ascites was removed
by i.p. injection and withdrawal of 3 ml PBS. Cellular drug levels were determined by
methods similar to those described in Chapter III. Briefly, cells were kept on ice and
rapidly washed two times in cold PBS by centrifugation at 100 x g. Cells were resuspended
in PBS, counted electronically (Coulter, Hialeh, FL), and again pelleted by centrifugation.
Cells were resuspended in 2 ml of 0.3 N HC1 in 50% ethanol, and sonicated for 10 pulses at
200 watt seconds with a Tekmar cell sonicator, followed by centrifugation for 60 sec at
11,000 x g using an Eppendorf 5415 microcentrifuge. Cell supernatants were removed and
assayed spectrofluorometrically for doxorubicin using excitation and emission wavelengths
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of 475 nm and 585 nm, respectively. Blank, control values were determined by similarly
assaying ascites cell extracts from a mouse which did not receive drug treatment.

C. Results
1.

Toxicity of Trans-Flupenthixol
The toxic effects of chronic frartf-flupenthixol administration to mice were determined

for a one week period. Figure 4-1 shows the effects of 50 to 100 mg/kg daily i.p. transflupenthixol on the survival of mice. None of these dosages proved to be acutely toxic,
with 100% survival after the first day of treatment. Doses greater than 50 mg/kg were
chronically toxic, causing death of all mice by 7 days of daily treatment Doses of 50 mg/kg
rrans-flupenthixol daily for 7 days was not toxic to mice, as assessed by survival (100%)
and weight loss

(0

%).

100

to

200

mg/kg rrans-flupenthixol also caused sedation,

diarrhea, and loss of smoothness of hair.
Since no mice treated with 50 mg/kg rrans-flupenthixol died after 7 days, in contrast to
100% of mice treated with the higher doses tested, the LD50 for this 7 day dosing regimen is
difficult to determine. (The LD50 after a 3 day treatment was 130 mg/kg, for instance).
However, a dose of 50 mg/kg for 7 days appeared to be the maximally tolerated dose in
Figure 4-1.

2.

In

Vivo

Antiproliferative

Effect

of

Trans-Flupenthixol and

Doxorubicin
The effects of a 10 day course of 50 mg/kg rranj-flupenthixol

and 1-3 mg/kg

doxorubicin individually, or in combination, on survival in sensitive or MDR P388-tumor
bearing mice is shown in Table 4-1. Treatment with 1 mg/kg doxorubicin caused a 34%
ILS in the doxorubicin-sensitive P388-tumor bearing mice, while 1 or 3 mg/kg doxorubicin
did not significantly alter the median life span of P388/DOX-tumor bearing mice compared
to control, untreated mice.
However, doses of 50 mg/kg rruns-flupenthixol alone proved toxic to both groups of
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tumor bearing mice, causing a 20% decrease in average length of survival. Furthermore,
rra^-flupenthixol plus doxorubicin displayed significant combined toxicity, regardless of
tumor type, causing a 31 to 42% decreased survival time in mice than untreated controls.

3.

Pharmacokinetic Studies
To determine if the doses of chemosensitizer used in this study were able to reverse the

doxorubicin accumulation defect of MDR cells in vivo, cellular doxorubicin levels were
determined for ascites cells in mice one hour after treatment with rrans-flupenthixol and/or
doxorubicin.

Table 4-2 shows that when treated with 1 mg/kg doxorubicin alone,

P388/DOX cells accumulate approximately 8-fold less doxorubicin than the parental cells
(40.4 versus 344.8 pmoles/106 cells). However, treatment of the MDR tumor bearing mice
with 50 mg/kg rrans-flupenthixol caused a 28% and 62% increase in doxorubicin
accumulation for

1

mg/kg and 3 mg/kg doxorubicin, respectively. Treatment with 3 mg/kg

doxorubicin plus 50 mg/kg rrans-flupenthixol in P388/DOX-tumor bearing cells caused
nearly equivalent levels of cellular doxorubicin as in the sensitive-tumor cell bearing mice
given similar doses of drug (301.6 versus 328.8 pmoles/106 cells). Tra/u-flupenthixol did
not cause an increase in doxorubicin accumulation in P388 sensitive cells.

D. Discussion
This chapter presents preliminary results from in vivo studies designed to determine
the toxicity, appropriate dosage and scheduling, and possible anti-MDR activity of transflupenthixol. It was first determined that daily i.p. treatment of healthy mice for one week
with rrans-flupenthixol was toxic for doses >

100

mg/kg, but caused no deaths in animals

which received 50 mg/kg (Figure 4-1). The only previous toxicological testing of i.p.
rrarts-flupenthixol in mice found an LD50 for acute toxicity from single i.p. injections of
270 ± 32 mg/kg,1 while the LD50 (i.p.) for racemic flupenthixol was reported as 150
mg/kg (237).
1 Hyttel, J., personal communication.
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While 50 mg/kg daily i.p. rrans-flupenthixol was well tolerated in healthy mice, for
tumor bearing mice this dose proved to be toxic, causing a 20% decrease in survival.
Furthermore 50 mg/kg rrans-flupenthixol in combination with otherwise non-toxic doses
doxorubicin showed greatly enhanced toxicity in tumor bearing mice (Table 4-2) than either
drug alone, or no treatment.
Unfortunately, due to the intrinsic toxicity of rra/iy-flupenthixol, and to the combined
toxicity of rrarts-flupenthixol plus doxorubicin at the doses tested, the possible anti-tumor
effects of chemosensitizing therapy with rram^-flupenthixol could not be determined from
the present results. Additional experiments are therefore in progress with changes in the
dosage (< 25 mg/kg) and route of administration (i.v., and subcutaneous, slow release
pellets) of rrans-flupenthixol treatment, to hopefully reduce toxicity and increase available
concentrations or drug.
Encouraging results came from pharmacokinetic studies of the alteration in doxorubicin
accumulation caused by rrarcs-flupenthixol in ascites tumor cells in vivo, however.
Specifically, while MDR P388/DOX cells accumulated nearly 10-fold less doxorubicin than
sensitive P388 cells, a single i.p. dose of 50 mg/kg rranj-flupenthixol was clearly sufficient
to cause up to a 2-fold increase in doxorubicin accumulation in MDR cells, in vivo. Similar
to in vitro accumulation studies, rrarts-flupenthixol did not cause an increase doxorubicin
accumulation in the sensitive cells, in vivo. Thus, while the presently studied doses of
trans-flupenthixol and doxorubicin demonstrated systemic toxicity in mice, they also
functioned to partially reverse the accumulation defect in MDR cells in vivo. Hopefully,
reducing the dose of rra/u-flupenthixol will eliminate toxicity but still cause increased
doxorubicin accumulation in MDR cell in vivo, resulting in an increased %ILS.
As discussed in Chapter I, there are a number of other mouse tumor models which may
more realistically reflect clinical MDR tumors in humans. If significant chemosensitizing
activity is shown for rranj-flupenthixol in combination with doxorubicin in the P388/DOX
screening model, further studies of the affect of rra/u-flupenthixol plus various cytotoxic
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drugs or drug combinations on solid tumor growth and drug pharmacokinetics in nude mice
with transplanted human tumor xenografts such as MCF-7/DOX, or an mdr 1 transfected
tumor cell line, may provide interesting and clinically useful data.
While the results from this pilot in vivo murine trial were disappointing due to the
unexpected toxicides, there is evidence to suggest that franj-flupenthixol may have great
potential for clinical use as a chemosensitizer. As discussed in Chapter n, clinical trials of
the antipsychotic effects of thioxanthene isomers have shown rra/u-flupenthixol to
completely lack dopaminergic activity and extrapyramidal side effects (116). Furthermore,
sensitive chromatographic and radioimmunoassays have been developed for the
measurement of tissue and plasma cis- and rrartj-flupenthixol levels for studies of the
psychopharmacologic effects of thioxanthenes in humans (117, 170, 194) which have
generated important clinical pharmacokinetics data possibly relevant to their proposed use as
modulators of tumor resistance. For example, flupenthixol has been shown to undergo
extensive first-pass hepatic metabolism and to have a high systemic clearance due to its high
hepatic extraction ratio, with mean systemic availability ranging from 30 - 70% (118).
Nevertheless, flupenthixol possesses an apparent half-life of elimination of 34 to 36 hours
due to a large volume of distribution (20 L/kg) (119). Also, flupenthixol's lipophilicity
results in selective partitioning into tissues (suggesting high tumor tissue levels may be
possible), making correlations between plasma levels and clinical effects notoriously
difficult (10). Reported peak plasma levels for cis-flupenthixol treatment (1 mg i.v. or 4
mg p.o.) have been 3-4 |ig/L ( ~ 7 nmolar) (120), 1000-fold less than concentrations
necessary for in vitro chemosensitizing activity. However, it is possible that far greater
doses of martj-flupenthixol may be safely administered to humans, due to its apparent lack
of clinical activity. In addition, a recent report measuring the steady state levels of cis- and
f/zms-flupenthixol resulting from 4 to 15 mg daily po doses of a 1:1 mixture of both drugs
resulted in rra^-flupenthixol levels of up to 20 nmolar, and indicated that 2-fold greater
rranj-flupenthixol steady state plasma concentrations were achieved in comparison to cisflupenthixol (11). These data suggest that it may be possible to achieve sufficient tissue
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levels of rr<2rt5-flupenthixol capable of producing anti-MDR activity in human tumors.

E. Summary and Conclusions
This thesis has attempted to better define a structural 'pharmacophore' for the reversal
of MDR, and characterized the in vitro and in vivo chemosensitizing activity of a newly
described class of anti-MDR agents, and has begun to explore the mechanisms involved in
the pharmacological reversal of MDR.
Specifically, systematic structure-activity relationships for the PTZs' ability to reverse
MDR in a human breast cancer cell line revealed the specific structural features, such as the
length and type of amino side chain, that in addition to hydrophobicity determined the
chemosensitizing activity of these drugs. Based on these predictions, the thioxanthene class
of chemosensitizers was identified, and shown to be potent and stereospecific antagonists of
MDR.

The thioxanthenes cis- and rruns-flupenthixol were further characterized for

chemosensitizing activity in several in vitro and in vivo MDR tumor cell lines, and shown
to partially reverse MDR and cause increased cytotoxic drug accumulation in cells which
overexpress P-gp. Furthermore, the mechanism of chemosensitizing effects of PTZs and
thioxanthenes was shown unlikely to be due to their known inhibition of CaM and PKC.
The results presented in this thesis have a number of implications for future basic and
clinical research in the field of cancer drug resistance.

First, based on the structural

principles derived from the PTZ anti-MDR model, it may be possible to rationally design
and synthesize novel drugs which possess greater chemosensitizing activity and less toxic
side effects than those currently known. Also, the identification of thioxanthenes as potent,
stereospecific chemosensitizers may provide useful pharmacologic probes for exploring the
biochemical basis of MDR and its reversal. Finally, the preliminary in vivo anti-MDR data
presented, together with the interesting clinical and pharmacological profile already known
for rra/ij-flupenthixol, suggest this drug may be a potentially useful candidate for clinical
trials testing the ability of drugs to modulate tumors resistance in humans.
In conclusion, a great deal of information has been gathered in the last decade
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concerning the cellular pharmacology and molecular biology of MDR cell lines in vitro, and
an understanding of the relevance and mechanism of MDR and P-gp in human tissues and
tumors in now beginning. The discovery of the chemosensitizer rrans-flupenthixol may
hopefully assist to further advance the knowledge of the mechanisms of MDR and its
reversal, and potentially contribute to the clinical reversal of tumor resistance in humans.
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TABLE 4-1

In Vivo Chemosensitizing Activity of /rarts-FIupenthixo!

Tumor
Drugs and Dose (mg/kg)

Survival
Days

% ILS

P388/S
Control
DOX(l)
tFPT (50)
DOX (1) + tFPT (50)

13.0
17.4
10.4
7.6

±
±
±
±

0.7
0.9
2.1
1.5

0
+34
-20
-42

P388/DOX
Control
DOX (1)
DOX (3)
tFPT (50)
DOX (1) +tFPT (50)
DOX (3) + tFPT (50)

10.4
10.2
9.8
8.2
6.4
7.0

±
±
±
±
±
±

1.3
0.8
0.4
2.5
2.2
0.7

0
-2
-6
-21
-38
- 31

Mean survival time in days ( ± S.E.) and percent increase in life span (%ILS) for P388/S
and P388/DOX-tumor bearing mice (5 mice per condition). 1 x 106 sensitive or MDR cells
were injected i.p. in adult, female DBA/2J mice on day 0, and drugs given daily from Day
1 to Day 10 dissolved in 0.1 ml saline.
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TABLE 4-2

Effect of /rans-FIupenthixo! on In Vivo Doxorubicin Accumulation
in Sensitive and MDR Tumor Bearing Mice

Drugs and Dose (mg/kg)

tFPT (50)

Doxorubicin (pmoIes/106 cells')
P388
P388/DOX

0.0

0.0

DOX(l)

344.8

40.4

DOX (3)

ND

185.8

DOX (1) + tFPT (50)

296.2

51.8

DOX (3) + tFPT (50)

328.8

301.6

DBA/2J mice were injected i.p. with 1 x 106 P388 or P388/DOX cells, and received no
treatment for 8 days. Drugs w'ere injected i.p. in 0.1 ml saline one hour before ascites cells
were removed and assayed spectrofluometrically for doxorubicin accumulation (pmoles/106
cells) as described in Materials and Methods. Control ascites cell levels were from a mouse
that did not recieve treatment.
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Figure 4-1. Toxicity of rrans-flupenthixol in mice. Adult, female Swiss Webster mice
were divided into 4 groups of 5 mice each and various doses of drug in 0.1 ml saline were
injected i.p.daily for 7 days. Surviving animals were observed daily for 2 weeks, and
mortality expressed as a percentage of total mice per group.
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